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SU M M A R Y
The m etabolic and functional effects of hypoxia, low -flow  and no-flow 
ischaemia were studied and com pared in the isolated perfused guinea-pig heart. 
The low-flow ischaemia model was identified as a suitable experimental system for 
investigating the role o f glucose and fatty acids as metabolic substrates during 
ischaemia.
Hypoxia and ischaem ia caused a reduction in high energy phosphate and 
glycogen in the perfused heart. These conditions also resulted in a rapid loss of 
contractile force and changes to diastolic tension (contracture developm ent). 
Substrate availability, heart rate, and the degree of ischaemia affected the metabolic 
and contractile responses. The effects of im paired glucose m etabolism  were 
dem onstrated by perfusing the heart in the absence o f exogenous glucose.
C ontracture developm ent was characteristic o f conditions in which the 
glycolytic capacity of the ischaemic heart was shown to be reduced (e.g. under 
glucose-free conditions and in no-flow ischaemia). Palmitate in the presence of 
glucose caused contracture developem ent in the low -flow  ischaem ic heart. 
Palmitate also increased the myocardial long-chain acylcamitine content which may 
increase ischaemic cell damage. The inhibitory effects of etomoxir on palmitoyl 
carnitine transferase-I activity were demonstrated in isolated mitochondria and the 
perfused heart. Albumin binding prevented further investigations into the beneficial 
effects of reducing fatty acid oxidation by this mechanism.
ATP-dependent potassium channel activation was investigated as a possible 
mechanism of early contractile failure (ECF). The effects of cromakalim in the 
guinea-pig papillary m uscle preparation were inhibited by glibenclam ide. 
Glibenclamide did not prevent ECF during hypoxia in this preparation.
The effects of the novel anti-ischaem ic agent, ranolazine (Syntex), were 
investigated in the low-flow ischaemia model. Ranolazine preserved the myocardial 
ATP content and reduced lactate and creatine kinase release during the ischaemic 
period. These protective effects were associated with an increased level of active 
pyruvate dehydrogenase.
The studies presented in this thesis have exam ined some of the potential 
mechanisms underlying the responses to hypoxia and ischaemia in the isolated 
perfused guinea-pig heart and papillary muscle. These results indicate that 
stimulation of glucose metabolism may be an important intervention in reducing 
ischaemic damage in the myocardium. Therapeutic strategies to achieve this are 
discussed.
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CHAPTER ONE 
GENERAL INTRODUCTION
1
INTRODUCTION
Cardiovascular disease remains one of the major causes of mortality in man and 
the past decade has seen a dramatic increase in the development of new chemical 
entities for the management of cardiovascular disease. At the present time, three 
main groups of cardioprotective drugs exist-
1) Drugs for treatment o f heart failure (e.g.digoxin)
2) Antiarrhythmic drugs (e.g. phenytoin, amiodarone)
3) Drugs for the treatment of cardiac ischaemia
Drugs used predominantly in the treatment of cardiac ischaemia, which is the 
topic of this thesis, include B-adrenoceptor blocking agents, e.g. propranolol, 
atenolol, which were first developed in the late 1950's (Moran and Perkins,
1958), vasodilating agents e.g. nitrates (Davis, 1955) and more recently calcium 
antagonists (Fleckenstein, 1977).
While improving cellular function during ischaemia, the action of these drugs is 
indirect in that their main effect is to improve the efficiency of myocardial oxygen 
utilisation either through increased blood flow or a reduction in cardiac workload. 
Much research, including that detailed in this thesis, is directed at investigations into 
the possible benefits of drug intervention. Through a direct action at the level of 
cell metabolism it may be possible to improve the specificity of drug action and 
reduce the side-effects associated with existing therapies.
This chapter presents a review o f the effects of ischaemia on myocardial 
function and metabolism in order to evaluate the potential of this novel approach to 
the treatment of myocardial ischaemia.
2
1.1 M Y O C A R D IA L ISC H A E M IA
1.1.1 Angina
Cardiac ischaemia represents an imbalance between the myocardial demand for 
oxygen and the vascular supply o f coronary blood. This condition, which exists 
when the uptake of oxygen in the heart is insufficient to maintain the normal rate of 
cellular oxidation, was first described by William Heberden in 1772 (Heberden, 
1772). His observations defined the classical symptoms of the ischaemic syndrome 
which is now known as angina pectoris. Since these early observations, three main 
types of angina have been classified (see Section 1.1.3):
1) Variant (Prinzmetal) angina.
2) Effort (chronic stable) angina.
3) Unstable angina.
1.1.2 Aetiology o f  angina
Angina has been defined as " a sense of discomfort arising in the myocardium 
as a result of myocardial ischaemia in the absence of infarction " (Julian, 1982). 
This syndrome can arise from vascular disorders including, i) vasospasm which 
results in a sudden reduction in coronary artery diameter and subsequent perfusion 
(d'Hemecourt and Detour, 1978), ii) vasoconstriction due to increased vascular 
sensitivity to physiological stimuli (Kawachi et al., 1984) resulting in restriction of 
coronary blood flow to vital areas of the myocardium or iii) an increased oxygen 
requirement of the heart which exceeds the existing maximum perfusion capacity of 
the coronary circulation (Marzilli et a l 1978). This may arise from a reduced 
perfusion capacity due to the presence of artherosclerotic lesions or as a 
consequence of platelet aggregation (Davies, 1990).
3
1.1.3 The  clinical  s y n d r o m e s  o f  angina
Variant (Prinzmetal) Angina
In 1959, Prinzmetal described an anginal condition which occurred at rest and 
was accompanied by elevation of the ST-segment of the electrocardiogram 
(Prinzmetal et al., 1959). Subsequent investigations identified the most frequent 
cause as vasospasm (Meller et al., 1976; Maseri et al., 1978). This was mediated 
through existing or developing atherosclerosis (Kawachi et al., 1984) or other 
endogenous agents which restricted flow through the coronary vessels (Sellke et 
al., 1990; Yang e t a i ,  1990).
Effort (Chronic stable) Angina
Effort angina differs from Prinzmetal's angina in that coronary perfusion is 
limited by a permanent restriction usually due to artherosclerotic lesions. The 
effects of reduced flow may not be apparent until the oxygen requirements of the 
heart are raised by exercise or some other stimuli (Nayler, 1988).
Unstable Angina
Unstable angina is characterised by a sudden increase in the severity of an 
existing anginal condition (Fowler, 1971) and is a condition associated with 
obstructive coronaiy artery disease, increased vasoactivity and thrombosis (Packer,
1989). Clinically, the severity of this condition lies between stable effort angina 
and acute myocardial infarction and early observations have recognised that 
myocardial infarction is frequently preceded by angina which has developed or 
progressed rapidly (Herrick, 1912; Kahn, 1926).
Myocardial ischaemia is common to all anginal syndromes, irrespective of their 
aetiology and the underlying mechanisms involve plaque formation (Garlin et al, 
1986; Feldman, 1987) although coronary artery spasm can occur in patients with 
normal or near normal arteries.
Myocardial Infarct
The biochemical consequences o f ischaemia are multiple and arise from a
complex of interrelated metabolic changes which have been extensively reviewed 
(Hearse, 1980; Hillis and Braunwald, 1977). The effects of ischaemia are 
dependent on both the duration and degree of the ischaemic insult (Jennings et a l.,
1990). It is generally accepted that, under experimental conditions, short durations 
of ischaemia (15 mins) produce changes to myocardial cell function which can be 
reversed on reperfusion. Longer periods o f ischaemia (40-60 mins) induce changes 
which are not reversed on reperfusion. In fact, reperfusion at this stage can result 
in increased myocardial cell damage and necrosis leading to the formation of an area 
o f myocardial infarction (Otani et a l., 1984).
Clinically, the major cause of ischaemia is blockade of major coronary blood 
vessels. However, the degree of infarction is usually smaller than the area perfused 
by the occluded artery because of influential factors such as vasodilatation and the 
existence and initiation o f collateral flow (Rivas et al., 1976; Jugdutt et a l., 1979).
1.2 M ETABOLISM  IN THE NORMOXIC MYOCARDIUM
1.2.1 General considerations
One aspect of this thesis is to examine the metabolic consequences of cardiac 
ischaemia on cardiac metabolism. In order to do this, it is first necessary to review 
the normal metabolic processes of the heart.
ATP is used in the activity of various intracellular enzymes, to maintain ionic 
equilibrium in the cell and to sustain the contractile process of the myocardium.
The major substrates for the production of ATP in myocardial cells are glucose and 
fatty acids although lactate, ketone bodies and proteins are also utilised. Limited 
amounts of endogenously stored glycogen and triglyceride are also available. ATP 
can be generated in the myocardium by the main metabolic pathways of glycolysis 
(anaerobic) and oxidative phosphorylation (aerobic). In the normal myocardium, 
the production of ATP is strictly coupled to myocardial oxygen consumption
(LaNoue and Schoolworth, 1979) and the majority of myocardial ATP (90%) is 
produced by oxidative phosphorylation (Kobayashi and Neely, 1979). Before 
glucose can enter the TCA cycle, it must pass through the glycolytic pathway where 
some ATP can be produced even in the absence of oxygen. Under aerobic 
conditions, the metabolism of 1 mole of glucose, via glycolysis and the 
tricarboxylic acid (TCA) cycle, generates 38 moles of ATP. The production of 
ATP from fatty acid oxidation is dependent on the carbon chain length and, on a 
molar basis, is much greater than that from glucose oxidation. For example, the 
complete oxidation of 1 mole of palmitate can produce 130 moles of ATP. 
However, the P/O ratio for the oxidation of lipid (2.83) is lower than that of 
glucose (3.17) indicating that more oxygen (-12% ) is required to completely 
oxidise fat compared to carbohydrate (Opie, 1991). Lipids undergo B-oxidation 
prior to oxidation in the tricarboxylic acid (TCA) cycle and can only be metabolised 
to ATP under aerobic conditions.
1 .2 .2  The control o f  glycolysis
The entry of glucose into the myocardial cell is facilitated by a carrier-mediated 
system which can be stimulated by external factors such as insulin and adrenaline. 
The metabolism of 1 molecule of glucose in the glycolytic pathway yields a net 
synthesis of 2 molecules of ATP per 6-carbon sugar and produces acetyl-CoA 
under normoxic conditions or lactate under anaerobic conditions (Figure 1.1).
The major control points affecting the glycolytic rate are: 1) glucose transport,
2) hexokinase, 3) phosphofructokinase, 4) glyceraldehyde-3-phosphate 
dehydrogenase, 5) lactate dehydrogenase , 6) pyruvate dehydrogenase .
1) Glucose transport
The rate of uptake of glucose can be modified to meet the energy requirements 
o f the cell (e.g. insulin) and is also influenced by alternative substrate availability 
(Randle et al., 1963).
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Figure 1.1 The Glycolytic Pathway
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2) Hexokinase
This reaction catalyses glucose phosphorylation and uses 1 molecule of ATP in 
the process. The activity of hexokinase is inhibited by high concentrations of 
glucose-6-phosphate which allosterically modifies the enzyme. High ATP levels 
inhibit hexokinase activity, low ATP and high ADP, AMP and P; stimulate activity, 
consequently glucose phosphorylation varies with the energy status of the cell.
3) Phosphofructokinase
Possibly the key enzyme in the control of glycolytic rate, phosphofructokinase 
catalyses the formation o f fructose-1,6, bisphosphate from fructose-6-phosphate. 
This reaction also utilises one molecule of ATP and phosphofructokinase activity 
can be affected by a number of factors. Citrate, an intermediate of the TCA cycle 
has an important inhibitory effect on phosphofructokinase which slows glycolysis 
when the level of TCA cycle intermediates is high. This represents an essential 
factor in the control of glycolysis with respect to oxidative metabolism. 
Phosphofructokinase is also inhibited by decreased intracellular pH which has a 
critical inhibitory effect on the glycolytic rate during ischaemia (Rovetto et al.,
1975)
4) Glyceraldehyde-3-phosphate dehydrogenase
This enzyme catalyses the formation of 1,3, bisphosphoglycerate from 
glyceraldehyde-3-phosphate and NAD+ is reduced to NADH + H+ in the reaction. 
Under aerobic conditions, this reaction has no regulatory role. However, under 
anaerobic conditions, control of glycolysis shifts from the energy requirements of 
the cell (phosphofructokinase) to the ability of the cell to oxidise substrates. When 
the heart becomes unable to oxidise NADH, accumulation of NADH slows the 
glycolytic rate at this step in the pathway.
5) Lactate dehydrogenase
Under aerobic conditions, pyruvate is convened to acetyl-CoA by pyruvate 
dehydrogenase. In the aerobic heart, lactate produced by muscle activity is 
extracted from the blood and subsequently oxidised. Under anaerobic conditions,
if NADH accumulates, the reduction of pyruvate to lactate by lactate dehydrogenase 
allows a limited capacity to regenerate NAD+ from NADH and further glycolysis is 
achieved. The production o f lactate by this reaction coupled with the reduction of 
lactate oxidation during ischaemia leads to high lactate levels in the bloodstream.
6) Pyruvate dehydrogenase (PDH)
Pyruvate crosses the inner mitochondrial membrane and is oxidised to acetyl- 
CoA by PDH. PDH is a multienzyme complex containing 3 component enzymes, a 
decarboxylase, a dihydrolipoamide acetyltransferase and a dihydrolipoamide 
dehydrogenase. Together, this complex catalyses the formation of acetyl CoA, 
NADH and CO2 from pyruvate. PDH phosphorylation and dephosphorylation 
together with product inhibition regulate PDH activity in the heart. Phosphorylation 
of PDH, catalysed by PDH kinase, inactivates the enzyme. NADH also promotes 
phosphorylation o f PDH and consequently inhibits PDH kinase activity indirectly. 
This effect of NADH can be reversed by NAD+. PDH phosphate phosphatase 
reactivates PDH . During ischaemia, when NADH and acetyl-CoA accumulate, the 
formation of more acetyl CoA is inhibited and lactate is preferentially produced.
The phosphatase is also inhibited by citrate. This inhibition promotes fatty acid 
metabolism and represents an important regulatory mechanism for the integration of 
carbohydrate and lipid metabolism.
1.2.3 Lipid Metabolism
In the nonnoxic heart, free fatty acids account for < 0.1% of the total cellular 
fatty acid content (van der Vusse et al., 1982). Long chain fatty acids are esterified 
as phospholipids (86%) or neutral lipids, primarily triglycerides (13%) (Corr et al., 
1984). Fatty acids are major substrates for energy metabolism in the normoxic 
heart (Bing et al., 1954; Carlsten et al., 1961) and may be used in preference to 
glucose (Randle et al., 1963). Fatty acids increase myocardial oxygen consumption 
(Challoner and Steinberg, 1966; Mjos, 1971; Kjekshus and Mjos, 1972), an effect
which can be stimulated by catecholamines (Challoner and Steinberg, 1966) and is 
sensitive to inhibition by anti-lipolytic agents (Mjos, 1971; Mjos et al., 1974; 
Simonsen and Kjekshus, 1978).
Fatty acid uptake
Fatty acids are transported in the plasma to the heart either as non-esterified 
fatty acids bound to albumin (Moirisett e ta l ., 1975) or as triacylglycerol complexed 
to hydrophilic lipoproteins (Fredrickson eta l., 1958).
The myocardium has a high capacity for the extraction of circulating NEFA. In 
dogs, 55% of plasma NEFA can be extracted during a single passage through the 
cardiac vessels (van der Vusse et al., 1983) indicating the existence of an efficient 
uptake process. It has been suggested that the plasma NEFAralbumin ratio may be 
an important factor in the control of NEFA uptake and that a high NEFA:albumin 
ratio may result in excess unbound NEFA being transferred into heart muscle 
(Evans, 1964). Although a mass action effect has been proposed as the major 
factor controlling NEFA uptake (Spector, 1971), a more specific interaction o f the 
NEFA-albumin complex with sites on the luminal membranes of endothelial cells in 
the coronary vessels has also been proposed (Little et al., 1986). Rauch eta l, 
(1987), have suggested that the NEFA-albumin complex binds to a sarcolemmal 
albumin receptor before translocation of the NEFA across the sarcolemmal 
membrane and specific albumin receptors have been located on capillary 
endothelium cells in the heart (Ghitescu et al., 1986). A role for fatty acid binding 
protein (FABP) in the intracellular transport of NEFA has been proposed and the 
presence of FABP in myocardial cell types has been confirmed (Fournier and 
Rahim, 1985). Stremmel et al, (1985) have isolated a protein in cardiac cells which 
may facilitate NEFA transport across the capillary endothelium It has been 
suggested that transport of NEFA from the plasma to the site of 6-oxidation may 
involve a sequence of specific binding proteins. However, the precise mechanism 
underlying fatty acid uptake remains unclear.
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Triglycerides
Endogenous triglycerides are a major source of substrate in the normoxic 
myocardium and are preferentially oxidised in the presence of glycogen (Olson and 
Hoeschen, 1967). These triglycerides are synthesised from glycerol-3-phosphate 
and fatty acyl CoA (Kennedy, 1961) and the synthesis pathway is shown in Figure 
1 . 2 .
Labelled palmitate injected into the coronary arteries of dog hearts, in vivo , was 
rapidly incorporated into the endogenous triglyceride store (Klein et al., 1979) 
indicating that some exogenous NEFA undergoes esterification before oxidation. 
Synthesis and degradation of triglycerides is a cyclical process which releases 
glycerol and fatty acids (Shipp et al., 1964). The fatty acids are subsequently 
activated by combination with CoASH and enter the mitochondrial 6-oxidation 
pathway (Groot et aL, 1976). The breakdown of triglycerides by hormone- 
sensitive lipase activity is regulated by feedback control and is subject to product 
inhibition (Severson and Hurley, 1982; Stam and Hulsmann, 1985).
Metabolic fate o f  fattv acids
After transport across the sarcolemma, NEFA molecules are either oxidised 
within the mitochondria or incorporated into esterified fatty acids and stored as 
triglycerides, phosphoglycerides or cholesteryl esters (van der Vusse et al., 1987; 
Crass, 1972). Fatty acids are "activated" to long chain acyl-CoA esters by ATP and 
acyl-CoA synthetase. Long chain acylCoA is converted to long chain acylcamitine 
and is subsequently translocated across the inner mitochondrial membrane 
(Haddock et a l 1970, Brosnan and Fitz, 1971). Transfer within the mitochondria 
involves the activity of carnitine acyltransferase I which is located on the inner face 
of the outer mitochondrial membrane, the acylcamitine: carnitine transporter and 
carnitine acyltransferase II which re-forms acyl-CoA prior to 6-oxidation (Pande, 
1975; Ramsay and Tubbs, 1975). Carnitine acyltransferase I has been identified as 
a key regulating enzyme in lipid metabolism (Pauly et al., 1991) and the activity of 
this enzyme can be inhibited by endogenous malonyl CoA (Haddock et al., 1970;
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Figure 1.3 fi-oxidation of Fatty Acids
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Brosnan and Fitz, 1971). Within the mitochondria, the acetyl-CoA produced from 
long chain fatty acyl-CoA in the B-oxidation pathway (Figure 1.3) is further 
oxidised in the TCA cycle (Figure 1.4 and Section 1.2.4).
Oxidation of fatty acids by cardiac muscle results in an increase in oxygen 
consumption (Challoner and Steinberg, 1966). However, oxygen consumption is 
increased by only 13% in isolated rat hearts perfused with 1.2mM palmitate bound 
to 3% albumin compared to hearts perfused with glucose (Oram et al., 1973). Opie 
(1991) reported a similar value. This agrees with the theoretical increase expected 
of a shift from oxidation o f glucose with a P/O ratio of 3.2 to oxidation of fatty acid 
with a P/O ratio of 2.8. Therefore, for the same rate of ATP synthesis, more 
oxygen must be consumed when fatty acids are used as substrate and Opie (1975), 
reported that the complete oxidation of fatty acids requires 11 % more oxygen per C 
unit compared with the oxidation o f glucose. However, Challoner and Steinberg 
(1966) found that perfusion with high concentrations of palmitate increased oxygen 
consumption by 40% and Mjos (1971) reported an increase of 25% during 
perfusion with lipid and heparin in the dog. The discrepancy between the actual 
and theoretical values for oxygen consumption in the presence of fatty acids has led 
to the suggestion that excess lipid uptake results in an "oxygen wasting" effect in 
which ATP and oxygen are used in increased esterification of fatty acids into 
triglycerides (Ball, 1965), uncoupling of oxidative phosphorylation (Borst et a l., 
1962) and heat dissapation (Mjos and Kjekshus, 1971).
1.2.4 The Tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation
Further oxidation o f the acetyl-CoA produced by B-oxidation and by the PDH
complex takes place within the inner membrane of mitochondria where it enters the
TCA cycle on condensation with oxaloacetate to form citrate (Figure 1.4).
Oxidation in the TCA cycle produces GTP, carbon dioxide and reduced forms of
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Figure 1.4 The Tricarboxylic Acid Cycle
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nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2).
Reoxidation of NADH and FADH2 also takes place in the mitochondria] inner 
membrane via electron transport. The transfer of a pair of electrons from NADH or 
FADH2 to the final acceptor, molecular oxygen, completes an electrochemical 
proton gradient across the mitochondrial inner membrane. Coupling of the energy 
available in this gradient to that required for the synthesis of ATP from ADP and 
inorganic phosphate occurs via the ATP synthetase enzyme. This protein complex 
is located in and on the inner membrane of the mitochondria. Before ATP can be 
used for cytosolic reactions, it must therefore be transported out of the mitochondria 
and this is achieved by adenine nucleotide translocase. The ATP transported is 
converted to creatine phosphate by creatine phosphokinase, located in the space 
between the two mitochondrial membranes, and ADP is liberated. The ADP re­
enters the mitochondrial matrix and creatine phosphate is converted to ATP by 
creatine phosphokinase, at the sites of ATP hydrolysis e.g. contractile proteins.
1.3 THE EFFECTS OF ISCHAEMIA ON MYOCARDIAL FUNCTION  
AND METABOLISM
Both acute and sustained ischaemia result in characteristic changes to 
myocardial function through energy deprivation and loss of ionic homeostasis and 
cell structure (Hearse, 1980).
1.3.1 Cell S tru c tu re
Hearse (1980) has described, in detail, the time-dependent sequence of cellular 
events induced by ischaemia. One of the earliest structural alterations is cell 
swelling due to osmotic changes resulting from ion imbalance. This is followed by 
mitochondrial and t-tubule swelling.
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In a study of acute ischaemia (30-40mins) induced by coronary artery occlusion 
in dogs, Jennings and Ganote (1974) found swollen mitochondria, decreased 
matrix density and deposits o f amorphous densities within the matrix space. The 
appearance of these amorphous densities within the mitochondria has been 
associated with the accumulation o f lipid metabolites (Feuvray and Plouet, 1981).
Longer periods of ischaemia result in contracture development, myofibrillar 
disruption, extensive cellular oedema and cell membrane damage. At later stages, 
proteins and enzymes leak from the cells (Hearse, 1980).
An important feature identified by Feuvray (1981) is that even after global 
ischaemia, ultrastructural changes were not homogenous indicating that the degree 
of ischaemia may vary within the affected area of myocardium.
1.3.2 Contractile Function
Two main changes to contractile function are evoked in response to ischaemia. 
Firstly, there is a rapid loss of contractile force, then as the ischaemic episode 
progresses, contracture develops when the ability to maintain the normal diastolic 
tension is lost.
1.3.2.1 Factors contributing to loss of  contractile force
The possible mechanisms of acute contractile failure have been reviewed by 
Allen and Orchard (1987). The relationship between ATP depletion and contractile 
failure is unclear. It has been suggested that contractile failure develops before 
substantial loss of high energy phosphates (Fawaz et al., 1957; Pool et al., 1966) 
while others have found that high energy phosphate loss preceeds or parallels this 
event (Hearse, 1979).Other potential mechanisms which have been considered 
include changes to the action potential, impairment of the contractile process and 
loss of calcium homeostasis.
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Changes in action potential configuration
Several studies have reported a positive correlation between action potential 
duration (APD) and the contractile amplitude in the normoxic heart (Vaughan 
Williams, 1959; Braveny and Sumbera, 1970; Morad and Goldman, 1973).
Others have found no such correlation (Sleator et al., 1964; Sumbera, 1970; Allen, 
1977). Although the reported changes in APD in both ischaemia and hypoxia are 
variable (Downar et al., 1977), shortening of APD is a consistent finding in both 
conditions (McDonald and MacLeod, 1973; Vleugels et al., 1980; Janse and 
Kieber, 1981). Metabolic inhibition (Kohlhardt and Kubler, 1975) or increased 
intracellular H+ (Kohlhardt et al., 1976) have been shown to cause a reduction in 
intracellular Ca++ Changes in Ca-1-1- current could also contribute to APD shortening 
(Vleugels et al., 1980). APD shortening has been associated with a reduction in the 
plateau (phase 2) of the action potential (Figure 1.5) and this may reflect decreased 
Ca++ entry via the slow inward current (Kholhardt and Kubler, 1975; Irisawa e ta l., 
1983). It has been demonstrated that the failure of contractility in hypoxic and 
ischaemic hearts is not due to a corresponding reduction of the Ca++ transient (Lee 
et al., 1988; Kihara et al., 1989; Koretsune and Marban, 1990), suggesting that 
contractile failure during ischaemia may be due to impairment of the Ca++ mediated 
excitation-trigger mechanism. However, other studies have not confirmed this 
finding ( Kihara et al., 1989 and have reported a decrease in the Ca++
transient.
A reduction in Ca++ release from the sarcoplasmic reticulum has been 
suggested as a possible mechanism (Allen and Orchard, 1983).
Potassium accumulation in the extracellular space is a common feature in 
ischaemia (Aksnes, 1992) and is associated with membrane depolarisation and APD 
shortening (Caimeliet, 1978). Vleugels et al (1980), suggested that an increase in 
K+ outward current was the major component of APD shortening in hypoxia and 
this event has been linked to the activation of ATP-dependent K+ channels (Noma
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Figure 1.5 The Cardiac Action Potential Configuration
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and Shibasaka, 1 9 8 5 ;  Stanfield, 1 9 8 7 ) .  However, it has been shown that the 
changes in extracellular K+ associated with ischaemia have only slight effects on 
contractility (Kavaler et a l., 1 9 7 2 )  and no correlation was found between APD 
shortening and early contractile failure under anoxic conditions (McDonald and 
MacLeod, 1 9 7 3 ) .  The hypothesis that contractile failure during ischaemia is a 
consequence of K atp  channel activation due to decreased ATP levels has not been 
fully accepted. One reason for this has been the lack of correlation between the 
decrease in ATP levels and the rate and degree of contractile failure (Elliot et al., 
1 9 8 9 ;  Arai et al., 1 9 9 2 ) .  As a result, compartmentation of ATP within the cell has 
been postulated (Gudbjarson et al., 1 9 7 0 ;  Bricknell and Opie, 1 9 7 8  ) and 
inhomogeneity of ATP concentrations within or between ischaemic cells has been 
proposed (Nichols et al., 1 9 9 1 ;  Allen and Orchard 1 9 8 7 ) .
Inorganic phosphate ( P j )  and protons ( H + )  have also been implicated in loss of 
contractilty during ischaemia. The Pi concentration rises at an early stage following 
the onset of ischaemia (Matthews et al., 1 9 8 1 ;  Allen at al., 1 9 8 5 ) .  Theoretically, a 
2 0 %  decrease in [ C r P ]  can account for an increase of 1 6 0 %  in [ P j ]  (Allen and 
Orchard, 1 9 8 7 ) .
1.3.2.2 Factors contributing to contracture development
Decreased ventricular distensibility has been associated with impaired 
myocardial relaxation during ischaemia (McLarin eta l., 1973; Bourdillon et al.,
1983). Diastolic relaxation is achieved by restoration of the intracellular resting 
calcium level (0. l|iM ) through the activity of energy-dependent C a ^  ATPase 
(Bricknell et al., 1981). Although contracture development during ischaemia has 
been closely associated with the decline of ATP (Hearse et al., 1977), several 
hypotheses have been proposed as potential mechanisms for this event:
1) Imbalanced cytosolic calcium homeostasis due to ATP deficiency (Nayler et al.,
20
1979).
2) Increased sensitivity of contractile proteins to calcium as a result of changes to 
Mg-n\ ATP and H+ (Holubarsch eta l., 1982).
3) Development of rigor complexes (Hearse et al., 1977; Bing and Fishbein, 1979; 
Allen and Orchard, 1983).
Contracture development may further restrict coronary blood flow through
subendocardial tissue exacerbating ischaemic damage (Bricknell et al., 1981) and
the resulting physical stress imposed on the myocytes may lead to increased
membrane permeability (Ganote et a l., 1981). This may also contribute to
reperfusion damage through defects in the glycocalyx and lipid bilayer (Frank et al.,
1982) caused by exposure to low extracellular calcium ( Zimmerman and Hulsmann
1966; Hearse eta l., 1978; Rich and Langer, 1982) and decreased oxygen
availability (Ganote and Kaltenbach, 1979) during the ischaemic period. Under in
vitro conditions, contracture development is dependent on the substrate supplied
(Lipasti eta l., 1978; Bricknell and Opie, 1984) and can be influenced by
interventions which alter ATP utilisation (Nayler et al., 1978).
The source of ATP production during ischaemic episodes may be important and
some evidence exists to support the theory that glycolytic ATP has a specific role in
maintaining diastolic relaxation and preventing contracture during ischaemia
(Hearse and Chain, 1972; Bricknell eta l., 1981; Doorey and Barry, 1983; Weiss
and Hiltbrand, 1985). Allen et al (1985), showed that hypoxic contracture was
dependent on simultaneous inhibition of oxidative phosphorylation and glycolysis
and contracture development has been shown to be lower in hearts perfused with
glucose compared to hearts perfused with acetate or under glucose-free conditions
(Bing et al., 1975). However, whether contracture is due to low ATP or high
calcium availability at the myofilaments remains unclear (N ayleretal., 1988).
Sarcoplasmic reticular dysfunction
In humans, the calcium release channel in the sarcoplasmic reticulum (SR) is
impaired in chronic ischaemia ( Movesesian et al., 1989; Brillantes et al., 1992) and
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impaired SR function has been associated with post-ischaemic "stunned" 
myocardium (Krause et al., 1989). Extensive swelling and distortion of the SR has 
been reported during 20-30 minutes of ischaemia (McCallister et al., 1978; de Leiris 
and Feuvray, 1977) and this damage has been attributed to decreased Ca+'+ATPase 
activation as a result of decreased high energy phosphate cycling and acidosis 
(Mandel, 1982; Krause and Hess, 1984). Recently, Kaplan e ta l  (1992), have 
indicated that sarcoplasmic reticular dysfunction is due to reduced Ca++ uptake 
rather than release. Calcium uptake into the SR has been shown to be impaired 
during ischaemia (Dawson et al., 1980). Sarcoplasmic reticular dysfunction has 
been implicated in the increase of intracellular calcium in ischaemic myocytes 
(Krause and Hess, 1984) and interventions which deplete calcium stores in SR 
have been shown to reduce the rise in [Ca-*-*-]; which occurs during ischaemia 
(Schoutsen et al; 1989; Northover, 1991). Increased calcium at the level o f the 
myofilaments (Lodge and Gelbland, 1988) and activation of Ca++ ATPases (Barry 
et al., 1987) may also increase the rate of ATP depletion leading to rigor 
contraction.
Intracellular calcium
The level of free Ca++ within the cell, at any time, is the net result o f Ca++ 
influx, Ca++ efflux, the capacity for Ca++ storage in organelles and the buffering 
capacity of cytosolic proteins.
Harding and Poole-Wilson (1980), have suggested that contracture 
development during hypoxia is independent of a net gain in calcium and Bourdillon 
and Poole-Wilson (1982), found no net increase in uptake or efflux of calcium 
during the ischaemic phase in ventricular tissue. Others have reported that total 
cystolic calcium rises during ischaemia (Marban et al., 1987; Steenbergen eta l., 
1987) suggesting that the increase in [ C a + + ] j  observed during ischaemia may
represent release from an intracellular source. An increase in free intracellular 
calcium has been reported to occur as early as 1-2 minutes after the onset o f global
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ischaemia (Lee et a l., 1987). Allen and Smith (1985), have shown that during 
hypoxia, contracture precedes a rise in [Ca++]i and these results are supported by 
studies using aequorin (Cobbold and Bourne, 1984). However, interpretation of 
changes in [Ca-*-*-]j from different studies requires caution since hypoxia and
ischaemia may produce different effects on calcium homeostasis (Kihara et a l., 
1989).
Sodiumi calcium exchange
More recently, increased calcium uptake related to Na+ accumulation under 
ischaemic conditions has been reported (Tani and Neely, 1989, 1990). Under 
normal conditions, Na+/Ca++ exchange is thought to promote calcium efflux 
(Mullins, 1979; Caroni and Carafoli, 1983;). In normoxia, the maximal calcium 
transport velocity of this process is 30-fold higher compared to the sarcolemmal 
Ca++/Mg++ ATPase (Caroni and Carafoli, 1981) but the activity of Na+/Ca++ 
exchange may be reduced in ischaemia (Bersohn et a l., 1982). The increase in 
[Na+]j observed during ischaemia may also be a consequence o f increased H+/Na+
exchange coupled with decreased Na+/K+ATPase activity (Ladzunski eta l., 1985; 
Tani and Neely, 1990). Lazdunski e ta l (1985), have proposed that a combination 
of Na+/H+ and Na+/Ca++ exchange would result in Ca++ influx with subsequent 
Ca-1-*- overload on reperfusion.
Agents which inhibit Na+ channels (Takeo et a l., 1989) or otherwise prevent 
Na++overload (Boddeke et al., 1989), have been shown to have beneficial effects 
under ischaemic conditions.
1.3.3 Metabolic function in ischaemia
Although the metabolic consequences of anoxia and hypoxia can be
fundamentally different from those of ischaemia (Hearse, 1980), these conditions
have proved useful in delineating some o f the effects of ischaemia.
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The principal difference between ischaemia and anoxia/hypoxia is the
maintenance of perfusion and substrate supply throughout the experimental period.
This prevents accumulation of metabolic products and, in particular, removes the
inhibitory effect o f lactate (i.e. H+) on phosphofructokinase. Consequently, under
conditions of anoxia and hypoxia, glycolysis contributes to ATP production, while
in ischaemia the activity o f this metabolic pathway will be progressively inhibited.
The principal events resulting from ischaemia are 1) deprivation of oxygen, 2)
deprivation of substrate supply and 3) the inability to remove the products of
cellular metabolism. As already mentioned the effects of ischaemia on cell
metabolism and structure are critically dependent on the duration of the ischaemic
insult (Hearse, 1980) and it is well recognised that a time-dependent transition from
reversible to irreversible cell damage occurs during ischaemia. In the absence of
oxygen, electron transport and oxidative phosphorylation are arrested and the
cytosolic and mitochondrial levels o f ATP decrease.
Glvcolvsis in the ischaemic heart
Under anaerobic conditions, it has been estimated that, at maximum, glycolysis
could supply 20% of the ATP required for normal cell function (Opie, 1968).
Anoxia accelerates glucose utilisation (Neely and Morgan, 1974) but in ischaemia,
although initially stimulated, the glycolysis pathway is inhibited at the level of
phosphofructokinase (Kubler and Spiekerman,1970) and glyceraldehyde-3-
phosphate dehydrogenase (Rovetto et al, 1975) by H+ accumulation .
This inhibitory effect reflects a reduction in flux through the glycolytic pathway, not
a lower rate of glucose transport, and cannot be reversed by increased glucose and
insulin. (Rovetto e ta l., 1973).
The association of enzyme release with infarcted myocardium has been well
described (Hearse, 1977; Lott and Stang, 1980). Under in vitro conditions,
enzyme release has been shown to be affected by substrate in that release is lower in
glucose perfused hearts compared to hearts perfused with free-fatty acid (deLeiris
and Opie, 1978). It is thought that the positive effects of glucose and insulin in the
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ischaemic heart are related to improved carbohydrate utilisation and a reduction in 
accumulated lipid intermediates (Farah and Alousi, 1981). ATP production from 
increased glycolytic flux (Opie and Bricknell, 1979) may diminish the effects of 
free-fatty acid (Kurien and Oliver, 1970; Weishaar eta l., 1977) and acyl CoA 
accumulation (Shug et a l., 1975). It has recently been suggested that the protective 
effect of glucose may be affected by dietary lipids (Moreau and Chardigny 1991) 
although the mechanism by which glucose exerts its protective effect remains under 
debate.
Experimental evidence indicates a protective role for glucose in the ischaemic 
myocardium (Opie and de Leiris, 1979; Opie and Bricknell, 1979). It has been 
suggested that ATP produced in the cytoplasm from glycolysis may have a special 
role in the maintenance o f membrane integrity and electrical stability (Bricknell and 
Opie, 1978a). Thus, glucose has been shown to protect against arrhythmia 
development in coronary ligated dog hearts (Surer et al., 1976; Russell and Oliver., 
1979.) in vivo and in vitro (Dennis et al., 1979) and on reperfusion (Bricknell and 
Opie, 1978b). Elevation o f extracellular glucose has also been shown to prevent 
shortening of action potential duration (APD) induced by inhibition of oxidative 
phosphorylation or hypoxia (MacLeod and Daniel, 1965; MacLeod and Prasad,
1969). APD shortening through glycolytic inhibition by 2-deoxyglucose is not 
affected by increased glucose indicating that increased glycolytic flux may be the 
main contributory factor in the protective effect o f exogenous glucose (Nakamura et 
al., 1989).
Intracellular acidosis
The effect of acidosis in conditions of oxygen deprivation may be two-fold. 
Through its negative inotropic effect, acidosis may conserve ATP and exert a 
protective effect (Bing et al., 1973) or it may decrease glycolytic production of ATP 
and enhance ischaemic damage. Protons accumulating in the cell arise from a 
number of sources including adenine nucleotide degradation, accumulation of 
carbon dioxide from residual oxidative metabolism, decarboxylation reactions and
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triglyceride cycling (Opie, 1976; Gevers, 1977). During sustained ischaemia, 
acidosis may cause activation of lysosomal hydrolases and lipoprotein lipases 
which can contribute to loss of cell structure (Ricciuti, 1972; Weglicki et al.,
1974).
Changes in intracellular pH are dependent on the degree and duration of 
ischaemia. Nuclear magnetic resonance studies have shown that, in global 
ischaemia and coronary artery occlusion, intracellular pH changes by about lpH  
unit (Pieper eta l., 1980; Flaherty et al., 1982; Malloy et al., 1986). Measurement 
of extracellular pH in ischaemic hearts have reported changes of 0.3-0.7pH units 
during transient and partial ischaemia (Momomura et al., 1985; Ichihara et al., 
1986). However, studies in cardiac muscle have shown that changes in 
extracellular pH are not representative of the change in intracellular pH. Ellis and 
Thomas (1976) have shown that the [pH]j changes by 0.2pH units for 1 unit 
change in [pH]c, indicating that studies using extracellular acidosis to investigate 
the effects of ischaemia may significantly overestimate the effect on intracellular 
pH.
Although the capacity o f glycolysis for ATP production in relation to the 
requirements of a normal cell may be limited under ischaemic conditions, cellular 
demands on energy reserves are markedly reduced by the subsequent decrease of 
contractile activity in the ischaemic area. In addition, collateral flow and incomplete 
occlusion will result in ischaemic conditions of varying intensity which will affect 
the degree of inhibition of glycolytic metabolism.
Glvcogen metabolism in the ischaemic heart
Glycogen represents a stored form of glucose that can be readily mobilised in 
heart muscle. It is present in the form of granules localised around the 
mitochondria, interfibrillar sarcoplasm and subsarcolemmal cistemae of the 
sarcoplasmic reticulum. The distribution of glycogen within the myocardium is not 
homogenous and levels in endocardial tissue are twice that found in the epicardium 
(Jedieken, 1964).
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Figure 1.6 The Enzymatic Control of Glycogen Metabolism
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Glycogen metabolism is controlled by the enzyme, phosphorylase, which exists 
in phosphorylated and dephosphorylated forms. Glycogen phosphorylase activity 
is under hormonal as well as intracellular control and regulates glycogen 
mobilisation and synthesis in conjunction with glycogen synthetase. When both 
enzymes are phosphorylated (e.g. as a result o f cAMP elevation and activation of 
protein kinase A), glycogen synthetase is present in the inactive b form and 
phosphorylase is activated (Figure 1.6). Under these conditions, glycogen 
synthesis is inhibited and mobilisation is accelerated. When both enzymes are 
dephosphorylated, glycogen synthesis is accelerated and mobilisation is inhibited. 
The significance of phosphorylation-dephosphorylation conversion o f enzyme 
activity in metabolic control mechanisms has been reviewed by Chock et a l.,
(1980).
The potential for glycogen to exert a protective effect during ischaemia is 
derived from the anaerobic synthesis of ATP through maintained glycolytic flux 
despite inadequate supply o f exogenous substrate. In theory, utilisation of 
glycogen would be advantageous since metabolism of 1 mole of glucose via 
glycogenolysis would yield 3 ATP molecules compared to 2 ATP molecules from 1 
mole of glucose supplied by uptake. Several studies have demonstrated glycogen 
utilisation in the ischaemic, hypoxic and anoxic myocardium (Neill et al., 1963; 
Weissler et al., 1968; Lolley et al., 1979; Grover et al., 1981). This may be caused 
by elevated cAMP and/or Ca++ mediated processes (Rovetto et al., 1975) and 
activation of glycolytic enzymes (Rovetto et al., 1973). Activation of 
phosphorylase has been observed in the ischaemic myocardium (Wollenberger and 
Krause, 1968; Kublerand Spiekerman, 1970; Sakai and Abiko, 1981) but 
phosphorylase activity can also be increased by inorganic phosphate and AMP as 
well as reduced ATP and glucose-6-phosphate concentrations (Opie, 1968). In 
addition, changes to metabolism in response to ischaemia have been observed in the 
absence of elevated cAMP (Podzuweit et al., 1978). Therefore, the role of cAM P
in glycogenolysis during ischaemia is still unclear.
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Although the ability of glycogen metabolism to alter the pathogenesis of the 
severely ischaemic area may be limited by glycolytic inhibition, it may be more 
important in the so called "border zone" where some degree of flow and 
oxygenation may continue. Rovetto et al., (1973), have reported that glycogen 
utilisation is much faster in anoxic rat hearts where perfusion was maintained 
compared to flow restricted (ischaemic) hearts and hearts with increased glycogen 
stores have been shown to have improved tolerance to conditions of oxygen 
deprivation (Scheur and Stezoski, 1970; Hewitt et al., 1973). However, the 
conclusions on the contribution o f glycogen to ischaemic energy production have 
been drawn from models using ischaemia, hypoxia and anoxia and require careful 
interpretation since anaerobic potential differs greatly in these models (Hearse 
1980).
Lipid metabolism in the ischaemic heart
Ischaemia is associated with altered lipid metabolism (Jodalen et al., 1985) and 
the potential adverse effects of accumulated fatty acids and other lipid intermediates 
in the ischaemic myocardium have been widely investigated (Liedtke, 1981; Katz 
and Messineo, 1981; Corr et al., 1984; H utterand Sobol, 1992).
A rapid elevation of mitochondrial NADH/NAD+ and FADH2/FAD ratios
(Neely and Morgan, 1974) inhibits fatty acid oxidation at the level of NAD-linked B-
hydroxyacyl-CoA dehydrogenase (Moore, 1985), resulting in increased levels of
NEFA, acyl CoA and acylcamitine (Opie, 1979; van Bilsen et al., 1989; Hutter and
Sobol, 1992). In severely ischaemic myocardium, NEFA levels can increase 6-7
fold (van der Vusse et al., 1982) while, under ischaemic conditions in vivo ,
acylcamitine levels have been reported to increase 18 fold (Liedtke et al., 1978).
Additionally, phospholipases are activated (Katz and Messineo, 1981) and
lysophospholipid levels are raised (Corr et al., 1982). In patients with myocardial
ischaemia, plasma fatty acid levels do not generally increase until 1-2 hours after the
onset of symptoms (Vetter et al., 1974). However, tissue levels of free fatty acid
can change, independently of plasma levels, through catecholamine mediated
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lipolysis and increased myocardial extraction of free fatty acid from the blood 
(Simonsen and Kjekshus, 1978; Vik-Mo et a l., 1979, 1981).
Free fatty acids and their metabolites have been associated with a number of 
effects which could contribute to ischaemic damage. They are amphiphilic and have 
been implicated in a number of membrane dysfunctions (Katz and Messineo, 1981; 
Corr et al., 1984). High concentrations o f fatty acids cause uncoupling of 
mitochondrial respiration (Borst et a l ,  1962) and the velocity and capacity of 
mitochondrial calcium uptake is decreased (Piper et al., 1983). Increased 
endogenous levels of NEFA may exert negative inotropic effects (Henderson et al.,
1970), alter mitochondrial permeability (Wotzak, 1974) and accelerate 
glycogenolysis during ischaemia (Cowan and Vaughan Williams, 1980). NEFA 
increase cardiac oxygen consumption (Mjos, 1971) and shorten action potential 
duration (Cowan and Vaughan-Williams, 1977). Action potential shortening is an 
early event in ischaemia (McDonald and MacLeod, 1973) and has been associated 
with the rapid loss o f contractile function in the ischaemic myocardium (Nayler et 
al., 1979). Elevated free fatty acids can also inhibit glucose oxidation (Renstrom et 
al., 1990) which may affect regions of the ischaemic myocardium during ischaemia 
(Piper and Das, 1986) and reperfusion (Lopashuk et al., 1990) through impaired 
glycolysis and increased oxygen consumption.
NEFA accumulation has been observed in glucose-perfused hearts subjected 
to no-flow ischaemia (van Bilsen et al., 1989). Under these conditions, tissue 
levels of NEFA increased between 30 and 60 minutes (Prinzen et al., 1984). 
However, the increase in fatty acid intermediates during no-flow ischaemia was 
minimal (Neely et al., 1979). These observations indicate that endogenous lipid 
contributes to NEFA accumulation during no-flow ischaemia. While levels of 
acylcamitine and acylCoA are not increased under no-flow ischaemic conditions 
(Poulson et al., 1984), NEFA and fatty acid metabolites increase under conditions 
of reduced flow and may exert profound effects on the ischaemic cell (Corr et al.,
1984). In dog hearts in vivo, coronary occlusion resulted in increased levels of
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acyl CoA and acylcamitine within 15 minutes of ischaemia (Suzuki et a l 1981) 
indicating that the increase in fatty acid metabolites is a rapid event. Mitochondrial 
accumulation of long chain acylCoA and increased cytosolic levels of acylcamitines 
(Idell-Wenger et al., 1978; Moore et al., 1984) are most pronounced in ischaemic 
hearts perfused with exogenous NEFA (Shug et al., 1978; Neely et al., 1979). In 
addition, high levels of plasma NEFA increase tissue accumulation of lipid 
intermediates during ischaemia (Liedtke et al., 1978).
Lipid intermediates
Long chain acyl-CoA and acylcamitines have been identified as the major 
metabolites of fatty acid metabolism and have been shown to affect a number of 
intracellular mechanisms. Mitochondrial respiration is inhibited by high 
concentrations of long chain acylcamitines and acyl-CoA (Pande and Blanchar, 
1971; Wood eta l., 1977). Palmitoyl carnitine alters Ca++ pump activity (Barry et 
al., 1978; Pitts et al., 1978) and enhances Ca-*-*- release (Pitts eta l., 1978; Messineo 
et al., 1982) by the sarcoplasmic reticulum (SR). These effects are dependent on 
the carbon chain length and concentration of acylcamitine (Owens et al., 1982). 
Low concentrations of palmitoyl carnitine (5-50|iM) stimulate C a ^  ATPase and 
Ca++ binding in the SR and high concentrations (50-200|iM) inhibit these activities 
(Adams et al., 1979). Palmitoyl carnitine may alter contractile force through 
inhibition of NaVCa-*-*1- exhange and increased Ca+-t' entry (Inoue and Pappano,
1983). The effect o f palmitoyl carnitine on Na+/K+ATPase activity is unclear 
(Adams et al., 1979; Osomio-Vargas eta l., 1981; Owens et al 1982) but inhibition 
of sodium pump activity by palmitoyl carnitine has recently been demonstrated in 
myocytes (Tanaka et al., 1992). The activity of palmitoyl carnitine is enhanced at 
pH values (6.7) consistent with ischaemic conditions and the electrophysiological 
effects of palmitoyl carnitine are not produced by palmitic acid or carnitine (Corr et 
al., 1984).
Inhibition of adenine nucleotide translocase by long-chain acyl CoA has been
reported (Shug et al., 1975; Shrago, 1976; La Noue and Schoolwerth., 1979). In
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contrast, short-chain acyl CoA (Woldegiorgis et al., 1981) and long-chain
acylcamitine (Shrago et al., 1976) do not inhibit this enzyme indicating a specific
interaction which may be receptor-mediated (Woldegiorgis et al., 1982). During
prolonged ischaemia, acylcamitines may leak from the cytosol to the extracellular
space (Shug et al., 1978), and the effects induced by extracellular compared to
intracellular acylcamitine may differ. Experimental evidence shows that the
increase in acyl-CoA is largely mitochondrial but mitochondrial membrane
permeability can be increased by high concentrations of acyl CoA (Wojtczak,
1974). The proximity of increased fatty acid intermediates to intracellular
membranes during ischaemia has not been elucidated and although autolysis and
cell damage can occur in the absence of fatty acid intermediate accumulation (Neely
et al., 1979), the diverse effects o f these amphiphilic moieties indicate the potential
contribution of impaired lipid metabolism to ischaemic cell damage.
Catecholamines and cAMP
Under ischaemic conditions, catecholamine release has a major influence over
the metabolism of lipid and glycogen. Since the early report, by Forssman et al
(1952) that myocardial ischaemia is associated with increased catecholamine levels
in the blood, it has been confirmed in numerous studies that this event leads to
exacerbation of ischaemic damage (Raab, 1963). This is due to stimulation o f
adenylate cyclase activity and the subsequent elevation of cAMP (Wollenberger et
al., 1967). In early ischaemia, the elevation of plasma NEFA may be a
consequence of raised catecholamine levels (Oliver et al., 1968) and Opie et al.
(1971) have suggested that adrenergic stimulation leads to increased lipid
metabolism. This causes elevated myocardial oxygen consumption (Mjos 1971)
and thus, increases the ischaemic area (Kjeksus and Mjos 1972). Summanson and
Kjeksus (1978), suggested that the free fatty acid concentration was not of primary
importance in affecting myocardial oxygen consumption unless accompanied by
catecholamine stimulation. The true relationship between catecholamines and
changes in lipid levels is unclear however, because the time of increase of plasma
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catecholamines following ischaemia does not correlate with the increase in plasma 
NEFA levels (Velter et al., 1974). In addition, Stam et al (1987) have proposed 
that increased lipolysis during ischaemia results indirectly from simultaneous 
glycolytic stimulation (Schoonderwoerdeta l., 1987).
Despite the low oxidation capacity o f ischaemic tissue (Schuer and Brachfield., 
1966), it has been reported that free-fatty acid uptake is increased in ischaemic 
tissue in the presence of catecholamines (Vik-Mo eta l., 1979). This contrasts with 
the finding that NEFA uptake is reduced in ischaemic tissue (van der Vusse et al., 
1982). The fate of these fatty acids is thought to be triglyceride esterification 
(Schuer and Brachfield, 1966) and it has been found that triglyceride lipolysis and 
re-esterification is enhanced in ischaemic tissue (Hough and Gevers 1975; 
Brownsey and Brunt, 1977).
Triglycerides
Recycling of free fatty acids in the triglyceride pool may contribute to the energy 
wasting effects of free fatty acids (Vik-Mo and Mjos, 1981). Under in vitro 
conditions, it has been shown that degradation of endogenous lipids such as
triglycerides and phospholipids can increase myocardial levels of NEFA in the
\
absence of exogenous lipid substrate (van Bilsen et al., 1989). The release of 
glycerol and the increased tissue level o f glycerol-3-phosphate in ischaemic tissue 
is thought to reflect enhanced activity of the NEFA-triacylglycerol cycle which 
maintains an equilibrium between the rate of hydrolysis and synthesis of 
triacylglycerol (Vik-Mo and Mjos, 1981). This cycle is associated with ATP 
consumption required for activation of NEFA to form acyl-CoA for subsequent re- 
esterification. The mechanisms involved in the regulation of this cycle, under 
ischaemic conditions, are unclear. Karwatowska-Krynska and Beresewicz (1983) 
suggested that glycerol production during hypoxia was the result of endogenous 
catecholamine release but it has been reported that the increase in glycerol output 
during hypoxia is not sensitive to B-adrenergic blockade (Larsen et al., 1989).
More recently, Myrmel et al (1991) have concluded that increased fatty acid cycling
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is the result of mass action by increased levels of glycerol-3-phosphate produced 
during increased glycolysis.
Lipase activity
Ischaemic conditions favour increased lipolytic activity in the myocardium. , 
Increased lipolysis due to release o f endogenous catecholamines and increased 
lipase activation during ischaemia has been reported (Vik-Mo and Mjos, 1981; 
Heathers and Brunt, 1985). A hormone-sensitive lipase activated by 
catecholamines has been identified in adipose tissue (Belfrage et al., 1984) and a 
similar lipase is thought to be present in heart (Christian et al., 1969; Goldberg and 
Khoo, 1985). In addition, AMP induced stimulation o f myocardial triacylglycerol 
lipase activity has been reported (Schoonderweoerd eta l., 1987). Acyl-CoA 
accumulation will also promote fatty acid esterification (Neely and Moran, 1974; 
Liedtke, 1981).
Lipolysis o f endogenous triacylglycerols has been shown to be dependent on 
glycolysis (Schoonderwoerd et al., 1987). This has led to the conclusion that 
increased lipolysis in the presence of isoprenaline is the result of increased 
glycolytic flux (Clark and Patten, 1984) and not cAMP-dependent lipase activation. 
The mechanism underlying increased lipolysis during ischaemia remains unclear.
1.4 CLINICAL TREATM ENT OF MYOCARDIAL ISCHAEMIA
The clinical treatment of cardiac ischaemia has been aimed at increasing the
supply of oxygen and substrate and/or reducing the metabolic requirements of the
heart. The first discovery of an effective treatment for angina was by Brunton in
1867, when the beneficial effects o f nitrates were described. These compounds
relieved the restriction of flow through the coronary circulation by coronary
vasodilatation (Hollmann 1963). Reducing metabolic demand was achieved by
slowing the heart rate or decreasing the force of contraction in addition to reducing
34
preload and afterload by decreasing peripheral vascular resistance. This led to the 
development of 6-adrenoceptor blocking agents (Black and Stephenson, 1962) and 
drugs which effectively reduced calcium entry7 into cardiac and vascular cells 
(Fleckenstein 1977).
A new direction in the pharmacological treatment of ischaemia has evolved with 
the advent o f putative metabolic modulators. Direct intervention in cardiac 
metabolism has been attempted with the discovery of carnitine palmitoyl transferase 
1 inhibitors which alter myocardial oxygen consumption by diverting metabolism 
from free fatty acid towards glucose utilisation. The beneficial effects of oxfenicine 
(Higgins et al., 1980) and phenylalkyloxirane carboxylic acid (POCA) have been 
already been described (W olf et al., 1981).
1.5 AIMS OF THIS THESIS
It is clear that much remains unknown about the functional and metabolic 
consequences o f ischaemia in the myocardium. The studies described in this thesis 
were therefore directed:
1) To examine functional and metabolic changes induced by ischaemia in cardiac 
tissue by a comparison of different experimental models.
2) To investigate metabolic interventions which may directly modify the effects of 
cardiac ischaemia.
The primary purpose of this work is to evaluate the potential of reducing the
effects of ischaemia by altering metabolism within the myocardial cell. The
introduction (Chapter one) has highlighted the existence of metabolic differences in
the response to ischaemia dependent on the method used to induce oxygen
deprivation. Chapter two describes the methods and experimental techniques used
and Chapter three uses these methods in order to identify an in vitro perfused heart
model suitable for this evaluation. Chapter four demonstrates the consequences of
impaired glucose metabolism on the functional and metabolic responses to
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ischaemia and hypoxia and examines the effects o f palmitate on cardiac function 
during ischaemia. Chapter five describes the effects of ranolazine, a novel anti- 
ischaemic agent, on the ischaemic myocardium and investigates the possible 
mechanisms o f action o f this drug. The recently described ATP-dependent K+ 
channel has been associated with the myocardial response to ischaemia. Chapter 
six examines the effects o f altering the activity o f these channels in the myocardium 
and addresses the question o f their contribution to the contractile effects o f 
ischaemia.
The potential for interventions at a metabolic level in the treatment of cardiac 
ischaemia are discussed in Chapter seven.
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CHAPTER TWO 
MATERIALS AND METHODS
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2.1 BIOCHEMICALS AND CHEMICALS
All chemicals and biochemicals were of analytical standard and, unless 
otherwise stated, were obtained from Fisons Ltd, Loughborough, U.K., BDH Ltd, 
Glasgow, U.K., Sigma Chemical Co., Ltd, Dorset, U.K., Aldrich Chemical Co., 
Ltd, Dorset, U.K., Boehringer Ltd, Sussex, U.K. Radiochemicals were obtained 
from Amersham International pic, Buckinghamshire, U.K. Gases were supplied 
by BOC Ltd, Glasgow, U.K.
Enzymes
Arylamine acetyltransferase (EC 2.3.1.5), carnitine acetyltransferase 
(2.3.1.21), creatine kinase (EC 2 .1 3 2 ) ,  glucose-6-phosphate dehydrogenase (EC 
1.1.1.49), glutamine-pyruvate aminotransferase (EC 2.6.1.15), hexokinase (EC 
2.7.1.1), L-lactate dehydrogenase (EC 1.1.1.27), luciferase (EC 1.13.12.7), 
pyruvate dehydrogenase (PDH) complex (EC 1.2.4.1/ 2.3.1.12/ 1.8.1.4), PDH 
phosphate phosphatase (EC 3.1.3.4).
2.2 EXPERIMENTAL ANIMALS
Female guinea-pigs (Dunkin Hartley), in the weight range 200-400 g, supplied 
by Harlan Porcellus, Sussex U.K., were used in all studies.
2.3 METHODS
2.3.1 The Langendorff perfused heart preparation
The method was a modification of the isolated perfused heart preparation 
described by Langendorff (1895).
Female guinea-pigs (Dunkin Hartley, 200-400g) were killed by cervical
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dislocation. The thoracic cavity was opened and the excised heart was transferred 
into ice-cold heparinised physiological salt solution (pH 7.4) of the following 
composition (mM) : NaCl 118.4, KC1 4.7, CaCl2 1.9, NaHC03 25, MgSC>4 1.2, 
Glucose 11.7, NaH2PC>4 1.2, Heparin 1 unit/ml and aerated with 95%C>2, 5%CC>2. 
The oxygen tension o f the equilibrated perfusate at 37°C was measured using a 
blood gas analyser (Corning 168) and was within a range of 450-650mmHg.
Using fine dissecting scissors, extraneous tissue was carefully removed and the 
aorta was cannulated using an intravenous cannula (size 5FG, Portex Ltd, Kent, 
U.K.). The cannulated heart was attached to the outlet of a glass perfusion 
chamber (10ml volume). This chamber was enclosed in a water jacket which was 
thermostatically heated to 37°C using a water circulator (Churchill Instrument Co. 
Ltd, Middlesex, U.K.). The perfused heart was also enclosed within a humidified 
semi-sealed glass water jacket heated to 37°C (Figure 2.1a).
Each heart was retrogradely perfused through the aorta with heparin-free 
physiological salt solution pre-heated to 37°C. The perfusion rate was controlled 
using a peristaltic pump (Gilson, France) and the perfusion pressure was recorded 
using an in-line pressure transducer (type PDCR 75, Druck Ltd, Leicestershire, 
U.K.) located immediately above the aortic cannula. Each heart was perfused for 
an initial 30 minute equilibration period during which the perfusion flow rate was 
increased to a perfusion pressure of around 50mmHg. This resulted in flow rates 
o f 9 ± 2ml/min.
Electrical pacing
hi electrically-paced preparations,transmural stimulation (1ms duration, 12V) 
was delivered through two platinum electrodes attached to the ventricle walls. The 
stimulation frequency was set at 25% above the spontaneous heart rate using an 
electronic stimulator (type S88, Grass Instruments, Massachusetts, USA.). In 
unpaced preparations, each heart was allowed to beat at the spontaneous heart rate. 
The relative heart rates in unpaced and paced hearts are shown in Chapter 3.
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Mechanical measurements
A ligature was attached to the ventricular apex of each heart and this was 
connected, through a pulley system, to an isometric tension transducer 
(Dynamometer UF1, Lectromed Ltd, Hertfordshire. U.K.) mounted on an 
adjustable clamp. Mechanical force of contraction was recorded using an electronic 
recorder (type MX212, Lectromed Ltd.) connected through a pre-amplifier (type 
3559, Lectromed Ltd.) to the transducer. Simultaneous measurements o f heart rate 
were made using an electronic ratemeter (type 4522, Lectromed Ltd.) which was 
triggered by electrical signals from the pre-amplifier. Changes in perfusion 
pressure, were recorded via a pressure transducer (type PDCR 75, Druck Ltd.) 
connected to a pressure pre-amplifier (type 4820, Lectromed Ltd.).
After the heart had been perfused for approximately 15 minutes, the tension on 
the ligature between the ventricular apex and the transducer was increased until the 
maximum force of contraction was achieved. The tension applied to each heart was 
equivalent to a load of around 7 g.
Collection o f samples for biochemical analysis
Miniature glass filter funnels were used to direct the perfusate collected from the 
ventricular apex of the heart into pre-cooled glass vials (10ml volume). The 
samples were immediately transferred to an ice bath (4°C) and the metabolite 
concentration and enzyme activities were assayed within two hours of collection.
At the end of each perfusion, hearts retained for biochemical analysis were 
frozen using W ollenberger clamps pre-cooled in liquid nitrogen. In this way, 
metabolic arrest was achieved without removing the hearts from the perfusion 
apparatus. The hearts were quickly weighed, wrapped in tinfoil and were stored 
under liquid nitrogen until the tissue metabolite content was analysed.
2.3.2 The isolated papillary muscle preparation
Guinea-pigs (Dunkin Hartley, 200-400g) were killed by cervical dislocation.
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The thoracic cavity was opened and the excised hearts were transferred to a beaker 
of ice cold physiological salt solution of the following composition (mM); NaCl 
146.5, KC1 6.0, MgCl2 1.0, Trizma HCI 7.28, Trizma base 2.74, CaCl2 2.0
Glucose 5.0 and aerated with oxygen. The pH of this solution was 7.8 at 40C and
7.4 at 370C.
Each heart was removed and placed in a petri dish containing the ice cold 
physiological salt solution and extraneous material was removed. Each heart was 
transferred to a dissecting dish and secured by dissecting pins at the ventricular 
apex and the left ventricle. Under a binocular microscope (Model 22995, PZO, 
Warsaw, Poland.), an incision was made down the side o f the right ventricle. The 
right ventricle wall was pinned back from the heart and the papillary muscle, 
attached to the inner wall o f the ventricle, was exposed. At one end of the muscle, 
the tendon (white and translucent) was cut and detached from the ventricle wall.
This allowed the muscle to be lifted up and dissected out of the ventricle.
Each muscle was then transferred to a continuous flow perspex organ bath 
(Figure 2. lb) and anchored in position by a pin which was placed through the end 
of the muscle. The tissues were superfused at 5ml/min with physiological salt 
solution and the flow rate was controlled using a peristaltic pump (type 502, 
Watson-Marlow Ltd, Cornwall, U.K.). Each muscle tendon was attached to an 
isometric force transducer (type 875, AME, Horten, Norway.). The temperature of 
the perfusate was monitored by a thermistor located within the superfusion chamber 
and this thermistor was connected to a peltier heat controller (Firbank Electronics, 
Norfolk, U.K.) which maintained the temperature of the solution at 37°C.
Electrical pacing
Electrical impulses (0.5ms duration, 1Hz), were delivered through two
platinum wire electrodes located on either side of the organ bath. Voltage output
from the electronic stimulator (Firbank Electronics) was set at zero and was
gradually increased until the threshold voltage required to initiate a muscle
contraction was achieved. This voltage was usually 2-3 volts. After tension had
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Figure 2.1 The Langendorff heart and papillary muscle 
perfusion apparatus
a) T he  L an g e n d o rff  h e a rt perfusion  system
b) T h e  p a p illa ry  m uscle su p erfu s io n  system
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been applied to the muscle, the threshold stimulating voltage was maintained at 1 
volt above threshold for the duration of the experiment.
Mechanical measurements
Mechanical force of contraction was recorded using an electronic recorder (type 
MX212, Lectromed Ltd.) connected through a pre-amplifier (Firbank Electronics) 
to the transducer. The tension between the muscle and the transducer was adjusted 
using a micromanipulator until the maximum force of contraction was achieved. 
The tension applied was equivalent to a load of around 500mg. Each tissue was 
allowed to equilibrate for 60 minutes prior to the start of the experiment.
Collection o f samples for biochemical analysis
At the end o f each perfusion, papillary muscles used for biochemical analysis 
were quickly transferred to a flask o f liquid nitrogen. The tissues were stored 
under liquid nitrogen until the tissue metabolite content was analysed.
2.3.3 Tissue metabolite extraction
Perfused heart tissue.
Each heart was removed from liquid nitrogen and transferred to a stone mortar 
pre-cooled in frozen CO2 pellets. Using a stone pestle cooled in liquid nitrogen, the
tissue was homogenised under liquid nitrogen to form a fine powder.
Around 400mg of frozen powdered tissue was weighed in a pre-cooled 
tinfoil container. This sample was quickly transferred to the pre-cooled mortar and 
liquid nitrogen was added. The mixture was homogenised with 1ml o f 6% (w/v) 
perchloric acid to form a dry white powder. The level of liquid nitrogen was 
maintained until homogenisation was complete. Using a pre-cooled metal spatula, 
the powder was transferred to a screw-topped cryotube (5ml capacity) which was 
placed in an ice bath to allow slow thawing of the sample.
When thawed, the sample was centrifuged in a bench centrifuge, at 2500xg, for 
5 minutes. The supernatant was transferred to a microcentrifuge tube (1.5ml
capacity) and neutralised using 5M potassium carbonate. The pH was monitored 
using pH indicator solution (Merck, pH4-10). The perchlorate precipitated as the 
K+ salt and carbon dioxide was evolved. The tube was sealed and centrifuged at 
12000xg for 2-3mins using a high speed centrifuge (Haemicrofuge, Wifug Ltd, 
Bradford, U.K.). After centrifugation, the supernatant was transferred to another 
microcentrifuge tube and stored at -20°C for subsequent metabolite assay.
Papillary muscle.
Papillary muscles were removed from liquid nitrogen and transferred to a glass 
micro-homogeniser (1ml capacity, Wheaton Scientific, New Jersey, USA.), pre- 
cooled in frozen CO2 pellets. A 30p.l volume of 6% (w/v) perchloric acid per lOmg 
sample was added to the tissues and the micro-homogeniser was transferred to an 
ice-bath to allow slow thawing o f the tissue/perchlorate mixture. The tissue and 
perchlorate were homogenised as thawing occurred and the homogenate was 
transferred to a microcentrifuge tube for centrifugation. An 8pJ volume of 5M 
potassium carbonate/IOO/il sample was used for neutralisation of the perchloric 
acid. The K+ perchlorate precipitate was removed by high-speed centrifugation, as 
described previously, and the neutralised extract was stored at -200C for metabolite 
determination.
2.3.4 Biochemical determination of enzyme activity and metabolite  
concentration
Measurements of metabolite concentrations in neutralised tissue extracts and
enzyme activities in perfusate samples were performed, using commercially
available standard assay methods (Boehringer Mannheim Diagnostics, East Sussex,
U.K.), on a Hitachi 705 automatic analyser (Boehringer Mannheim Diagnostics).
Most of the methods used are based on the changes in absorbance of NAD(P)H at
340nm where a millimolar extinction co-efficient of 6.22 was used in the calculation
of the metabolite concentrations or the rate of enzyme catalysed reactions. All
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reagents were prepared according to the manufacturer's instructions. For the 
analysis of tissue concentrations of adenosine triphosphate and creatine phosphate, 
samples of the neutralised extract were diluted appropriately in Tris acetate buffer 
(e.g. 1:100/ 1:25/)). Measurements of cyclic AMP and lactate were made in 
undiluted neutralised extract samples.
Lactate dehydrogenase
Lactate dehydrogenase (LDH) activity was measured spectrophotometrically 
(Boehringer Mannheim Kit No. 620092), using a modification of the method 
described by Weisshaar (1975) in which pyruvate is reduced to lactate and NAD+: 
Pyruvate + NADH + H+ Lactate dehydrogenase Lactate + NAD+
For the determination of LDH activity, an aliquot of 5|_il of perfusate sample 
was used in an assay volume of 4 20p l Final concentrations o f the reagents in the 
assay mixture were 50mM phosphate buffer pH 7.5, 0.18mM NADH and 0.6mM 
pyruvate. Absorbance was read at 340nm and was proportional to LDH activity in 
the original sample over the range, 0-1200 IU/litre. Where necessary, the samples 
were diluted and LDH activity was measured within this range.
Creatine nhosnhokinase
Creatine phosphokinase (CK) activity was measured spectrophotometrically 
(Boehringer Mannheim Kit No. 763870), using a modification of the method 
described by Gruber (1978) in which NADPH is produced in the oxidation of 
glucose-6-phosphate:
Creatine phosphate + ADP Creatine phosphokinase Creatine + ATP
Glucose + ATP Hexokinase Glucose-6-phosphate + ADP
Glucose-6-phosphate + NADP+ Glucose-6-phosphate Gluconate-6-phosphate+
dehydrogenasc
NADPH + H+
An aliquot of lOpl of perfusate or undiluted neutralised extract sample was used
in an assay volume of 4 2 0 p l Final concentrations of the reagents in the assay
mixture were 0.1M imidazole buffer pH 6.7, 20mM glucose, lOmM magnesium
acetate, 2mM EDTA, 2mM ADP, 5mM AMP, 2mM NADP, 20mM N-acetyl-
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cysteine, lOfiM di-adenosine pentaphosphate, >2.5 IU/ml hexokinase, >1.5 IU/ml 
glucose-6-phosphate dehydrogenase and 30mM creatine phosphate. Absorbance 
was read at 340nm and was proportional to CK activity in the original sample over 
the range, 0-1500 IU/litre. Where necessary, the samples were diluted and CK 
activity was measured within this range.
Pvruvate dehydrogenase
The frozen tissue powder (50mg) was extracted in lm l of ice-cold medium 
comprising lOOmM potassium phosphate pH 7.3, 2mM EDTA, ImM dithiothreitol 
and 50fil of rat serum/ml. The last two components were added on the day of use. 
The sample was disrupted in this medium using a Polytron homogeniser (setting 5, 
lcm  probe, Kinematic GmbH, Lucerne, Switzerland). EDTA was added to chelate 
Mg** thus preventing any alteration to the existing tissue level of active, non- 
phosphorylated PDHa by PDHa kinase and PDH-phosphatase activity. After 
homogenisation, the sample was centrifuged (10,000xg for 1 min) and an aliquot 
o f the infranatant removed for measurement o f PDHa content.
Pyruvate dehydrogenase (PDH) activity was measured using the method 
described by McCormack and Denton (1989). This assay utilises the acetylation of 
p-(p-aminophenylazo) benzenesulphonic acid (AABS) in the determination o f PDH 
activity:
Pyruvate + NAD+ + CoA Pyruvate dehydrogenase acetyl CoA + CO2 + NADH
Acetyl CoA + AABS Arvlamine acetyltransferase acetylated AABS + CoA
To 1.5ml of buffer (lOOmM Tris, 0.5mM EDTA and ImM  M gS04 pH 7.8 
containing 20p.l/ml of AABS solution and 0.2p.l/ml of mercaptoethanol added on 
the day of the assay), 20p.l of a substrate mixture, containing 36mg thiamin 
pyrophosphate, 23mg NAD+, 9mg pyruvate and 7.5mg CoA dissolved in lm l 
H2O, was added. The decrease in optical density was followed at 460nm after the 
addition of 20jrl arylamine acetyltransferase and 10-200fil of the extracted sample. 
AABS was prepared as the sodium or Tris salt in water at lmg/ml. The millimolar
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extinction co-efficient o f AABS was 6.5 at this wavelength. AABS was obtained 
from Pfaltz and Bauer, Stamford, CT0690; arylamine acetyltransferase was kindly 
supplied by Dr.J.G. McCormack, then of Dept.Biochemistry, University o f Leeds.
The amount of PDH present in the active form (PDHa), was expressed as a 
percentage o f the total amount o f PDH (PDHt) present in the sample. This was 
assayed, as described above, after the conversion o f ail o f the PDH-phosphate in a 
portion of the sample to PDHa. This was achieved by incubation with 20-40|il of 
pig heart PDH-phosphate phosphatase, in the presence of 25mM MgCl2 and ImM  
CaCl2, at 30°C, for 15 minutes. PDH-phosphate phosphatase was also kindly
supplied by Dr. McCormack.
Glucose
Glucose concentration was measured spectrophotometrically (Boehringer 
Mannheim Kit No. 704067), using a modification of the method described by 
Schmidt (1961) in which NADPH is produced in the oxidation of glucose-6- 
phosphate:
Glucose + ATP H&xokinase Glucose-6-phosphate + ADP
Glucose-6-phosphate + NADP+ Glucose-6-phosnhate Gluconate-6-phosphate+
dehydrogenase
NADPH + H+
An aliquot of 3p.I o f perfusate or undiluted neutralised extract sample was used 
in an assay volume of 400jil. Final concentrations of the reagents in the assay 
mixture were 69.5mM phosphate buffer pH 7.7, 3.97mM Mg++, 1.29mM ATP, 
1.29mM NADP, >1.1 IU/ml of hexokinase and >1.9 IU/ml of glucose-6- 
phosphate dehydrogenase. Absorbance was read at 340nm and was proportional to 
the glucose concentration in the original sample over the range, 0-50mM. Where 
necessary, the samples were diluted and glucose concentration was measured 
within this range.
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Lactate
Lactate concentration was measured spectrophotometrically (Boehringer 
Mannheim assay kit, No.256773), using a modification of the assay method 
described by Noll (1974) in which lactic acid is oxidised to pyruvate and NADH: 
L-lactate + NAD+ Lactate dehvdroeenase Pyruvate + NADH + H+ 
Pyruvate + L- glutamate Alanine transaminase L-alanine + oxoglutarate 
An aliquot o f 5|il o f perfusate or neutralised extract sample was used in an 
assay volume of 400pL Final concentrations of the reagents in the assay mixture 
were 4mM NAD, 0.43M  carbonate buffer pH 10, 54mM L-glutamate, >1.9 IU/ml 
of alanine transaminase (glutamine-pyruvate aminotransferase), >31 IU/ml of 
lactate dehydrogenase and 16mM sodium chloride. Absorbance was read at 340nm 
and was proportional to the lactate concentration in the original sample over the 
range, 0-11.1 mM. Where necessary, the samples were diluted and the lactate 
concentration was measured within this range.
Adenosine triphosphate
Adenosine triphosphate (ATP) was determined using a bioluminescent assay 
(ATP monitoring kit, No. 1243-102, BioOrbit, Turku, Finland.), based on the 
quantitative measurement of light produced by the reaction:
ATP + luciferin + O2 Luciferase oxyluciferin + AMP + 2 P j  + CO2 + LIGHT 
An aliquot of IOOjj.1 o f diluted neutralised extract was added to 400|il 0 .1M Tris 
acetate/2mM EDTA buffer pH 7.75. Standard ATP solutions were also prepared in 
Tris acetate buffer to give final concentrations o f 50-500 pmols per assay tube. The 
total volume (500p.l) was kept constant for each assay sample. The reaction was 
started by adding lOOjil o f ATP monitoring reagent which contained Firefly 
luciferase, D-luciferin, 50mg bovine serum albumin, 0.5mmoles magnesium acetate 
and 0. ljim oles inorganic phosphate reconstituted in lOmls of distilled water.
The concentration of ATP in the tissue extract sample was compared to the 
standard ATP sample using a luminometer (Model No. 1250, LKB Wallac, Turku,
Finland.). A range of ATP concentrations over which luminescence was directly
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proportional to concentration was established using standard solutions and the ATP 
content of tissue extracts was estimated within this range. Where necessary, 
samples were diluted within this range.
Creatine nhosnhate
Quantitation o f creatine phosphate (CrP) depends upon the complete conversion 
o f creatine phosphate to ATP in the presence of Mg-*-1-, adenosine diphosphate 
(ADP) and creatine phosphokinase (CK). The ATP produced in this reaction was 
measured using the method described in the previous section. Standard CrP 
solutions were prepared in Tris acetate buffer to give final concentrations of 50 - 
500 pmols per assay tube. The efficency of the conversion o f CrP to ATP was 
determined by comparison to standard solutions of ATP which were assayed over 
the same concentration range and under identical conditions.
For the determination of CrP-derived ATP, 100p.l of diluted neutralised extract 
was added to an assay mixture containing 340|il of 0.1M Tris acetate/2mM EDTA 
buffer pH 7.75, 50jil of O.lmM ADP, 5p.l of 0.3M Mg-*-*- acetate and 5p.l o f CK 
(lm g  protein/ml). The total assay volume (500|il) was kept constant for each 
sample. The assay tubes were incubated for 30 minutes in a water bath maintained 
at 25°C. At the end of this period, 100p.l of ATP monitoring reagent was added, 
and luminescence measured, as described in the previous section.
The ATP measured after this conversion represented both ATP and CrP-derived 
ATP. The amount of CrP in the sample was calculated by subtracting the ATP 
concentration measured, using the method described in the previous section from 
the amount determined after this conversion step.
Glvcopen
For the measurement of glycogen, around 500mg of powdered, freeze-clamped 
heart tissue was transferred to round bottom tubes pre-cooled in frozen CO2 pellets. 
After the addition of lml of 30% (w/v) potassium hydroxide, the tubes were 
capped and heated in a boiling water bath for 30 minutes. At the end of this period,
the tubes were removed from the water bath, cooled and lm l of ethanol was added.
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The tubes were reheated until the boiling point of the sample was reached and 
precipitation of glycogen had occurred. The tubes were then removed from the 
water bath, allowed to cool at room temperature and centrifuged at 2500xg for 
lOmins using a bench centrifuge. The supernatant was discarded and the tubes 
were inverted for 30 minutes to allow excess potassium hydroxide to drain from the 
glycogen pellet. After the addition o f lm l of 0.6M hydrochloric acid, the glycogen 
was hydrolysed in a boiling water bath for 2 hours. The glucose concentration was 
measured using the method described previously (see Glucose) and glycogen levels 
were expressed in glucose equivalent units.
Cyclic AM P
Cyclic AMP (cAMP) was measured using an assay system ([3H] cAMP assay 
kit, No.TRK 432, Amersham International pic.), based on competition between 
unlabelled cAMP and a fixed quantity of [3H] cAMP for binding to a protein which 
has a high specificity and affinity for cAMP. The amount of radio-labelled protein- 
cAMP complex formed is inversely related to the amount of unlabelled cAMP 
present in the assay sample. Measurement o f the protein-bound radioactivity 
enables the amount o f unlabelled cAMP in the sample to be calculated. The protein 
bound cAM P is separated from the unbound cAMP by adsorption of the free 
nucleotide onto coated charcoal which is removed by centrifugation. An aliquot of 
the supernatant is removed and [3H] cAMP measured by scintillation counting.
The assay mixture contained 50|il of undiluted neutralised sample extract, 50jil
o f [3Hj cAM P and 100}il o f binding protein. In addition, a zero blank sample
comprising 50fil o f buffer, 50fil o f [3H] cAMP and 100|il of binding protein, was
included in the assay. Standard cAMP solutions were prepared to give final
concentrations o f 1-16 pmols per assay tube. The total assay volume of each
sample (200jil) was constant. The assay tubes were vortexed and incubated at 40C
for two hours in an ice-bath. After this period, lOOfil of charcoal reagent was
added to each tube and the samples were centrifuged for 2-3 mins at 12000xg.
Aliquots of 200jil were removed to vials containing 4mls scintillation fluid
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(Optiphase, Beckman Instruments (UK) Ltd, High Wycombe, Buckinghamshire, 
U.K.) and radioactivity (cpm) was counted for a period of 3 minutes using a 
scintillation counter ( LS 5000CE, Beckmann Instruments (UK) Ltd.). A range o f 
cAMP concentrations over which cpm was directly proportional to concentration 
was established using standard solutions and the cAMP content of tissue extracts 
was estimated within this range.
Protein assay
The assay procedure used was as described in the commercially available Peirce 
BCA protein assay kit (Pierce 23225X, USA). Protein determinations were made 
using the 2 hour incubation at room temperature protocol. Standard bovine serum 
albumin concentrations ranging from 0.2 - 2mg/ml produced a linear plot from 
which the concentrations of the unknown protein samples were measured.
Long chain acylcamitines
Long-chain acylcamitines (C>10) are insoluble in PCA and were measured as 
carnitine after alkaline hydrolysis of the extracted protein pellet (Pearson et a l., 
1974).
Heart tissue was extracted in 6% (w/v) perchloric acid (PCA), as described in 
Section 2.3.3. The extracted protein pellet was re-suspended in lm l of 0.5M KOH 
and the sample was incubated in a water-bath for 60 minutes at 65°C. During the 
incubation, the pellet was homogenised, using a PTFE rod, to ensure maximum 
hydrolysis of the acylcamitine. After the incubation, the sample was centrifuged at 
2500xg and the alkaline supernatant was transferred to another tube. The sample 
was cooled on ice and acidified by the addition o f 40|il of 70% (w/v) PCA. At this 
stage, a white precipitate formed and the sample was re-centrifuged. The 
supernatant was transferred to another tube and the pH was adjusted to pH 7 using 
6M KOH. The pH was monitored using pH indicator solution (Merck, pH 4-10).
A 50pl aliquot of the neutralised sample was assayed for carnitine content.
Standard concentrations of carnitine and long-chain acylcamitine, over the range 
2-20 nmoles, were assayed simultaneously and the concentrations of the unknown
51
samples were determined with reference to the standards.
Carnitine assay
The assay method used was a modification of that described by Bohmer et al. 
(1974) and is based on the production of acetylcamitine in the following reaction: 
Acetyl CoA + carnitine Carnitine acetyltransferase acetylcamitine + CoASH 
A 50|il aliquot o f sample or carnitine standard solution was added to an assay 
mixture containing 50jil of 0.2mM  acetyl-CoA, 50pl o f lOmM 5,5'-dithiobis-(2- 
nitrobenzoic acid), 50|il o f [14C] acetyl-CoA (equivalent to 18.5p.Bq) and 50pl o f 
0.05M Tris buffer pH 7.4. The reaction was started by the addition of 50pl of 
carnitine acetyltransferase (40 IU/ml). The samples were vortexed and incubated in 
a water-bath for 30 minutes at 37°C. At the end o f the incubation period, 200pl o f 
each sample was removed and passed through plastic syringe columns (1cm x 6cm) 
containing 5g of Dowex 2x[C l] (200-400 mesh) suspended in water before use. 
Radiolabelled acetylcamitine was eluted from the column using 2 x 500p.l volumes 
of water. A 200p.l aliquot of the eluted sample was added to lOmls scintillation 
fluid (ReadySafe, Beckman Instruments (UK) Ltd.) and radioactivity was counted 
for 3 minutes (Packard Tri-carb 460, Canberra Packard Ltd, Pangbourne, 
Berkshire, U.K.).
2.3.5 Conversion of wet tissue weight to dry tissue weight
Frozen powdered tissue was weighed in a tinfoil weighing boat and transferred 
to a vacuum oven (Fisons Ltd, U.K.) maintained at a vacuum pressure o f 800 mbar 
and heated to 80-l()0°C for 24 hours. After this time, the samples were allowed to 
cool to room temperature under vacuum. The samples were then transferred to a 
portable vacuum dessicator and quickly reweighed to determine the dry weight. A 
wet/dry weight conversion factor was calculated by dividing the wet weight of the 
sample by the dry weight and metabolite concentrations were expressed as dry 
weight values.
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2.3.6 Preparation o f  palmitate solution
In perfused heart experiments, it was necessary to modify the preparation o f the 
perfusate to allow the addition o f palmitic acid. In these experiments, albumin 
(fatty acid content < 0.02%, Cat No A-7030, Sigma.) was dissolved in water and 
the appropriate physiological salts were added to give a 3% (w/v) albumin solution. 
Palmitic acid (Na+ salt, Cat No P-9767, Sigma.) was dissolved in hot water (70°C) 
and added slowly to a second solution o f 3% (w/v) albumin dissolved in water.
The appropriate physiological salts were added to give a 1.5mM palmitate : 3% 
albumin solution. These final solutions were vacuum-filtered through cellulose 
nitrate filters (0.45|im, Cat No 7184-004, Whatman Ltd, Maidstone, U.K), gassed 
and heated to 37°C prior to perfusion.
2.3.7 Electrophysiological measurements in the papillary m uscle  
prepa ration
Electrode preparation
Glass capillary microelectrodes (Clark CG 150F-15) were formed using a
microelectrode puller (Sutter Instruments) and filled with 3M potassium chloride
solution. The standard tip diameter o f the electrode was 3 |i and the resistance to a
InA current was 60megafL
Intracellular recordings
The microelectrode was placed in an electrode holder and lowered onto the
surface of the tissue using a micromanipulator. A satisfactory single cell
impailment was demonstrated by stable recordings of Vmax and action potentials.
The Vmax represents a measure of the fast sodium current (phase 0, see Figure 1.6)
and is normally around 15()V/sec. The normal action potential duration is around
200msec and the resting diastolic potential is around -85mV. The action potential
signal was digitised using an A-D converter (MacLab) and displayed and stored on
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an Apple Macintosh computer.
2.3.8 Preparation of  heart mitochondria
The isolation o f heart mitochondria was carried out essentially as described by 
McCormack and Denton (1984). Female guinea-pigs were killed by cervical 
dislocation and the hearts immediately removed. Each heart was transferred to a 
tube containing 10ml o f ice-cold buffer (pH 7.4) containing 250mM sucrose, 
20mM Tris-HCl, 2mM EGTA and 1% bovine serum albumin (STEA). The tissue 
was disrupted using a Polytron (Kinematica) homogeniser (setting 5, 2x2sec 
bursts).
Differential centrifugation was used to isolate the mitochondria. The 
homogenates were centrifuged at lOOOxg for 90 seconds at 4°C in a refrigerated 
superspeed centrifuge (Sorvall RC-5B). The resultant supernatant was centrifuged 
at 10,000xg for 10 minutes at 40C. The pellet produced was resuspended in 2-3ml 
of ice-cold buffer without albumin (STE) and re-centrifuged at 10,000xg for 10 
minutes at 40C. The pellet was carefully resuspended in 1ml of STE buffer. The 
metabolic viabilty of the mitochondria was assessed using a Clark oxygen 
electrode. Coupling ratios (± ADP) greater than 3-6 were routinely obtained using 
2-oxyglutarate, malate or succinate as substrates.
This chapter describes the standard procedures applied to the 
experiments performed in this thesis. Any modification to these  
methods are specified in the relevant chapters
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CHAPTER THREE
CHARACTERISATION OF ISCHAEMIC AND HYPOXIC 
MODELS IN THE PERFUSED GUINEA-PIG HEART
PREPARATION
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3.1 INTRODUCTION
The development of models for the study of ischaemia in the mammalian heart 
has recently been reviewed (Opie, 1992). In general, two different isolated heart 
preparations have been used under in vitro conditions. The earliest of these, the 
retrogradely perfused heart, was first described by Langendorff (1895). More 
recently, the working heart was developed by Neely et al. (1973). In the 
Langendorff preparation, coronary perfusion is maintained by the aortic pressure, 
and although the heart does not pump in the physiological sense, this model has 
been widely employed in the study of contractile and metabolic changes to cardiac 
function due to ischaemia. In the working heart preparation, perfusion is in the 
normal direction and physiological "work" is induced by pumping against an 
imposed afterload.
Under in vitro conditions, ischaemia has been achieved in these models either 
by subjecting the whole heart to ischaemia insult by reducing or stopping flow, or 
by producing a localised area o f ischaemia by occlusion o f one or more major 
coronary arteries. The latter method has been criticised on the basis that accurate 
definition of the ischaemic area is difficult and therefore the presence of normal 
tissue in the ischaemic biopsy cannot be excluded (Neely etaL,  1973).
Several different conditions of oxygen and substrate deprivation have been used 
to delineate the effects of ischaemia. Anoxia defined as the total absence o f oxygen 
but with continued perfusion of the coronary vasculature, hypoxia in which oxygen 
supply is reduced and perfusion is again maintained, and low  or no-flow ischaemia 
where the oxygen and substrate supply are both limited by a reduction or complete 
arrest of perfusion; removal of metabolic products is similarly diminished. Low 
and no-flow ischaemic conditions are most representative o f the clinical situation 
although it is uncertain which of these conditions predominates during ischaemia in 
man (Hearse, 1980).
In this chapter a Langendorff-perfused isolated guinea-pig heart method was
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used to investigate the functional and metabolic changes induced by both hypoxia 
and ischaemia in vitro. Comparison of these results led to the choice and 
development of a global low-flow ischaemia model which was used in further 
studies of the effects of ischaemia described in the subsequent chapters.
3.2 RESULTS AND DISCUSSION
3.2.1 The perfused guinea-pig heart preparation
The isolated guinea-pig heart preparation, described in section 2.3.1, was used 
in all o f the experiments described in this chapter. The aim of these experiments 
was to assess the changes to contractile function and metabolic characteristics 
induced in the heart by hypoxia, no-flow ischaemia and low-flow ischaemia. These 
studies also examined the effects of electrical pacing on the response of the heart to 
these experimental conditions. Each heart was perfused for a 30 minute 
equilibration period during which electrical stimulation, when used, was introduced 
and transducer tension was applied. After this time, hypoxic or ischaemic 
conditions were introduced for a further 30 minutes. In control hearts, normoxic 
perfusion was continued during this period.
3.2.1.1 Contractile function and the metabolic characteristics of the perfused heart 
at the end of the equilibration period
The contractile and metabolic stability of the control hearts during 30 minutes of 
normoxic perfusion was assessed by a comparison with hearts perfused for the 30 
minute equilibration period only. In unpaced hearts (n=6), contractile force at the 
end of the equilibration period was 1.6 ± 0.3g. During the control perfusion 
period, contractile force was relatively stable and after 30 minutes was 107.8 ±
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2.9% of the measurement made at the end of equilibration. Diastolic tension was
4.7 ± 0.4g after equilibration and decreased to 84.8 ± 2.4% of this value during the 
control perfusion period. The spontaneous heart rate which was 260 ± 5 beats/min 
at the end o f the equilibration period did not change significantly during the control 
perfusion period.
At the end o f the equilibration period in paced hearts (n=8), the contractile force 
and diastolic tension were 0.9 ± 0.08g and 4.6 ±  0.2g, respectively. During the 
control perfusion period, these parameters decreased to 86.9 ± 3.9 and 81.2 ±
5.8% of control, respectively. The electrical pacing rate was 323 ± 10 beats/min.
The metabolic status o f the unpaced and paced normoxic control hearts are 
shown in Tables 3.1 and 3.2, respectively. In comparison to the values obtained 
from perfused hearts at the end o f the equilibration period, the tissue lactate 
concentrations in the normoxic groups were significantly greater (p< 0.01) than that 
measured at the end o f equilibration (unpaced 2.3 ±  0.7 vs 8.1 ± 0.8p.mol/gm dry 
wt.; paced 4.3 ±  0.3 vs 5.5 ± 1.8|imol/gm dry wt. ). However, compared to the 
changes o f tissue lactate in hypoxic and ischaemic hearts, these differences were 
relatively small. The glycogen content of the paced normoxic hearts was lower (p< 
0.05) than that measured at the end of equilibration (118.5 ± 20.5 vs 157.6 ± 
5.9|im ol/gm  dry wt.). This could reflect increased energy requirements o f paced 
hearts since there was no change to the glycogen content of unpaced hearts. The 
concentrations of ATP, CrP and cAMP in the unpaced and paced normoxic hearts 
did not change during the 30 minute normoxic perfusion period.
3.2.2 The effects of hypoxia
3.2.2.1. The effects of hypoxia on the contractile function of the unpaced perfused 
heart.
Control measurements of contractile force prior to hypoxia were 1.0 ± 0.1 g.
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Figure 3.1 The effects of hypoxia on the contractile 
function of unpaced and paced perfused guinea-pig hearts
Simultaneous measurements of the changes in a) contractile force and b) 
diastolic tension during 30 minutes of hypoxia in unpaced (open circles, n=4) and 
paced hearts (closed circles, n=4). Prior to hypoxia, the hearts were perfused for 
30 minutes with physiological salt solution (containing 11.7mM glucose and gassed 
with 95% oxygen:5% carbon dioxide, PC>2 = 450 - 650mmHg) and a stable 
contractile response was obtained. Electrical pacing was set at 25% above the 
spontaneous rate as described in section 2.3.1. Hypoxia was induced by gassing 
the physiological salt solution with 95% nitrogen : 5% carbon dioxide 
(p02~35mmHg). The values shown are mean ± S.E. expressed as % o f pre- 
hypoxic values.
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Figure 3.2 The comparative effects of hypoxia, no-flow 
and low-flow ischaemia on the spontaneous beating rate in 
unpaced perfused guinea-pig hearts
Unpaced hearts were perfused under hypoxic (open circles, n=5), no-flow
ischaemic (closed circles, n=7) and low-flow ischaemic (open triangles, n=4), 
conditions for 30 minutes as described in section 2.3.1. Control spontaneous 
beating rates were recorded prior to the introduction of hypoxia or ischaemia.
The values shown are mean ± S.E. expressed as % of the control spontaneous 
beating rates.
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The effects of hypoxia on contractile force was biphasic and after an initial decline 
to 51.7 ± 8.5% of control, contractility recovered to 82.6 ± 5.1% of control after 
10 minutes of hypoxia (Figure 3. la). At the end of the hypoxic period, contractile 
force was 74.6 ± 9.7% of control. The observed recovery o f contractility could 
have been related to slowing of the spontaneous beating rate during the hypoxic 
period (Figure 3.2). because the amplitude of the contractile response was 
inversely related to the frequency of the heart rate in this preparation.
Diastolic tension decreased during hypoxia in the unpaced hearts. Control 
diastolic tension was 4.5 ±  O.lg prior to hypoxia. This decreased to 66.6 ±  4.4% 
of control during the hypoxic period (Figure 3.1b).
The spontaneous beating rate prior to hypoxia was 258 ± 5 beats/min. After 10 
minutes o f hypoxia, the spontaneous heart rate was approximately 50% o f control 
and decreased to 43.8 ± 1.3 % o f control after 30 minutes (Figure 3.2). The onset 
o f this negative chronotropic effect occurred on average at 275 ± 32 seconds after 
the introduction of hypoxia and was observed in all unpaced hearts.
3.2.2.2. The effects of hypoxia on the metabolic characteristics of the unpaced 
perfused heart
The metabolic responses of unpaced hearts to hypoxia are compared with 
normoxia in Table 3.1. At the end of the hypoxic period, the ATP content was 
virtually unchanged while CrP was reduced to approximately 38% of the normoxic 
value. The glycogen content was reduced to approximately 73% of the normoxic 
value after 30 minutes of hypoxia. This showed that even in the presence of 
glucose, glycogen was utilised during the hypoxic period.
In hypoxic hearts, the tissue lactate concentration was increased to 21.7 ± 
l.Ofimol/gm dry wt. This showed that despite wash-out by continuous perfusion, 
lactate accumulated in the tissue. The average rate of lactate efflux was 27.2 ± 
0.9|imol/min per g dry wt. Cyclic AMP concentrations were similar in both
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norm oxic and hypoxic hearts.
3.2.2.3. The effects of hypoxia on the contractile function of the paced perfused 
heart
In this group, control measurements of contractile force prior to hypoxia were 
0.9 ±  0. lg  (n=4) and the pacing rate was 300 ± 1 8  beats/min (25% over the 
spontaneous rate: see section 2.3.1). After 5 minutes of hypoxia, contractile force 
had decreased to 49.9± 4.8% of control which was a similar effect observed in 
unpaced hearts at this time point. However, in the paced hearts, contractile force 
continued to decrease to 43.3 ±  2.9% at 10 minutes and 35.4 ± 3.2% of control 
after 30 minutes of hypoxia (Figure 3. la). In contrast to the response to hypoxia 
in unpaced hearts, no recovery of contractile force was observed during hypoxia 
under paced conditions supporting the theory that in unpaced hypoxic hearts, 
contractile force may be affected by changes in heart rate.
The reduction of diastolic tension in paced hearts was very similar to the 
unpaced measurements. Control diastolic tension was 4.8 ± 0.2g prior to hypoxia 
and decreased to 67.4 ± 3.1 % after 30 minutes of hypoxia (Figure 3.1 b).
3.2.2.4. The effects of hypoxia on the metabolic characteristics of the paced 
perfused heart
The metabolic responses of paced hearts to hypoxia are compared with 
normoxia in Table 3.2. During hypoxia in paced hearts, ATP, CrP and glycogen 
content were all reduced to approximately 50% of the normoxic values which was 
greater than the reduction observed in the unpaced hypoxic hearts. This result 
could be explained by the prevention of compensatory slowing of the heart rate in 
paced hearts and may account for the inability of these hearts to maintain contractile 
force during hypoxia. The tissue lactate content of paced hypoxic hearts was 3-
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Figure  3.3 T he  e f fects  o f  n o - f lo w  ischaem ia  on the  
contract i le  function  of  u n p a ced  and paced perfused  guinea-  
pig hearts
Simultaneous measurements o f the changes in a) contractile force and b) 
diastolic tension during 30 minutes o f no-flow ischaemia (NFI) in unpaced (open 
circles, n=5) and paced (closed circles, n=4) hearts. Prior to NFI, the hearts were 
perfused with physiological salt solution (containing 11.7mM glucose and gassed 
with 95% oxygen:5% carbon dioxide,PO 2 = 450 - 650mmHg) and a stable 
contractile response was obtained. Electrical pacing was set at 25% above the 
spontaneous rate as described in section 2.3.1 No-flow ischaemic conditions were 
induced by stopping the perfusion pump. The values shown are mean ± S.E. 
expressed as % of pre-ischaemic values.
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fold greater than in normoxic hearts. These tissue concentrations were similar to 
those reported for unpaced hearts in Table 3.1. The average rate of lactate efflux 
. was 34.8 ± 3.5pxnol/min per g dry wt. This increase in lactate release was slightly 
higher than in the unpaced hearts. This indicated that although tissue accumulation 
was similar under paced and unpaced conditions, the overall production of lactate 
during hypoxia in the paced hearts was higher.
Cyclic AMP concentrations, as in unpaced hearts, were similar in both the 
normoxic and the hypoxic groups.
3.2.3. The effects o f  no-flow ischaemia
During ischaemia the myocardium may experience different degrees of 
perfusion. The following series o f experiments were carried out to examine the 
effects of complete cessation o f perfusion on cardiac function and metabolism
3.2.3.1. The effects of no-flow ischaemia on the contractile function of the unpaced 
perfused heart.
Control measurements of contractile force prior to no-flow ischaemia were 1.2 
± 0.1 g. No-flow ischaemia caused a rapid and progressive decrease of contractile 
force in the unpaced heart. Within 30 seconds, the force of contraction had 
decreased to 54.1 ± 3.9% of control and was 4.4 ± 3.3 % of control at the end of 
the 30 minute ischaemic period (Figure 3 .3 a ). This loss of contractile force was 
more rapid and to a greater degree than observed in unpaced hypoxic hearts and 
although a reduction in heart rate occurred, there was no recovery of contractility 
during the ischaemic period (see section 3.2.2.1).
Control diastolic tension prior to no-flow ischaemia was 4.1 ± 0.3g. In
comparison to hypoxia (Figure 3.1b), the decrease in diastolic tension was also
greater and rapidly fell to around 45% of control after only 2 minutes. This initial
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effect was almost maximal and at the end of the ischaemic period, diastolic tension 
was 42.9 ± 2.2% of control (Figure 3.3b).
The control spontaneous beating rate recorded prior to no-flow ischaemia was 
259 ± 11.0 beats/min (Figure 3.2). Ischaemia caused a rapid decrease in heart rate 
to 50% of control after only 90 seconds. The onset o f this negative chronotropic 
effect was approximately four times faster than observed in hypoxia and occurred 
on average at 71.3 ±  7.9 seconds after the introduction of ischaemia. As in 
hypoxia, this reduction in rate was observed in all hearts and at the end of the 
ischaemic period the spontaneous rate was 2.0 ±  1.5 beats/min. Although this 
reduction in heart rate did not result in a recovery of contractile force as was 
observed in unpaced hypoxia, several additional factors may affect contractile 
activity under no-flow conditions. These factors include, loss of perfusion pressure 
which would result in a reduction of intraventricular pressure, total loss of oxygen 
and substrate supply, and accumulation of lactate and other metabolites.
3.2.3.2. The effects o f no-flow ischaemia on the metabolic characteristics of the 
unpaced perfused heart
The changes in the metabolic characteristics of the unpaced heart during no-flow 
ischaemia are shown in Table 3.2.
After 30 minutes o f no-flow ischaemia, the ATP content was unchanged but 
creatine phosphate was markedly reduced to approximately 30% of the normoxic 
values. The glycogen concentration was not decreased. In addition to the reduced 
energy requirements of these hearts, the accumulation of lactate which is known to 
inhibit glycolysis, may also have contributed to the lack o f glycogen utilisation.
Tissue lactate concentrations in the no-flow ischaemic hearts were increased 10- 
fold from normoxic concentrations and were much higher than those observed in 
the unpaced hypoxic hearts (see Table 3.1). Cyclic AMP concentrations at the end 
of the unpaced no-flow ischaemic period were slightly but significantly higher than
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the normoxic concentration
3.2.3.3. The effects o f no-flow ischaemia on the contractile function of the paced 
perfused heart
In the paced hearts, control measurements o f contractile force prior to no-flow 
ischaemia were 0.7 ±  0. lg  and the pacing rate was 302 ±  9 beats/min. Within only 
30 seconds, the force o f contraction had decreased to 57.8 ± 6.5% of control 
(Figure 3.3a). After 2 minutes, contractile force was 7.3 ± 2.6% of control 
compared to the corresponding measurement o f 35.4 ±  2.8% of control in unpaced 
hearts. In the paced heart, contractility had completely stopped after 5 minutes of 
no-flow ischaemia, whereas under unpaced conditions, contractile force was not 
reduced to this level even after 30 minutes.
Control diastolic tension prior to no-flow ischaemia was 4.6 ±  0.3g. After 5 
minutes of no-flow ischaemia, diastolic tension had decreased to 55.3 ± 8.3% of 
control compared to 44.6 ± 1.8% of control in unpaced hearts (Figure 3.3b). 
However, in contrast to the unpaced group, diastolic tension in the paced hearts 
then increased and was 181.3 ± 7.5% o f control after 30 minutes of no-flow 
ischaemia. This increase in diastolic tension was clearly the result o f complete 
ischaemia coupled with the inability to reduce the spontaneous rate since this effect 
was not seen in either unpaced no-flow (Figure 3.3b) or paced hypoxic hearts (see 
Figure 3.1b).
3.2.3.4. The effects of no-flow ischaemia on the metabolic characteristics of the 
paced perfused heart
At the end of the no-flow ischaemic period, both the ATP and CrP contents 
were reduced to 30% and 10% of normoxic values, respectively (Table 3.2). There 
was no evidence of increased glycogenolysis since the glycogen contents of the no-
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Figure 3.4 The effects of low-flow ischaemia on the 
contractile function of unpaced and paced perfused guinea- 
pig hearts
Simultaneous measurements of the changes in a) contractile force and b)
diastolic tension during 30 minutes of low-flow ischaemia (LFI) in unpaced (open 
circles, n=4) and paced (closed circles, n=4) hearts. Prior to LFI, the hearts were 
perfused with physiological salt solution (containing 11.7mM glucose and gassed 
with 95% oxygen : 5% carbon dioxide, P C ^  450 - 650mmHg) and a stable 
response was obtained. Electrical pacing was set at 25% above the spontaneous 
rate as described in section 2.3.1. LFI conditions were induced by reducing the 
perfusion rate from a control flow rate of around 9ml/min to 0.7ml/min. The values 
shown are mean ±  S.E. expressed as % of pre-ischaemic values.
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flow ischaemic hearts and normoxic hearts were similar. In severe ischaemia, 
lactate accumulation would inhibit glycolysis and the lactate levels in these hearts 
were increased 26-fold compared to the normoxic hearts. This was 2.5-fold greater 
than the increase measured in unpaced no-flow ischaemic hearts (see Table 3.1) and 
7-fold greater than the increase observed in paced hypoxia (Table 3.2). Cyclic 
AMP concentrations in the paced no-flow ischaemic hearts were not statistically 
significantly different from normoxic values (Table 3.2).
3.2.4 The effects of  low-flow ischaemia
In this series of experiments, low-flow ischaemic conditions were induced by 
reducing the coronary perfusion rate by approximately 90%. The effects o f low- 
flow ischaemia on contractile function and the metabolic status of unpaced and 
paced hearts were determined.
3.2.4.1. The effects of low-flow ischaemia on the contractile function o f the 
unpaced perfused heart.
The control measurements o f contractile force prior to low-flow ischaemia were
1.1 ± 0.1 g. As observed in hypoxia and no-flow ischaemia, contractile force 
decreased during low-flow ischaemia. After an initial reduction to 46.3 ± 3.5% of 
control after 2 minutes of ischaemia (Figure 3.4a), contractile force stabilised and 
was maintained at approximately 50-60% of control throughout the remainder o f the 
ischaemic period. At the end of the low-flow ischaemic period, contractile force 
was 58.1 ±  8.3% of control (Figure 3.4a). Although the spontaneous beating rate 
slowed in response to low-flow ischaemia, no recovery of contractile force was 
observed (see section 3.2.2.1).
Control diastolic tension prior to low-flow ischaemia was 4.1 ± 0.3g. After an 
initial rapid decrease to approximately 60% during the first two minutes of
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ischaemia, diastolic tension decreased to 46.9 ± 2.9 % of control at the end of the 
ischaemic period. No increase in diastolic tension was observed during unpaced 
low-flow ischaemia (Figure 3.4b).
The spontaneous beating rate prior to low-flow ischaemia was 240 beats/min 
and low-flow ischaemia caused a 50% reduction in the heart rate within 
approximately 120 seconds. The onset of this effect was at 75 ± 11.9 seconds after 
the reduction in flow and was observed in all hearts. The overall reduction was less 
than in no-flow ischaemia and after 30 minutes o f low-flow ischaemia, the 
spontaneous rate was still approximately 32% of control (see Figure 3.2).
3.2.4.2. The effects o f low-flow ischaemia on the metabolic characteristics of the 
unpaced perfused heart
Low-flow ischaemia did not markedly affect the metabolic status of the unpaced 
heart. At the end o f the 30 minute low-flow ischaemic period, ATP was reduced to 
85% and CrP was reduced to 78%. The glycogen content fell to approximately 
70% of the normoxic value (Table 3.1). These results were similar to those 
observed during unpaced hypoxia except for a smaller reduction of CrP in the low- 
flow ischaemic hearts. However, in comparison to hypoxia, low-flow ischaemia 
caused a greater reduction in contractile activity which would explain the absence of 
a marked metabolic difference between these two groups.
Compared to normoxia, tissue lactate increased 3-fold in the low-flow 
ischaemic group and this was similar to the hypoxic group. The average rate of 
lactate efflux was 8.8 ± l.Opmol/min per g dry wt. Cyclic AMP concentrations at 
the end of the low-flow period in the unpaced hearts were not significantly different 
from the normoxic concentrations (Table 3.1).
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3.2.4.3. The effects of low-flow ischaemia on the contractile function of the paced 
perfused heart
Control measurements of contractile force prior to low-flow ischaemia in the 
paced hearts were 0.9 ±  O.lg and the pacing rate in this instance was 309 ± 11  
beats/min. Low-flow ischaemia caused a rapid and progressive decrease in 
contractile force (Figure 3.4a). Within 30 seconds, the contractile force had 
declined to 58.6 ± 5.1% of control which was similar to the effects observed in 
unpaced hearts. However, after 30 minutes, contractile force in the paced hearts 
was only 6.3 ±  2.3% o f control compared to 58.1 ± 8.3% of control observed 
under unpaced conditions.
Control diastolic tension prior to low-flow ischaemia was 4.2 ± 0.5g. Within 
two minutes of ischaemia the diastolic tension decreased to around 60% of con tro l. 
After 30 minutes, the diastolic tension was further reduced to 50.1 ± 3.4% of 
control. No increase in diastolic tension was observed during low-flow ischaemia 
under paced conditions. This was therefore similar to the effect observed in 
unpaced low-flow ischaemic hearts (Figure 3.4b) but in contrast to effect observed 
under no-flow ischaemic conditions (see Figure 3.3b).
3.2.4.4. The effects of low-flow ischaemia on the metabolic characterisdcs of the 
paced perfused heart
ATP and CrP were both reduced during paced low-flow ischaemia (Table 3.2).
At the end of the ischaemic period, ATP was 58% and CrP was 40% of the
normoxic tissue content. This showed that residual flow prevented the substantial
depletion of high energy phosphate previously observed under the no-flow
conditions (Table 3.2). Glycogen was reduced to approximately 30% of the
normoxic value. This was greater than the reduction measured in paced hypoxic
hearts (Table 3.2). During hypoxia, glycogenolysis would be expected to proceed
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Table 3.1 The effects of hypoxia, no-flow ischaemia and 
lo w-flow ischaemia on the metabolic characteristics of 
unpaced perfused hearts
Unpaced hearts were freeze-clamped after 30 minutes perfusion under 
normoxic, hypoxic, no-flow ischaemic, or low-flow ischaemic conditions. The 
conditions associated with the induction of hypoxia and ischaemia and the 
measurement of high-energy phosphates, glycogen, lactate and cyclic AMP (cAMP) 
were as described in Chapter 2. The effects of hypoxia and ischaemia were 
evaluated by a comparison to the normoxic values obtained from hearts perfused 
with physiological salt solution containing 11.7mM glucose and gassed with 95% 
oxygen:5% carbon dioxide. The cAM P values are expressed as nmol/gm dry wt. 
and all other values are jimol/gm dry wt. The values shown are mean ±  S.E. 
Statistical comparison to normoxic control levels was by analysis of variance and 
application of a 2-sided t-test; *p<0.05; ***p<0.001.
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Table 3.2 The effects of hypoxia, no-flow ischaemia and 
low-flow ischaemia on the metabolic characteristics of 
paced perfused hearts
Paced hearts were freeze-clamped after 30 minutes perfusion under 
normoxic, hypoxic, no-flow ischaemic, or low-flow ischaemic conditions. Details 
of the measurements made and the statistical analysis performed are given in the 
legend for Table 3.1.
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at a higher rate than during low-flow ischaemia. However, unlike hypoxia, low- 
flow ischaemia would result in a reduction of the exogenous glucose supply which 
may have caused an increase in glycogen utilisation.
The tissue lactate content o f the low-flow ischaemic hearts was increased 10- 
fold compared to normoxia but remained lower than in the no-flow hearts since 
lactate was also removed in the perfusate. The average rate o f lactate efflux was
12.8 ± 2.4p.mol/min per g dry wt. Compared to the normoxic concentration, a 
small but significant elevation o f cAMP was observed in the paced low-flow 
ischaemic hearts .
3.3 DISCUSSION
These experiments have compared the effects of different degrees o f oxygen 
and substrate debt in the unpaced and paced guinea-pig heart. Many studies have 
examined the effects of ischaemia and hypoxia in cardiac tissue but the majority 
have been performed using rat tissue. However, compared to other species, the rat 
heart shows considerable differences in receptor types (Flynn et al., 1978; Steinfath 
eta l., 1992) and in the excitation-contraction coupling mechanism (Clarke and 
Patmore, 1984). The guinea-pig heart, which is similar to the human myocardium 
in these respects, was therefore used in the studies described in this thesis. This 
thesis would also contribute to the general assessment of the effects o f ischaemia in 
the myocardium since less information is available on such studies in the guinea-pig 
heart.
Under in vitro conditions, the isolated perfused guinea-pig heart proved to be a 
reliable preparation in that the contractile and metabolic responses in each of the 
groups investigated were consistent. The ATP content of the nonmoxic perfused 
guinea-pig hearts in these studies was similar to the perfused rat heart values 
reported by van Bilsen et al., (1991) and Lipasti et al., (1984). However, the 
literature data varies widely depending on the species used and the perfusion 
conditions applied. 7Q
In each group of unpaced hearts, it was clear that changes to the spontaneous 
heart rate influenced the response of the heart to hypoxia and ischaemia. This was 
especially so in the case of hypoxia where the continuous supply of exogenous 
glucose coupled with the removal of metabolites resulted in only minor changes to 
contractile activity. The effects of hypoxia were more evident in the metabolic 
response of the heart. The degree of oxidative metabolism was reduced as indicated 
by the increased concentration o f tissue lactate and although ATP levels were not 
significantly decreased, both creatine phosphate and glycogen levels were reduced. 
Utilisation o f these substrates would maintain ATP at a normal concentration. It 
was o f interest that glycogen levels were reduced even in the presence o f glucose. 
This suggested that even 11.7mM glucose was not sufficient to saturate the 
glycolytic capacity of the hypoxic-perfused heart.
The extent of the compensatory effect o f the changes in the spontaneous beating 
rate during hypoxia were clearly demonstrated when the same experiment was 
repeated in paced hearts. Under paced conditions, the increased mobilisation of 
both creatine phosphate and glycogen failed to sustain ATP at the normal level.
Unpaced hearts subjected to no-flow ischaemia also exhibited negative 
chronotropism but this effect was very rapid and resulted in almost complete 
cessation o f beating during the ischaemic period. This may have been the result of 
the inhibitory effect of lactate on glycolysis and the results obtained from the no­
flow ischaemia experiments would be compatible with this hypothesis. If this was 
the case then the elevated lactate levels found in these hearts must have been 
produced from a small degree o f glycogen utilisation in the early stages of the 
ischaemic episode and metabolism of residual glucose within the tissue. The results 
from these experiments also showed that while glycogen utilisation was restricted, 
this was not the case with creatine phosphate. ATP levels were high which may 
have been the result o f the rapid reduction in heart rate coupled to markedly reduced 
contractile force. This theory is supported by the fact that in paced hearts during no­
flow ischaemia, both ATP and creatine phosphate were depleted. However, as in
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the unpaced hearts, glycogen levels were not significantly lowered yet lactate levels 
were found to be even higher than in unpaced hearts. Further experiments to 
determine relative changes in glycogen and lactate at different time-points in this 
type of experiment would be required to clarify this finding.
A major difference between unpaced and paced hearts during no-flow ischaemia 
was the development o f contracture (increased diastolic tension). This was 
associated with low ATP levels and a high tissue lactate concentration. Acidosis 
and the subsequent increase of intracellular [H+] is known to antagonise 
intracellular Ca++ binding (Katz, 1973; see section 4.4). If Ca++ is involved in 
contracture development when ATP levels are low (Steenbergen et al., 1990), then 
these results demonstrated that contracture development was not prevented by the 
high level o f lactate present after no-flow ischaemia. It could also be argued from 
these results that since lactate levels were high in hearts which developed 
contracture, some causal link between the two events may exist. However, recent 
evidence supports the theory that ATP depletion is the major factor in contracture 
development (Bowers et al., 1992).
The differences between unpaced and paced hearts established in the hypoxia
and no-flow ischaemia models was also true for low-flow ischaemia. Low-flow
ischaemia had an intermediate effect on the reduction of spontaneous heart rate.
Interestingly, in both hypoxia and low-flow ischaemia, after an initial rapid decline,
the rate stabilised over the remainder o f the perfusion period suggesting that a
balance between rate, contractile force and energy supply had been achieved. This
was reflected in the maintenance o f contractile force at a stable albeit lower level in
these hearts. In contrast to hypoxia, no depletion of creatine phosphate was found
during unpaced low-flow ischaemia although glycogen had been utilised. During
unpaced hypoxia, contractile force increased and the spontaneous rate was
maintained at a relatively high level. Contractile activity was therefore greater
during unpaced hypoxia than during unpaced low-flow ischaemia. It was therefore
possible that the energy requirements of the unpaced low-flow ischaemic heart were
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adequately met by glycogen utilisation and residual exogenous glucose supply. The 
metabolic response to low-flow ischaemia changed under paced conditions.
Creatine phosphate and glycogen decreased. Although tissue lactate levels were 
increased, they were not as high as those measured after no-flow ischaemia. This 
was presumably due to the removal o f lactate by the residual perfusion and would 
have allowed some degree o f glycolysis to continue. This would explain the high 
level o f glycogen depletion compared to no-flow ischaemia. Contracture 
development was not observed during low-flow ischaemia but the ATP level in low- 
flow ischaemic hearts was not as low as in no-flow ischaemia.
In conclusion, the ability of the myocardium to exhibit negative chronotropism 
had an important influence on the contractile and metabolic effects in experimental 
models o f hypoxia and ischaemia. The comparative study of hypoxia, no-flow and 
low-flow in paced hearts has shown that the changes in myocardial function varied 
according to the model used (NFI > LFI > Hypoxia) and that only no-flow 
ischaemia was associated with contracture development. The next chapter 
examined the potential effects of impaired glucose metabolism in the perfused heart 
by investigating the effects of glucose-free perfusion on the contractile and 
metabolic responses to hypoxia and ischaemia.
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CHAPTER FOUR
STUDIES ON GLUCOSE AND FATTY ACID 
METABOLISM DURING NORMOXIA, HYPOXIA AND 
ISCHAEMIA IN THE PERFUSED GUINEA-PIG 
HEART PREPARATION
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4.1 INTRODUCTION
The previous chapter has described the effects of hypoxia and different grades 
of ischaemia on the contractile and metabolic response of the isolated perfused 
guinea-pig heart. The low-flow ischaemia model has been identified as a suitable 
preparation for further investigations into metabolic factors which may alter the 
effects of ischaemia on myocardial function. In this chapter, the influence of the 
two major substrates, glucose and fatty acid, on the metabolic and contractile 
responses of the heart to low-flow ischaemia have been examined. A protective 
role for glucose in the ischaemic myocardium has been proposed (Opie and de 
Leiris, 1979; Opie and Bricknell, 1979) and ischaemia-induced changes to lipid 
metabolism have been associated with exacerbation of myocardial cell damage (Katz 
and Messineo, 1981). Since the relative plasma levels of these two substrates in 
vivo have been shown to control their uptake into the myocardium (Randle, 1963), 
it is important that aspects of both glucose and fatty acid metabolism are addressed.
The effects of glucose-free perfusion in hypoxic and low-flow ischaemic hearts 
were investigated to demonstrate the potential effects of impaired glucose 
metabolism and the effects of palmitic acid, a long-chain fatty acid 
(CH3(CH2)i4COOH) which gives rise to a major accumulation of biologically 
active metabolites during ischaemia (Idell-Wenger et al., 1978), were studied.
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4.2 RESULTS AND DISCUSSION
The contribution of exogenous glucose metabolism to the contractile activity and 
the metabolic status of the normoxic-perfused heart was studied by perfusing the 
hearts in the presence and absence of glucose (section 4.2.1). A high incidence of 
fibrillation was unexpectedly observed during glucose-free perfusion and this was 
further investigated both in the guinea-pig perfused heart and papillary muscle 
preparation (section 4.2.2). The glucose-free studies in hypoxia and ischaemia 
(section 4.2.3) extended the information obtained in the previous chapter by 
demonstrating the contribution of exogenous glucose to the contractile and 
metabolic characteristics of the perfused guinea-pig heart. The effects of glucose 
on lactate production (section 4.2.4) and contracture development during ischaemia 
(section 4.2.5) were investigated.
4.2.1. The effects of  glucose-free perfusion in the normoxic-  
perfused heart.
4.2.1.1. The effects of glucose-free perfusion on the contractile function of the 
normoxic-perfused heart
Glucose-free conditions were produced in the perfusate by substituting glucose 
with equimolar mannitol. The osmolality of the glucose and mannitol solutions 
were similar (284 and 287mosmol/Kg, respectively). The contractile effects of 
glucose-free perfusion, for 30 and 90 minutes, in the paced normoxic heart are 
shown in Figure 4.1. All contractile changes were expressed as a % of the 
measurement made at the end of the 30 minute equilibration period prior to the start 
of glucose-free perfusion.
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Figure 4.1 The effects of glucose-free perfusion on 
contractile force and diastolic tension in the paced 
normoxic perfused guinea-pig heart
Time-course of changes to contractile force (open circles) and diastolic 
tension (open squares) during a) 30 minutes (n=3) and b) 90 minutes (n=3) of 
glucose-free normoxic perfusion. Mannitol (1 1.7mM) was substituted for glucose 
and the hearts were paced and perfused as described in Chapter 2. Values are mean 
± S.E. and are expressed as % of the contractile values measured prior to the 
introduction o f glucose-free conditions.
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F i g u r e  4 .2  T h e  m e t a b o l i c  c h a r a c t e r i s t i c s  o f  the  p a c e d  
g u i n e a - p i g  h e a r t  a f t e r  g l u c o s e - f r e e  n o r m o x i c  p e r f u s i o n
The metabolic status of paced normoxic hearts perfused for 30 minutes 
under glucose-free conditions was determined as described in Chapter 2. The 
changes in contractile activity in these hearts are described in Figure 4.2. Values 
are mean ± S.E. (n=3). Statistical evaluation o f the comparison between normoxic 
values taken from Table 3.3 (n=6, dark hatch bars) and glucose-free normoxia for 
30 minutes (n=3, light hatch bars) or 90 minutes (n=3, dark shaded bars) was by 
analysis of variance and application o f Dunnett's t-test (**p< 0.01).
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The introduction of glucose-free conditions caused an initial transient decrease 
in contractile force to 79.2 ± 5.4% of control. Contractile force subsequently 
recovered to 87.8 ± 3.8% of control after approximately 120 seconds. Thereafter, 
contractile force progressively decreased to 49.5 ± 5.8% of control during the 
remainder of 30 minute period (Figure 4.1a). Diastolic tension showed a gradual 
decline to 78.8 ± 4.5% of control during the 30 minute period (Figure 4.1a).
When glucose-free perfusion was prolonged for 90 minutes, there was a 
progressive decrease in contractile force to around 40% of control after 30 minutes 
and 1.8 ± 1.1% of control after 90 minutes. Thus, contractile force was almost 
completely abolished during the 90 minute period (Figure 4. lb). Diastolic tension 
was only slightly affected by glucose-free conditions and decreased to 83.2 ± 
10.4% during the 90 minute period (Figure 4.1b).
4.2.1.2. The effects of glucose-free perfusion on the metabolic characteristics of 
the normoxic-perfused heart
Normoxic values for ATP, creatine phosphate, glycogen and lactate were 
obtained from hearts perfused with glucose for 30 minutes (Figure 4.2). These 
values are also shown in Table 3.2. After 30 minutes of glucose-free perfusion, 
ATP, creatine phosphate and glycogen levels remained high and were not 
significantly different from the normoxic values in glucose-perfused hearts (Figure 
4.2). After 90 minutes of glucose-free perfusion, ATP, creatine phosphate and 
glycogen were significantly decreased (Figure 4.2).
These results showed that in the absence of exogenous glucose, contractile 
activity in the normoxic heart was supported by the metabolism of
endogenous substrates during the 30 minute period. However, the marked 
decrease of contractile force shown after 90 minutes of glucose-free perfusion was 
associated with depletion of these energy reserves.
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4.2.2. S tud ies on the  m echan ism  of fib rilla tio n  observed  in the 
n o rm o x ic -p e rfu sed  h e a r t d u r in g  g lucose-free  p erfu sion .
Although no significant effects on the endogenous energy reserves had been 
observed during 30 minutes of glucose-free perfusion, there was a greater tendency 
towards fibrillation in hearts perfused without glucose. Fibrillation was not 
preceeded by arrhythmia and did not occur in every heart. This observation was of 
interest because it has been suggested that ATP produced from glycolysis may have 
a special role in the maintenance of membrane integrity and electrical stability 
(Bricknell and Opie, 1978). The relationship between fibrillation and glucose 
metabolism was investigated by assessing the biochemical status of these hearts at 
the time of fibrillation.
4.2.2.1. The high-energy phosphate and glycogen content during fibrillation in the 
normoxic heart perfused in the absence o f glucose
The fibrillation times for 6 hearts were recorded and the metabolic status of each 
heart, immediately after fibrillation, was determined.
Time to ATP* Creatine phosphate* Glycogei
fibrillation
5 mins 11.4 13.0 81.4
14 mins 1 1.9 13.1 90.0
30 mins 10.3 8.5 50.7
47mins 10.3 8.2 50.6
28 mins 13.1 13.5 145.1
47 mins 1 1.5 9.5 76.5
(* all values expressed as pmol/g dry wt.)
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Figure 4.3 The effects of glucose-free superfusion on the 
action potential duration in the normoxic guinea-pig 
papillary muscle
Figure a) shows a representative trace of the time-dependent decrease in 
action potential duration (APD) during glucose-free superfusion of the guinea-pig 
papillary muscle. Recordings were made at 0.5, 1.0, 1.5, 2, 3, 4, 5, 7, 10, 15, 
20, 25 and 30 minutes after the introduction of glucose-free conditions. The effects 
of glucose-free (n=3, open circles) and glucose-free + 10|iM glibenclamide (n=3, 
closed circles) superfusion over a 60 mins normoxic period are shown in Figure b). 
Maximum depolarisation was measured at the peak o f the initial upstroke (around + 
40mV) shown in Figure a) and the APD (msecs) shown in Figure b) represents the 
time to 90% repolarisation from + 40mV. 90% repolarisation is the standard 
measurement of APD in this type o f experiment. Values shown are mean ± S.E.
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Despite variation between hearts, there was no correlation between the duration 
of glucose-free perfusion and the measured metabolic characteristics of the hearts 
which might have explained the incidence of fibrillation. However, it was possible 
that changes to the stability of the cell membrane may have occurred in the absence 
of glucose. This was investigated using electrophysiological measurement of the 
cardiac action potential in guinea-pig papillary muscles which were superfused 
under similar conditions to those used in the whole heart.
4.2.2.2. Measurement of the cardiac action potential duration (APD) in the isolated 
guinea-pig papillary muscle during glucose-free superfusion.
The methodology used in these experiments has been described in section
2.3.2. Briefly, normal cardiac action potentials were recorded after a 60 minute
equilibration period in bicarbonate-buffered physiological salt solution containing
11.7mM glucose. Glucose-free buffer was introduced and changes in the APD
were compared to the normal action potential. A representative recording of the
changes to the normal APD in response to glucose-free perfusion is shown in
Figure 4.3a. In control experiments, the normal APD measured in the presence of
glucose was 177 ± 5msecs (n=9). This value was stable (101 ± 0.3%) over 60
minutes. In the absence o f glucose, the APD shortened from 174.1 ± 8.9msec to
122.8 ± 16.0msec (p< 0.001) over a 30 minute period. At the end of this period,
perfusion for a further 30 minutes with 10pM glibenclamide, still under glucose-
free conditions, reversed the shortening of the APD to 157.0 ± 14.0msec (p< 0.001
compared to 122.8 ± 16.0msec; Figure 4.3b). Since glibenclamide is a specific
blocker of the ATP-dependent K+ channel (Kantor et a l., 1990), this reversal
indicated the involvment of these channels in the effect of glucose-free conditions in
this preparation. Prolongation of the action potential duration is an effective anti-
arrhythmic mechanism (Singh et al., 1980). If the results obtained in the papillary
94
Figure 4.4 The effects of glucose-free hypoxia on 
contractile force and diastolic tension in the paced 
perfused guinea-pig heart
This figure shows the time-course o f the changes in a) contractile force and 
b) diastolic tension during glucose-free hypoxia in paced hearts (n=4). Mannitol 
(1 1.7mM) was substituted for glucose and hypoxic conditions were as described 
for Figure 3.1. Values shown are mean ± S.E. and are expressed as % of the 
contractile values measured prior to the introduction of hypoxia.
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muscle experiments are representative of the effect of glucose-free perfusion in the 
isolated heart , then shortening of the action potential in glucose-free perfused 
hearts could have precipitated fibrillation through reduction of the refractory period.
4.2.3. The effects of  glucose-free perfusion in the paced hypoxic  
and low-flow ischaemic perfused heart
Hypoxia was used because the high rate of glycolysis associated with hypoxia 
suggested that this model might be highly sensitive to changes in glycolytic 
substrate.
4.2.3.1. The effects of glucose-free perfusion on the contractile function of the 
paced hypoxic-perfused heart.
Control measurements of contractile force prior to glucose-free hypoxia were 
0.9 ± 0. lg (n=4) and the pacing rate was 242 ± 10.3 beats/minute. After 5 minutes 
of paced glucose-free hypoxia, contractile force was reduced to 15.8 ± 1.7% of the 
control value and after 20 minutes, contractile activity had almost ceased (Figure 
4.4a). Thus, the effect of hypoxia on contractile force was greatly increased in the 
absence of exogenous glucose.
Control diastolic tension prior to glucose-free hypoxia was 4.8 ± 0.3g. This 
had decreased to 61.4 ± 1.7% of control after 5 minutes of glucose-free hypoxia. 
Over the remainder of the hypoxic period, diastolic tension increased to 137.1 ± 
6.9% of control (Figure 4.4b). This effect was not observed under paced hypoxic 
conditions in the presence of glucose (section 3.2.2).
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4.2.3.2. The effects of glucose-free perfusion on the metabolic characteristics of 
the paced hypoxic-perfused heart.
The effects of glucose-free hypoxia on the metabolic characteristics of paced 
hearts after 30 minutes are shown in Table 4.1. ATP and creatine phosphate were 
reduced to approximately 20% and 25% and glycogen was reduced to 26% of the 
amount measured in paced glucose-perfused hearts. Tissue lactate concentrations in 
the glucose-free hypoxic group were increased to approximately 300% of the 
normoxic value and the average rate of lactate efflux was 3.9 ± 0.4|imol/min per g 
dry wt. There was no change in the cyclic AMP content.
In hearts subjected to glucose-free hypoxia, high energy phosphates and 
glycogen were depleted to a greater degree than observed during hypoxia in the 
presence of glucose (see Table 3.2). Although tissue lactate concentrations were 
similar in both glucose and glucose-free hypoxic hearts, more lactate was released 
into the perfusate from hearts provided with glucose (see section 3.2.2.4).
4.2.3.3. The effects of glucose-free perfusion on the contractile function of the 
paced low-flow ischaemic-perfused heart
Control measurements of contractile force prior to glucose-free low-flow 
ischaemia were 0.8 ± 0. lg  (n=5) and the pacing rate was 324 ± 9 beats/min. 
Contractile force decreased rapidly after the onset of glucose-free ischaemia and 
was reduced to 30.9 ± 1.4% of control after 60 seconds. This compared to 36.9 ± 
3.6% of control in low-flow ischaemic hearts perfused with glucose (section
3.2.4). After 10 minutes, contractile force had been reduced to 2.1 ± 1.0% of 
control (Figure 4.5a).
Control diastolic tension prior to glucose-free low-flow ischaemia was 4.5 ±
0.2g. Ischaemic contracture developed within 10 minutes of the start of glucose-
98
Figure 4.5 Comparison of the effects of low-flow 
ischaemia with and without glucose on contractile function 
in the paced perfused guinea-pig heart
This figure compares the effects of low-flow ischaemia on a) contractile 
force and b) diastolic tension in paced hearts perfused with and without glucose.
As in hypoxia (Figure 4.4), contracture development was observed only under 
glucose-free conditions (n=6, open circles). The data for low-flow ischaemia in the 
presence of glucose (n=6, closed circles) is taken from Figure 3.4. Values shown 
are mean ± S.E. and are expressed as % of pre-ischaemic values.
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Table 4.1 The comparative effects of hypoxia and low- 
flow ischaemia on the metabolic characteristics of paced 
guinea-pig hearts perfused in the absence of glucose
At the end of the glucose-free hypoxic and low-flow ischaemic periods (see 
section 4.2.3), the hearts were freeze-clamped and changes to the normal metabolic 
characteristics of the tissues were measured as described in Chapter 2. Glucose- 
free values were compared to the corresponding measurements from normoxic 
hearts perfused in the presence of glucose (Table 3.2). Statistical evaluation of the 
differences was made by analysis o f variance and application of a 2-sided t-test 
(**p<0.01; ***p<0.001). All values are expressed as pmol/g dry wt.
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free ischaemia and was 158.3 ±  9.8% o f  control after 30 minutes (Figure 4.5b). 
This was in contrast to low-flow ischaemia in the presence o f  glucose in which no 
increase in diastolic tension was observed.
4.2.3.4. The effects of glucose-free perfusion on the metabolic characteristics of 
the paced low-flow ischaemic-perfused heart.
At the end of the glucose-free ischaemic period, ATP and creatine phosphate 
were both reduced to approximately 28% and glycogen levels were reduced to 
approximately 18% of the glucose-perfused normoxic value (Table 4.1). Thus, the 
decrease in high energy phosphate and glycogen was greater under glucose-free 
conditions than in glucose-perfused low-flow ischaemic hearts (see Table 3.2). 
These results showed the relative contributions of glucose and glycogen to the 
cellular energy requirements of the low-flow ischaemic heart.
4.2.4. Lactate production in the paced ischaemic heart
Total lactate production during the low-flow ischaemic period was determined 
by the combined measurement of lactate efflux collected in overflow perfusate 
samples and the lactate content of post-ischaemic tissue.
4.2.4.1. Low-flow  ischaemia in the presence o f  glucose
Total lactate efflux during 30 minutes low-flow ischaemia was 480.9  ±  
3 8 .9um ol/g  dr)' wt. (n=7). This was equivalent to 16.0 ±  1.3|imol/min per g dr)' 
wt. The post-ischaemic tissue content was 46.7 ±  5.0jimol/g dry wt. Therefore 
the total lactate produced during the ischaemic period was approximately 526p.mol/g 
dry wt.
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Figure 4.6 Time-dependent lactate efflux during low- 
flow ischaemia with and without glucose in the paced 
perfused guinea-pig heart
The perfusate was collected over 2 minute intervals throughout the 30 
minute low-flow ischaemic period and the lactate content of the samples was 
measured as described in Chapter 2. Lactate efflux during low-flow ischaemia in 
the presence of glucose (n=5, closed circles) was compared with lactate released 
during glucose-free low-flow ischaemia (n=6, open circles). Values shown are 
mean ± S.E.
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In order to determine the rate of increase in lactate production during low-flow 
ischaemia, efflux was measured over 2 minute intervals throughout the 30 minute 
ischaemic period. There was an initial rapid increase in lactate production from a 
basal rate of 0.28 ± 0.09|J.mol/min per g dry wt. to 16.2 ± 1.6p.mol/min per g dry 
wt. after 8 minutes of low-flow perfusion. After this time, lactate was released at a 
relatively constant rate o f 17.2 ±  0.1|imol/min per g dry wt. (Figure 4.6).
4.2.4.2. Low-flow ischaemia in the absence of glucose
Total lactate efflux during 30 minutes of glucose-free low-flow ischaemia was 
87.7 ± 16.9|imol/g dry wt. (n=6). This was equivalent to 2.9 ± 0.6p.mol/min per g 
dry wt. The post-ischaemic tissue content was 12.3 ± 1.7|imol/g dry wt. (n=6). 
Therefore, the total lactate production under glucose-free conditions, was 
approximately 100|imol/g dry wt. This was approximately 5-fold less than lactate 
production during low-flow ischaemia in the presence of glucose. Lactate efflux 
increased from basal levels o f 0.40 ± 0.20p.mol/min per g dry wt. to 11.4 ± 
0.8fimol/min per g dry wt. during the initial 8 minutes of glucose-free low-flow 
ischaemia but efflux then decreased progressively to only 1.8 ± 0.2p.mol/min per g 
dry wt. at the end of the ischaemic period (Figure 4.6). Since the post-ischaemic 
glycogen content of these hearts was very low (Table 4.1), this decrease in lactate 
efflux could be explained by the loss of glycolytic substrate.
4.2.4.3. No-flow ischaemia
In these hearts, all of the lactate produced during the ischaemic period was 
retained within the tissue. After 30 minutes of no-flow ischaemia, tissue lactate 
levels were 153.7 ± 12.0(imol/g dry wt. (n=6). This corresponded to 30% of the 
total lactate produced during low-flow ischaemia indicating a reduction of
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Figure 4.7 Comparison of tissue lactate accumulation 
during low-flow and no-flow ischaemia in the paced 
perfused guinea-pig heart
Hearts were freeze-clamped after 2, 5, 10, 15, 20 and 30 minutes of low- 
flow (light hatch bars ) or no-flow ischaemia (dark hatch bars) and tissue lactate 
levels were measured as described in Chapter 2. Single observations at each time- 
point were made for the two ischaemic conditions .
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glycolysis in this model.
The rate of lactate accumulation during no-flow ischaemia was measured after 
2, 5, 10, 15, 20 and 30 minutes. This enabled a comparison to be made between 
the rate of lactate production during low-flow ischaemia and no-flow ischaemia 
(Figure 4.7). The accumulation of tissue lactate was almost linear during the first 
15 minutes of no-flow ischaemia but was only slightly increased between 15 and 30 
minutes. This showed that glycolysis was inhibited in the later stages of this 
ischaemic insult.
While lactate production was sustained during low-flow ischaemia in the 
presence of glucose, under glucose-free conditions it reached a peak concentration 
at approximately 4 - 8 minutes and decreased beyond that time-point. The 
corresponding changes in contractile function shown in Figure 4.6 indicate that the 
onset of contracture development occurred at approximately 5 - 1 0  minutes after the 
introduction of glucose-free low-flow ischaemia. Therefore, contracture 
development occurred shortly after the decrease o f glycolytic output.
4.2.5. Contracture development in the paced low-flow ischaemic 
heart perfused in the absence of glucose
The development of contracture in glucose-free low-flow ischaemic hearts may 
reflect varying degrees of ATP depletion in different areas of the myocardium rather 
than a uniform loss of energy reserves. Contracture development does not correlate 
with the loss of ATP in the ischaemic heart (van der Merwe et al., 1983). These 
findings were confirmed in the guinea-pig heart by measuring the ATP content of 
the low-flow ischaemic heart at the onset o f contracture (section 4.2.6.1).
It was evident from the tissue concentrations of lactate (Table 4.1) that the
reduction in the release of lactate into the perfusate during glucose-free low-flow
ischaemia did not reflect retention of lactate within the tissue. However, contracture
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developed in these hearts and this could restrict tissue perfusion, resulting in 
reduced lactate production. The consequences of contracture development 
(increased diastolic tension) on lactate release in the ischaemic heart were therefore 
investigated (section 4.2.6.2).
4.2.5.1. The metabolic characteristics of the glucose-free perfused low-flow 
ischaemic heart at the onset of contracture
The energy status of paced glucose-free low-flow ischaemic hearts was 
measured after a small degree of contracture had developed. The mean increase in 
diastolic tension was 7.4 ± 1.5% (n=5) and the mean sampling time was 7.3 ±  0.8 
minutes after the start of the ischaemic period. This was similar to the time-course 
of contracture development observed in earlier experiments (see Figs 4.4b and 
4.5b).
In comparison to paced normoxic hearts, both creatine phosphate and glycogen 
showed marked reductions to 4.6 ± 0.5 and 41.6 ± 5.6pmol/g dry wt but ATP 
concentrations were still relatively high at 11.1 ± 0.7fimol/g dry wt. The tissue 
lactate content was 17.3 ± 3.3jimol/g dry wt.
These results suggested that at the onset of contracture in these experiments, 
glycogen and creatine phosphate were available in amounts adequate to support 
ATP requirements. Contracture commenced in these experiments at a time when 
the total tissue ATP was high. However, the measurement of whole tissue ATP 
gives no indication as to the distribution of energy deprivation in the myocardium.
4.2.5.2. The potential consequences of contracture development in the paced 
perfused heart during low-flow ischaemia.
The relationship between contracture and glycolysis was further investigated by
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Figure 4.8 The effect of glucose on contracture 
development during low-flow ischaemia in the paced 
perfused guinea-pig heart
This figure shows the effects of 60 minutes of low-flow ischaemia in the 
presence of glucose (n=4, closed circles), 60 minutes of glucose-free low-flow 
ischaemia (n=6, open circles) and 60 minutes of low-flow ischaemia which 
comprised 30 minutes of glucose-free low-flow followed by 30 minutes of low- 
flow in the presence of glucose (n=6, open triangles). Values represent changes in 
diastolic tension and are mean ± S.E. expressed as % of pre-ischaemic values.
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studying lactate release during low-flow ischaemia. In the first set of experiments, 
the low-flow ischaemic period in glucose perfused hearts was extended to 60 
minutes and the lactate released into the perfusate was collected in two separate 
samples between 0 - 30 minutes and between 3 0 -6 0  minutes. The total lactate 
released during the 0 - 3 0  minute period was 402.6 ± 29.9p.mol/g dry wt. During 
the 30 - 60 minute period, 443.5 ± 28.5jimol/g dry wt were released. This data 
showed that the glycolytic flux during both periods of ischaemia was similar and 
Figure 4.8 showed that no contracture development took place during the 60 minute 
ischaemic period.
These results were compared with lactate release during two consecutive 30 
minute periods o f glucose-free low-flow ischaemia. The diastolic tension 
measurements made in this group are also shown in Figure 4.8. Total lactate 
release during the two 30 minute periods was 167.2 ± 9.6 and 20.0 ± 3.2|imol/g 
dry wt, respectively. This reduction of lactate production was associated with 
contracture development and was consistent with earlier findings that lactate 
production decreased during glucose-free low-flow ischaemia (see Figure 4.6).
Finally, the ability of the ischaemic heart to produce lactate after contracture had 
developed was investigated. Hearts were perfused for 30 minutes under glucose- 
free low-flow conditions, during which contracture developed, then while low-flow 
conditions were maintained glucose was re-introduced and perfusion continued for 
a further 30 minute period. The total lactate production during 30 minutes of 
glucose-free low-flow ischaemia was 106.5 ± 13.8p.mol/g dry wt. During this 
period contracture developed to 195.9 ± 17.6% of control. Following the re- 
introduction of glucose to these hearts, lactate release during the remaining 30 
minutes of low-flow ischaemia was 109.7 ± 15.8p.mol/g dry wt. Although this 
represented an increase of approximately 5-fold compared to the lactate released 
during the corresponding period of glucose-free ischaemia, it was only 25% of the 
total amount released during the same period of low-flow ischaemia in the presence
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F ig u r e  4.9 T he  effect  o f  co n tr a c tu r e  d e v e lo p m e n t  on  
m y o c a r d ia l  per fu s ion  d u r in g  lo w -f lo w  isch a em ia  with  and  
w ith o u t  g lu co se  in the  p a ced  p er fu sed  g u in e a -p ig  heart
The area of perfusion during low-flow ischaemia in the presence o f glucose 
(Figure a) was compared with the area perfused after contracture development 
following glucose-free perfusion (Figure b); (see section 4.2.5.2). These 
photographs represent transverse sections o f the myocardium after perfusion with 
0.1% Evan's blue dye at the end o f the ischaemic period. Each section was 
prepared histologically and the degree of perfusion was differentiated using an 
image analyser (Turnkey TK/20). In Figure a) the epicardial areas (blue/yellow) 
were perfused to a greater degree than the endocardium (pink). In Figure b) there is 
almost complete loss of perfusion.
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of glucose. Despite the 5-fold increase in glycolysis, ischaemic contracture was not 
reduced (Figure 4.8).
The consequences of contracture on the degree of perfusion in the low-flow 
ischaemic heart are shown in Figure 4.9. This shows that the low-flow perfused 
area can be markedly reduced, with a corresponding increase in the no-flow area, 
after ischaemic contracture has developed. At least two factors can therefore 
account for the loss of lactate production after contracture: 1) under conditions of 
low perfusion pressure, contracture decreases perfusion and increases the no-flow 
ischaemic area leading to 2) restricted glycolytic capacity and subsequently 
increased cell death.
4.3 Lipid metabolism in the normoxic and ischaemic perfused heart
In the normoxic rat heart in vitro, endogenous triglyceride metabolism
contributes to over 11% of the ATP production even in the presence of high
concentrations of exogenous lipid; in the absence of exogenous lipid, triglycerides
can become the major myocardial substrate (Saddik and Lopashuk, 1991).
Glycerol derived from triglycerides (Shipp et al., 1964) is not re-metabolised by the
heart and glycerol production has been used to demonstrate increased lipolysis
(Myrmel et al., 1991; van Bilsen et a l., 1989) in ischaemic hearts (Myrmel et al.,
1991). Accumulation of lipid intermediates, such as long-chain acylcamitines
(LCA), arising from impaired metabolism of both endogenous and exogenous
lipids may result in increased ischaemic damage (Katz and Messineo, 1981; Knabb
et a l 1986). The prevention of LCA accumulation (e.g. by inhibition of carnitine
palmitoyl transferase I (CPT-I)) may be beneficial in ischaemia (Paulson etaL,
1986). The availability of fatty acids can also decrease glucose utilitisation (Randle
et aL, 1963; Weiss et al., 1989) and inhibition of glucose utilisation, as
demonstrated in the previous sections, can markedly alter the myocardial response
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to ischaemia Much of the published data has been derived from studies using rat 
tissue, therefore the following experiments have been performed to study some of 
the effects of fatty acid metabolism in the normoxic and ischaemic-perfused guinea- 
pig heart.
If endogenous lipids are metabolised in the isolated heart, then increased 
concentrations of LCA should be detected in the low-flow ischaemic heart perfused 
in the absence of exogenous fatty acids. This hypothesis was tested by comparing 
the LCA content of normoxic hearts and hearts subjected to 30 minutes of low-flow 
ischaemia with and without palmitate (4.3.1). The effect of lowering the glucose 
concentration from 11.7mM to 5mM on the response to palmitate was also 
investigated (4.3.2). Inhibition of CPT-I by etomoxir was studied in isolated 
mitochondria (4.3.3) and in the perfused heart (4.3.4). The potential effects of 
albumin - binding in perfusion studies are described in section 4.3.5. The effects 
o f etomoxir on cardiac function and glycogen utilisation in normoxic hearts was 
examined (4.3.6).
4.3.1. The LCA content of the paced normoxic and low-flow ischaemic perfused 
heart
This study compared the LCA content of hearts perfused for 30 minutes under
conditions of normoxia, low-flow ischaemia (no albumin/palmitate) and low-flow
ischaemia with either 3% albumin alone (albumin group) or 1.5mM palmitate bound
to 3% albumin (palmitate group). Several studies have used 1.5mM palmitate
bound to 3% albumin to investigate the effects of fatty acids during ischaemia in the
heart (Feuvray, 1981; Lopaschuk et al., 1988) and the method of preparation of the
palmitate: albumin solution is described in Section 2.3.2. Contractile activity and
perfusate concentrations of creatine kinase were measured prior to and during the
ischaemic period. The latter measurements were made on the basis that if fatty
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Figure 4.10 Comparison of the contractile changes in the 
paced normoxic and low-flow ischaemic guinea-pig heart 
in the presence of albumin or albumin-bound palmitate
The effects of normoxia (n=3, open circles) and low-flow ischaemia (n=3, 
closed circles) on contractile function are shown in Figures a) and b), respectively. 
The changes to contractile activity in hearts pre-treated for 10 mins with albumin 
(n=3, open circles) or palmitate (n=4, closed circles) prior to the 30 minute low- 
flow ischaemic period are shown in Figures c) and d), respectively. Albumin ± 
palmitate was also present in the perfusate during the ischaemic period. Values 
shown are mean ± S.E. expressed as % o f the measurement made at the end of 30 
minutes equilibration.
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acids increased ischaemic damage in this model, this may be reflected in increased 
release o f  creatine kinase.
4.3.1.1 The effects of albumin and albumin-bound palmitate on contractile function 
in the paced perfused heart during low-flow ischaemia
Control measurements of contractile force and diastolic tension taken at the end 
of the equilibration period in the normoxic group were 1.0 ± 0.3 and 4.3 ±  O.lg, 
respectively and in the ischaemic group, the corresponding measurements were 0.9 
± 0 .1  and 4.6 ± 0.3g. In the albumin group, the values were 1.1 ± 0.2 and 4.8 ± 
0.4g and in the palmitate group were 0.8 ± 0.1 and 4.6 ± 0.3g, respectively. The 
pacing rate was 320 ± 29 beats/min in the normoxic group, 345 ± 4 beats/min in the 
ischaemic group, 341 ± 2 7  beats/min in the albumin group and 352 ± 1 5  beats/min 
in the palmitate group.
Contractile changes during normoxia and low-flow ischaemia are shown in 
Figure 4.10 (a) and Figure 4.10 (b).
Pre-treatment with albumin or palmitate prior to ischaemia caused a reduction in 
contractile force to 65.6 ± 3.2% and 6 2 3  ± 2.3% of control, respectively. The 
reason for this effect was unclear. There was no significant difference in the 
decrease in contractile force during ischaemia in the albumin and palmitate groups 
(Figure 4 .10c).
Diastolic tension was only slightly decreased during the pre-treatment period. 
While diastolic tension in the albumin group was 55.8 ±  10.7% o f  control after 30  
minutes o f  ischaemia, it increased to 132.2 ±  9.7% o f  control in the palmitate 
group (Figure 4. lOd).
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Figure 4.11 Long-chain acylcarnitine content and 
creatine kinase release in the paced normoxic, low-flow 
ischaemic and low-flow ischaemic guinea-pig heart 
perfused with albumin or albumin-bound palmitate
The tissue content o f long chain acylcarnitine (LCA) after 30 minutes of 
normoxia (n=3, dark filled bars) or low-flow ischaemia (n=3, dark hatch bars) are 
shown in Figure a). Figure b) shows the LCA content of albumin-perfused 
normoxic (n=3, light hatch bars) and low-flow ischaemic hearts (n=7, dark hatch 
bars) compared to palmitate-perfused normoxic (n=3, light shaded bars) and low- 
flow ischaemic hearts (n=7, dark shaded bars).
Creatine kinase (CK) concentrations during low-flow ischaemia (shaded 
bars) and low-flow ischaemia with albumin ±  palmitate (light and dark hatch bars, 
respectively) are shown in Figure c). The enzyme concentrations were measured in 
perfusate samples collected at the times indicated (14 -16 mins and 28 - 30 mins). 
Time 0 represents basal release prior to low-flow ischaemia. Values are mean ± 
S.E. expressed as mlU/min per g dry wt after conversion according to the flow 
rate/min divided by the dry tissue wt.
In figure b), statistical comparison o f the albumin and palmitate groups was 
by unpaired t-test (# p< 0.05 compared to albumin control; **p< 0.01 compared to 
low-flow ischaemia + albumin). In figure c), the 15 and 30 mins values shown for 
low-flow ischaemia alone and for low-flow ischaemia in the presence of albumin 
were not significantly different. These values were significantly higher compared 
to time 0 (p< 0.05, not indicated). Enzyme release at 15 and 30 mins o f low-flow 
ischaemia in the presence o f palmitate was significantly higher compared to low- 
flow ischaemia ± albumin (*p< 0.05; ***p< 0.001)
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4.3.1.2 The metabolic characteristics of the paced heart following perfusion with 
albumin and albumin-bound palmitate.
No significant difference was found in the LCA content of normoxic and low- 
flow ischaemic hearts (Figure 4.1 la). This was also the case in normoxic and low- 
flow ischaemic hearts perfused with albumin (Figure 4.1 lb). The LCA content of 
the albumin-perfused hearts was higher than the hearts perfused without albumin 
but the reason for this was unclear since the albumin used in these studies was 
essentially fatty acid free (0.004%). Palmitate increased the LCA contents of both 
normoxic and ischaemic hearts (Figure 4.1 lb).
Measurement of creatine kinase release in the perfusate, prior to and at 15 and 
30 minutes of ischaemia, indicated that an increase in the concentration of this 
enzyme had occurred during the ischaemic period. In the palmitate group, this 
increase was time-dependent and significantly greater than in the albumin group 
(Figure 4.11c).
The presence of LCA in the normoxic and ischaemic hearts perfused with and 
without albumin suggested that endogenous lipid was used as a substrate in the 
absence of exogenously supplied fatty acids. However, ischaemia alone did not 
result in LCA accumulation which was seen only in the presence of palmitate. The 
presence of palmitate during ischaemia was also associated with contracture 
development and increased release of creatine kinase.
4.3.2. The effects of albumin and albumin-bound palmitate during low-flow 
ischaemia in paced hearts perfused with 5mM glucose.
While the indices of ischaemic damage, described in section 4.9.4, indicated a 
greater degree of damage in the palmitate-perfused hearts, it could not be concluded 
that this was a direct consequence of elevated LCA. The availabilty of fatty acid is
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known to affect glucose metabolism and this could account for the effects observed 
in these experiments. To determine whether the concentration of glucose could 
affect the response of the heart to low-flow ischaemia, a similar set of ischaemic 
experiments using 5mM instead o f 11.7mM glucose in the presence of albumin or 
albumin-bound palmitate were performed.
As in the previous experiments, the hearts were perfused with albumin (albumin 
group) or albumin-bound palmitate (palmitate group) for 10 minutes prior to 
ischaemia but in initial experiments some o f the hearts fibrillated at this stage. To 
reduce the possibility of fibrillation, the hearts in these experiments remained 
unpaced during the equilibration period and the pre-treatment period. Electrical 
pacing was introduced after the onset o f ischaemia at the time when the heart rate 
spontaneously slowed in response to ischaemia (see Figure 3.2). Thereafter, the 
hearts were paced at the rate recorded prior to the ischaemic period. This allowed 
the hearts to be paced at a slower rate than the usual 25% above the spontaneous 
rate. After the pre-treatment period, each heart was perfused for 60 minutes of low- 
flow ischaemia. The ischaemic period was extended from 30 to 60 minutes in an 
attempt to amplify the effects of ischaemia on contractility and enzyme release.
4.3.2.1 The effects of albumin and albumin-bound palmitate on contractile function 
during low-flow ischaemia in the paced heart perfused with 5mM glucose
The control values for contractile force measured at the end of the 30 minute
equilibration period were 1.0 ± O.lg (albumin group) and 1.2 ± 0.1 g (palmitate
group). Perfusion with albumin or palmitate during the 10 minutes pre-treatment
period before low-flow ischaemia caused a decrease in contractile force to 58.3 ±
6.0% and 55.8 ± 3.1% of the control values, respectively (Figure 4.12a). Control
measurements of diastolic tension were 4.5 ± 0.3g and 4.1 ± 0.3g, respectively.
The diastolic tension was also slightly reduced during the albumin and palmitate pre-
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Figure 4.12 Comparison of the contractile changes in the 
paced low-flow ischaemic guinea-pig heart perfused with 
albumin or albumin-bound palmitate in the presence of 
5mM glucose
The perfusate concentration of glucose in these experiments was 5mM (see 
section 4.3.2). Each heart was also perfused with albumin or albumin-bound 
palmitate for 10 minutes prior to the low-flow ischaemic period. The effects of low- 
flow ischaemia in the presence of albumin (n=5, open circles) or albumin-bound 
palmitate (n=5, closed circles) on contractile function are shown in Figures a) and 
b), respectively. Albumin ± palmitate was also present in the perfusate throughout 
the ischaemic period. Values shown are mean ± S.E. expressed as % o f the 
measurement made at the end of the 30 minutes equilibration period prior to 
perfusion with albumin ± palmitate. Statistical analysis comparing corresponding 
time-points in the albumin and palmitate groups was by analysis of variance and 
application o f a 2-sided t-test (*p< 0.05; **p< 0.01).
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treatment periods (Figure 4 .12b). The pacing rate during ischaemia was 232 ± 10 
beats/min in the albumin group and 243 ± 6 beats/min in the palmitate group.
The loss of contractile force during low-flow ischaemia in the presence of 
5mM glucose was greater than that observed with 11.7mM glucose. After 10 
minutes, contractile force had ceased in both groups (Figure 4 .12a). In addition, 
contracture developed in both groups during the ischaemic period. This was in 
contrast to the effects of low-flow ischaemia in the presence of 11.7mM glucose 
where contracture development was observed in the palmitate group alone (section
4.9.4). In the present study, contracture development was greater in the palmitate 
group and reached statistical significance between 25 - 40 minutes of ischaemia. 
This effect was most pronounced after 30 minutes of ischaemia when diastolic 
tension in the palmitate group was 194.6 ± 15.6% of control (p< 0.01) compared 
to 147.9 ± 11.0% of control in the albumin group (Figure 4.12b).
4.3.2.2 The effects of albumin and albumin-bound palmitate on the metabolic 
characteristics of the paced low-flow ischaemic heart perfused with 5mM glucose
Control LCA concentrations, measured at the end of the 10 minute pre-treatment 
period, were 1863 ± 179nmol per g dry wt (albumin) and 3094 ± 292nmol per g 
dry wt (palmitate). These values were similar to the previous study (see Figure 
4.11). At the end of 60 minutes of ischaemia, the LCA concentrations in the 
albumin group were 3415 ± 404nmol per g dry wt and 5539 ± 242nmol per g dry 
wt in the palmitate group. This showed that although LCA concentrations in the 
palmitate group were higher after low-flow ischaemia, this increase was partly due 
to the increased LCA concentration observed during the pre-treatment period. The 
myocardial LCA content after 30 minutes (see Figure 4.11) of ischaemia was not 
significantly different from 60 minutes of ischaemia. This suggested that further 
accumulation of LCA had not taken place during the 3 0 -6 0  minute period although
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Figure 4.13 Lactate and creatine kinase release in the 
paced Iow-flow ischaemic guinea-pig heart perfused with 
albumin or albumin-bound palmitate in the presence of 
5mM glucose
Lactate release from low-flow ischaemic hearts (see Figure 4.12) perfused 
with albumin (n=5, light hatch bars) or albumin-bound palmitate (n=5, dark hatch 
bars) is shown in Figure a). Creatine kinase (CK) release is shown in Figure b). 
All measurements were made from the total perfusate collected between 0 - 3 0  
minutes and 30 - 60 minutes of ischaemia. Values are mean ±  S.E. and are 
expressed as described in Figure 4.16 legend. Statistical analysis comparing 
albumin and palmitate values was by analysis of variance and application of a 2- 
sided t-test. (Figure a) # p< 0.05, **p< 0.01 compared to 30 mins albumin, ***p< 
0.001 compared to 30 mins palmitate; Figure b) **p< 0.01 compared to both 30 
mins values and to the 60 mins albumin value).
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the possible loss o f  LCA into the perfusate could not be excluded in these 
experiments.
During the 0 - 30 minute ischaemic period, lactate production in the presence of 
palmitate was, in fact, significantly greater (p< 0.05) than in the albumin perfused 
group (Figure 4 .13a). Therefore, there was no evidence from these results that the 
presence o f palmitate had reduced glycolysis during 30 minutes o f ischaemia. 
Lactate release was not sustained in either group and subsequently decreased 
during the 3 0 -6 0  minute ischaemic period. Although these latter values 
represented mean reductions o f 38% (albumin) and 63% (palmitate) from the 0 - 3 0  
minutes values, this difference was due to the higher lactate concentration released 
from the palmitate-treated hearts during the 0 - 30 minute ischaemic period. 
Therefore, the effects of palmitate on lactate release were unclear in these 
experiments. The results did suggest however, that 5mM glucose, unlike 11.7mM 
(see section 4.2.5.2), did not adequately support ischaemic metabolism since lactate 
release decreased over the 60 minute period .
Although creatine kinase release in the albumin and palmitate groups was 
similar during 0 - 3 0  minutes of ischaemia, it was significantly greater in the 
palmitate group during the 30 - 60 minute ischaemic period (Figure 4.13b). This 
showed that ischaemic damage was increased when palmitate was present.
Although the effect of palmitate during ischaemia in this model was associated with 
elevated LCA concentrations, a causal link between the two events could not be 
definitely established. Subsequently, it was considered that if etomoxir, an 
inhibitor of fatty acid oxidation (W olf et al., 1981), could be shown to reduce LCA 
concentrations and ischaemic damage in palmitate-perfused low-flow ischaemic 
hearts, this would give greater support for the hypothesis that elevated LCA and 
ischaemic damage are linked.
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Figure 4.14 The effect of etomoxir on palmitoylcarnitine 
transferase 1 (CPT-1) activity in rat and guinea-pig heart 
mitochondria
The relative sensitivities of CPT-1 activity to etomoxir in rat (n=3, open 
circles) and guinea-pig (n=3, open squares) heart mitochondria were measured as 
described in section 4.3.3. Values shown are mean ± S.E. and are expressed as a 
% o f the activity measured in untreated control mitochondria.
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4.3.3. Inhibition of myocardial CPT-I by etomoxir in the isolated mitochondria 
preparation
Before studies into the effects of etomoxir in the heart were performed, the 
activity of this compound as an inhibitor of carnitine palmitoyltransferase I (CPT-1; 
Selby and Sherratt, 1989), was investigated. This was done using an assay system 
which had already been established in this laboratory. However, this assay system 
involved the use of mitochondria prepared from rat heart and the first experiment 
was to determine the activity of etomoxir using guinea-pig heart mitochondria. A 
full description of the assay procedure is given in Section 2.3.4 and the assistance 
o f Dr. Katrina Wyatt (Syntex) with these studies is gratefully acknowledged.
The ability of etomoxir to inhibit CPT-I in rat and guinea-pig isolated 
mitochondria was studied over the concentration range 1 0 8 to lO 3 M. The assay 
system was based on the amount of palmitoyl-[3H]-carnitine produced in 5 minutes 
and the degree of inhibition, at each concentration of etomoxir investigated, was 
determined by a comparison with control mitochondria. From this data a pICso 
value for etomoxir in both preparations was calculated.
A comparison of the relative sensitivities of rat and guinea-pig myocardial CPT- 
I to etomoxir is shown in Figure 4.14 and it was found that the inhibitory potency 
of etomoxir was greater in rat (pICso 6.32) than in guinea-pig mitochondria (pICso 
5.12). As a result, 10|iM etomoxir was used for further studies in the guinea-pig 
heart.
4.3.4. Evidence for CPT-I inhibition by etomoxir in the paced normoxic-perfused 
heart
The method of measuring CPT-I activity using isolated mitochondria was
modified to demonstrate that when etomoxir, which is an irreversible inhibitor of
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CPT-I (Selby and Sherratt, 1989), was perfused into the heart, the CPT-I enzyme 
was inhibited. Each heart was perfused with IOjiM etomoxir for 30 minutes and 
the mitochondria were isolated. The CPT-I activity was measured as before and the 
changes in the activity o f the enzyme in each group investigated are shown below.
Six groups o f hearts (n=3) were used:
% CPT-I 
activity
1) Normoxia 100
2) Normoxia + etomoxir 44
3) Normoxia + 3% albumin 100
4) Normoxia + 3% albumin + etomoxir 88
5) Normoxia + albumin : palmitate (1.5mM) 100
6) Normoxia + albumin : palmitate (1.5mM) + etomoxir 87
These results showed that the potency of etomoxir as an inhibitor of the CPT-I 
enzyme in the intact heart was affected by the presence of albumin in the perfusion 
solution. This observation suggested that studies involving the effects of drugs in 
albumin : palmitate-perfused preparations may underestimate the potency of those 
drugs. Conclusions drawn from such studies should therefore be viewed with 
caution.
4.3.5. The potential effects of albumin-binding in the perfused heart studies.
The degree to which LCA accumulation can increase ischaemic damage is
uncertain because intracellular fatty acid binding proteins exist (Fournier et al.,
1983) and these may lower the free intracellular concentration of fatty acid
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Figure 4.15 The effect of albumin on the positive 
inotropic activity of palmitoylcarnitine in the paced 
superfused guinea-pig papillary muscle preparation
The contractile response to 10pM palmitoylcarnitine (PC) in the absence of 
albumin (n=5, open squares) was compared with the response to PC in the 
presence o f 0.02% albumin (n=6, closed squares). Tissues were pre-treated with 
either albumin or PSS for 15 minutes prior to the addition of PC. Values shown 
are mean ±  S.E. expressed as % of the contractile measurement made prior to the 
pre-treatment period.
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intermediates. Although it was not possible to demonstrate this interaction by 
intracellular methods, the effect of albumin-binding on the response of the guinea- 
pig papillary muscle to exogenous palmitoyl carnitine was investigated.
In previous studies, palmitoyl carnitine has been shown to increase contractile 
force in the guinea-pig papillary muscle preparation (Clarke et al., 1990). The 
papillary muscles were set up as described in Section 2.3.2 and at the end o f the 
equilibration period were superfused with either PSS (control group) or 0.02% 
albumin for 15 minutes. After this time, both the control group and the albumin 
group were perfused with 10p.M palmitoyl carnitine for 60 minutes. The albumin 
was present throughout the 60 minute period. Since 3% albumin was used to bind 
1.5mM palmitate in the previous experiments, the concentration of albumin used to 
bind 10p.M palmitoyl carnitine experiments was scaled down to 0.02%. Changes 
to contractile force were measured every 15 minutes and the results were expressed 
as % of the contractile force measured at the end of the equilibration period.
4.3.5.1. The effects of albumin on the positive inotropic response to palmitoyl 
carnitine in the guinea-pig papillary muscle preparation.
Contractile force increased to 141.2 ± 3.2% of control in the presence o f 10|iM 
palmitoyl carnitine. In contrast, palmitoyl carnitine in the presence of albumin, had 
no positive inotropic effect. This suggested that the interaction between palmitoyl 
carnitine and albumin had prevented the effect on contractile force (Figure 4.15). 
This supported the theory that binding proteins could alter the potential effects of 
LCA in the heart. In the time available it was not possible to resolve the problem of 
albumin : etomoxir binding and this prevented further studies of the effects of 
etomoxir in the palmitate-perfused ischaemic heart. However, the effect of 
etomoxir on carbohydrate utilisation was investigated further in the normoxic heart.
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Figure 4.16 The effects of etomoxir on contractile 
activity in the paced guinea-pig heart during normoxic 
perfusion with and without glucose
This figure shows the changes to a) contractile force and b) diastolic tension 
in glucose (1 1.7mM, n=4, open circles), glucose-free (n=4, open squares), glucose 
+ 10pM etomoxir (n=4, filled circles) and glucose-free + 10|iM etomoxir (n=4, 
filled squares) perfused hearts. Values shown are mean ± S.E. expressed as a % of 
the measurements made at the end o f the equilibration period and prior to each 
treatment.
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4.3.6. The effects o f etomoxir in the normoxic-perfused heart
In previous experiments (see section 4.3.1.2), the presence of LCA in isolated 
hearts perfused in the absence of exogenous fatty acids suggested that endogenous 
lipids may be used as substrates. The aim o f these experiments therefore, was to 
investigate whether CPT-I inhibition could cause an increase in glycogen utilisation 
in the normoxic heart.
These experiments were performed using normoxic hearts perfused with and 
without 11.7mM glucose. In the glucose-free experiments, glucose was replaced 
by equimolar mannitol in order to restrict the substrate utilisation to endogenous 
lipid and glycogen. The hearts were unpaced to avoid possible fibrillation but the 
glucose-free perfusion time was extended to 60 minutes in an attempt to increase the 
degree of endogenous substrate utilisation.
4.3.6.1. The effects of etomoxir on contractile function in the unpaced normoxic 
heart perfused with and without glucose
Contractile force in normoxic glucose-perfused hearts was 1.8 ± 0.5g at the 
stan of the 60 minute perfusion period. The contractile force was relatively stable 
throughout the perfusion period. Prior to perfusion with etomoxir, the contractile 
force in a second group of hearts was 1.5 ±  0.3g. Etomoxir in the presence of 
glucose caused a small but non-significant decrease of contractile force to 74.7 ± 
18.5% of control over 60 minutes (Figure 4.16a).
Contractile force prior to glucose-free perfusion was 1.5 ±  0.1 g.
Subsequently, glucose-free perfusion for 60 minutes caused a decrease in 
contractile force to 17.3 ± 5.4% of control. Prior to glucose-free perfusion in the 
presence of 10|iM etomoxir, the contractile force in a second group of hearts was
1.1 ± O.lg. When 10}iM etomoxir was perfused under glucose-free conditions, a
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Figure 4.17 The effects of etomoxir on glycogen levels in 
the paced guinea-pig heart during normoxic perfusion with 
and without glucose
The figure shows the changes to glycogen levels in glucose (1 1.7mM, n=4, 
light hatch bars), glucose + IOjiM etomoxir (n=4, dark hatch bars), glucose-free 
(n=4, light shaded bars) and glucose-free + 10pM etomoxir (n=4, dark shaded 
bars) perfused hearts (see Figure 4.16). Values shown are mean ± S.E. and 
statistical comparison to glucose-perfused control values was by analysis of 
variance and application o f Dunnett's t-test (*p< 0.05; **p< 0.01). Comparison o f 
the glucose-free control group and the glucose-free + etomoxir group was by 
unpaired t-test (# p< 0.05).
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greater decrease of contractile force, which was significant at all time-points beyond 
10 minutes, was observed and after 60 minutes, contractile force had been reduced 
to 2.2 ± 0.8% of control (Figure 4.16a).
Changes to diastolic tension were not significantly different in these groups 
(Figure 4.16b) and there were no significant changes in the spontaneous heart rates 
during the perfusion periods.
4.3.6.2. The effects of etomoxir on the glycogen content of the unpaced normoxic 
heart perfused with and without glucose.
After 60 minutes, the control glycogen content of the glucose-perfused hearts 
was 121.4 ± 9.2|imol per g dry wt (Figure 4.17). In the presence of etomoxir, this 
concentration was significantly reduced to approximately 73% of control. In the 
glucose-free perfused group, the glycogen concentration was approximately 50% of 
control which was compatible with increased glycogen utilisation in the absence of 
exogenous glucose. The glycogen concentration in glucose-free hearts perfused 
with etomoxir was further reduced to approximately 30% of control. These results 
showed that etomoxir increased glycogen utilisation in both glucose and glucose- 
free perfused hearts.
The increased use of glycogen under glucose-free conditions could be explained
by etomoxir-induced inhibition of lipid metabolism and this would support the
theory that lipid may contribute to energy production in the perfused heart under
normoxic conditions. However, in the presence of glucose, it might be expected
that this loss of lipid substrate would be compensated for by increased glucose
utilisation and Lopashuk et al. (1988) have proposed that etomoxir increases
glucose utilisation in the heart. However, since glycogen utilisation in the presence
of etomoxir was similar in both glucose and glucose-free perfused hearts in these
experiments, there was no evidence that the presence of glucose altered the effects
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o f etomoxir.
4.4 DISCUSSION
In this chapter, the influence of the two major substrates, glucose and fatty acids, 
on the myocardial response to hypoxia and ischaemia have been studied. It is well 
documented that the concentration of fatty acids available to the heart can lead to a 
reduction of glucose metabolism and in this thesis, the potential effects of reducing 
glucose metabolism have been demonstrated in normoxic, hypoxic and ischaemic 
hearts.
It is clear from these studies that any reduction of glucose availability will result 
in increased ischaemic damage. In these experiments, a consistent response 
associated with the lowering o f the glucose concentration w'as contracture 
development. This response was observed under glucose-free hypoxic conditions, 
a model in which glycolysis is not inhibited by accumulating metabolites and 
lactate. Therefore, even under conditions allowing glycolysis, maintenance of 
normal diastolic tension is limited by the availability of glycogen. The initial studies 
in this chapter examined the potential of glycogen to support normoxic function by 
removing the exogenous supply o f glucose.
In the paced normoxic heart, the loss of contractile function over 90 minutes of 
glucose-free perfusion was associated with marked depletion o f glycogen. In 
contrast, lactate efflux data suggested that the use of glycogen during low-flow 
ischaemia was relatively rapid under glucose-free conditions. In these experiments, 
glycogen was markedly reduced and the initial high rate of lactate efflux was not 
sustained in comparison to glucose-perfused low-flow ischaemic hearts.
Contracture developed under glucose-free conditions in hypoxia and low-flow 
ischaemia and also in no-flow ischaemia. All of these conditions were associated 
with reduced glycolysis.
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Although it is unclear whether the initiation of contracture development is loss 
of ATP or an increase in intracellular [Ca-*-*-] (Lipasti et al., 1984), both o f these 
events would be important in contracture development during ischaemia. Acidosis 
and the subsequent increase of intracellular [H+] can displace Ca++ from the 
troponin binding site (Katz, 1973). When Ca-^ binds to troponin, the inhibitory 
action o f troponin on actin is removed leading to contraction. Therefore, if  Ca++ 
binding is inhibited by [H+], it could be argued that the result would be a permanent 
actin-myosin complex which could account for contracture development especially 
if the ATP concentration is low. However, in these studies no correlation between 
contracture and acidosis was found since contracture developed in paced hearts with 
high tissue lactate (no-flow ischaemia) and low tissue lactate (glucose-free hypoxia 
and glucose-free low-flow ischaemia). On the other hand, a high degree of ATP 
depletion was common to all of these hearts. The fact that contracture has been 
detected when the ATP concentration o f whole tissue samples is relatively high can 
be explained by a variation in the distribution of ischaemia under low-flow 
conditions. This has been shown clearly in Figure 4.9a which indicates a higher 
degree of endocardial ischaemia.
Figure 4.9b shows the consequences o f contracture development on the low- 
flow perfused heart. Contracture under these conditions exacerbates ischaemia by 
increasing the no-flow ischaemic area.
It was of interest therefore that contracture development was observed in the 
presence of glucose only when the glucose concentration was reduced from
11.7mM to 5mM or when palmitate was present. The observations with palmitate 
supported the theory that the presence of fatty acids could increase the effects of 
ischaemia. Whether this was due to a reduction of glucose uptake or the 
accumulation of fatty acid metabolites would require more investigation. Either 
explanation could account for the effects of palmitate in the low-flow ischaemic 
studies. However, contracture development during no-flow ischaemia cannot result
from the action of fatty acid intermediates since the oxidation of fatty acids would 
be completely inhibited. This is supported by the finding that fatty acid 
intermediates do not accumulate under no-flow conditions (Paulson et a l 1984). 
During low-flow ischaemia, residual flow may allow some degree of oxidative 
metabolism to continue. Under these conditions, fatty acid metabolism would 
inhibit glucose oxidation and increased oxygen utilisation (Lopaschuk et al., 1990). 
These factors coupled with the accumulation o f lipid intermediates (Katz and 
Messineo, 1981) could increase ischaemic cell damage.
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CHAPTER FIVE
THE EFFECTS OF RANOLAZINE,
A NOVEL ANTI-ISCHAEMIC AGENT, IN THE 
NORMOXIC AND ISCHAEMIC MYOCARDIUM
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5.1 INTRODUCTION
Ranolazine, [(±)-N-(2,6-dimethyI-phenyI)4[2-hydroxy-3(2-methoxyphenoxy) 
propyl]-1-piperazine acetamide di-hydrochloride; RS-43285-193] is being 
developed by Syntex Research as a novel anti-anginal agent. It has been shown to 
be effective in inhibiting both the biochemical and gross electrocardiographical 
consequences of transient myocardial ischaemia in an intact dog model (Allely et 
al., 1987; Allely and Alps, 1988) but without causing any direct haemodynamic 
effects. Ranolazine has been shown to be effective in preventing myocardial 
enzyme release in an intact primate model of ischaemia with reperfusion (Allely and 
Alps, 1990) and it has been suggested that ranolazine may alleviate the symptoms 
of transient myocardial ischaemia by altering substrate utilisation (Allely et al., 
1987). This compound has also been shown to reduce cAM P elevation in response 
to ischaemia in the in vitro perfused rat heart (Ferrandon et al., 1992).
The studies described in this chapter have examined the effects of ranolazine on 
cAMP-mediated positive inotropism in comparison to other forms of inotropic 
intervention using the normoxic guinea-pig papillary muscle preparation. The 
effects of ranolazine have also been investigated in the guinea-pig low-flow 
ischaemic heart model to obtain direct biochemical evidence of cardioprotection and 
to gain some insight into the mechanism(s) underlying the anti-ischaemic properties 
of this compound.
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5.2 METHODS
5.2.1. The guinea-pig papillary muscle preparation
The papillary muscles were prepared as described in Section 2.3.2. All 
contractile force measurements were expressed as a % of the measurement made at 
the end of the 60 minutes equilibration period. At the end of the equilibration 
period, the following protocols were applied:
5.2.1.1. Ranolazine vs elevated extracellular calcium concentration [Ca+^jo
Tissues were superfused for 20 minutes with either normal PSS (control 
experiments) or PSS containing IOjiM ranolazine. This was followed by 
superfusion for 10 minutes with PSS containing 5mM Ca++ ± IOjiM ranolazine.
5.2.1.2. Ranolazine vs Bay K 8644
Tissues were superfused for 20 minutes with either normal PSS or PSS 
containing 0.1, 1 or 10p.M ranolazine. This was followed by superfusion for 60 
minutes with PSS ± l|iM  Bay K 8644. Ranolazine was present throughout this 60 
minute period and control tissues were superfused with PSS + Bay K 8644 alone.
5.2.1.3. Ranolazine vs orciprenaline
In each experiment, 4 consecutive responses to 3jiM orciprenaline were 
obtained. Each response was measured over a 5 minute period. The first 
orciprenaline response in each experiment was used as the control response and all 
subsequent responses were expressed as a % of that value. In control experiments,
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each response to orciprenaline was followed by a wash-out period of 20 minutes.
In experiments using ranolazine, each of these wash-out periods contained 0.1, 1 
or 10(iM ranolazine, respectively. Ranolazine was also added to the appropriate 
orciprenaline solutions.
5.2.1.4. Ranolazine vs forskolin
Two studies were carried out. The first examined the effects of ranolazine on 
the positive inotropic response to forskolin and the second was used to confirm the 
findings of the first study and in addition measure any changes to cAMP 
concentrations in the tissues.
In the first study, the effects o f 20 minutes pre-treatment with a single 
concentration of either 0.01,0.1,1 or IOjiM ranolazine followed by 30 minutes 
superfusion with 0.3jiM forskolin was investigated. The relevant concentration of 
ranolazine was included in the forskolin solution and a time-matched control group 
perfused in a similar way but without ranolazine was included to assess the 
response to forskolin alone. Changes in contractile force were expressed as a % of 
the measurement made at the end of the equilibration period.
The response to forskolin in this preparation could be altered by the strength of
the electrical stimulation. This may have been due to endogenous catecholamine
release. In the second study, this effect was used to achieve a similar response to
forskolin in each group of tissues. Thus, each group of tissues was perfused with
().3jj.M forskolin for 20 minutes during which time the intensity of the electrical
stimulation was adjusted to increase the contractile force to approximately 300% of
the contractile force measured at the end of the equilibration period. This response
was similar to that of control tissues in the previous study. The average stimulation
voltage used during the equilibration period was 3.2V and this was increased to an
average of 4.7 V during the forskolin treatment period. Each group of tissues was
then perfused with consecutive concentrations o f ranolazine over the concentration
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range 0.1, 1 and lOmcM. Each concentration was perfused for 20 minutes and 
forskolin was present in the ranolazine solutions. Control tissues were perfused 
with forskolin alone. Changes in contractile force were measured at the end of 
each 20 minute period. The tissues were frozen in liquid nitrogen at the end of the 
experiment. Any tissue which became arrhythmic or did not respond adequately to 
forskolin was excluded. An additional group of tissues perfused under 
equilibration conditions for the duration of the experiment were used to assess basal 
concentrations of cyclic AMP. The average voltage applied to these tissues was 
3.3V.
5.2.2. The perfused guinea-pig heart preparation
The effects of 10p.M ranolazine on the contractile activity and metabolic 
characteristics of the low-flow ischaemic heart were examined. Each heart was 
perfused as described in Section 2.3.1 and where appropriate was pre-treated with 
ranolazine for 20 minutes prior to ischaemia. The hearts were subjected to 30 
minutes of low-flow ischaemia and when used, ranolazine was present throughout 
the ischaemic period. Untreated ischaemic hearts were perfused with normal PSS 
during the pre-treatment period. Normoxic control hearts were perfused with 
normal PSS throughout the experimental period. Contractile changes at the end of 
the pre-treatment period and during ischaemia were expressed as a % of the 
measurement made after 30 minutes equilibration. The hearts were frozen in liquid 
nitrogen after 30 minutes of ischaemia and biochemical analysis of ATP, creatine 
phosphate, glycogen and cyclic AMP was performed as described in Chapter 2. In 
addition the release of lactate and creatine kinase into the perfusate was measured.
151
5.3. RESULTS AND DISCUSSION
5.3.1. The effects of ranolazine in the guinea-pig papillary muscle preparation
The effects of ranolazine on positive inotropic responses which were not 
mediated through changes in cAM P concentrations were investigated using elevated 
[Ca++10 and the calcium entry facilitator Bay K 8644 (Schramm et al., 1983).
These results were compared with the effects of ranolazine on cAMP-mediated 
inotropic responses induced by the 6-adrenoceptor agonist orciprenaline and the 
direct activation of adenylate cyclase by forskolin (Seamon and Daly, 1983).
5.3.1.1. The effects of ranolazine on contractile force prior to the addition of 
elevated [Ca++]0 or Bay K 8644
Since each tissue was perfused with ranolazine for 20 minutes prior to the 
addition of elevated calcium or Bay K 8644, the effects of ranolazine during this pre- 
treatment period were measured. Time-matched control data obtained from 
experiments performed in the absence o f ranolazine showed that under normoxic 
conditions, contractile force decreased to 88.1 ± 3.4% of control during the 20 
minutes following the equilibration period. After treatment with 0.1, 1 or IOjiM 
ranolazine for 20 minutes, contractile force decreased to 90.2 ± 1.8%, 92.3 ± 5.4% 
and 65.3 ± 5.2% (p< 0.001) of control, respectively. Only 10pM ranolazine had a 
significant effect on contractile force but this effect did not influence the subsequent 
responses to elevated fCa++]0 or Bay K 8644.
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Figure 5.1 The effect of ranolazine on the positive 
inotropic response to Bay K 8644 in the paced guinea-pig 
papillary muscle preparation
lpM  Bay K 8644 was introduced after a 20 minute pre-treatment period 
with 0.1 (n= 6, open squares), 1 (n=5, open triangles) or 10|iM (n=4, open circles) 
ranolazine. Ranolazine was also included in the Bay K 8644 solutions. Control 
tissues (n=5,filled circles) were perfused with normal PSS during the pre-treatment 
period. The values shown are mean ± S.E. and are expressed as a % of the 
measurement made at the end of a 60 minute equilibration period. The area under 
the curve for each treatment group was calculated and was compared to the control 
group by analysis of variance and application of Dunnett's t-test.
153
L 
009
GOc
d)
E
c.o
\n
13t0)
CL
(lOJJUOO JO % )  
0OJOJ 0 |!P B J} U O Q
154
5.3.1.2. The effects o f  ranolazine on the positive inotropic response to elevated  
[Ca-^+Jo and Bay K 8644
In control experiments, increasing [Ca++]0 from 2mM to 5mM caused an 
increase in contractility to 471.2 ± 56.1 % of control. After treatment with lOfiM 
ranolazine for 20 minutes, the response to 5mM Ca++ was 472.3 ± 148.6% of 
control.
Superfusion with lpM  Bay K 8644 for 60 minutes increased contractile force to 
256.6 ± 34.2% of control. Bay K 8644, in the presence of 0.1, 1 or 10p.M 
ranolazine, increased contractile force to 350.7 ± 81.9%, 231.6 ± 23.2% and 318.8 
± 88.7% of control, respectively (Figure 5.1). Measurements of contractile force 
were made at 5 minute intervals throughout the 60 minute period and the area under 
the curve (AUC) for each treatment was compared with the control Bay K 8644 
group. Ranolazine did not inhibit the positive inotropic responses associated with 
increased calcium influx in either experiment and it was concluded that the effect o f 
10p.M ranolazine on contractile force during the pre-treatment period did not result 
in a subsequent inhibition of positive inotropism. The lack of inhibitory activity of 
ranolazine on the positive inotropic effects of '“W ared calcium and Bay K 8644 
indicated that ranolazine does not interact directly with calcium entry through 
voltage-operated calcium channels. This is illustrated when the effects of ranolazine 
are compared to known calcium entry blockers (Figure 5.2).
5.3.1.3. The effects of ranolazine treatment prior to the addition o f  orciprenaline
The protocol used in these experiments is described in section 5.2.1.3. Data
horn control experiments without ranolazine treatment showed that during the wash
periods following each of the 4 orciprenaline responses, contractile force decreased
to 88.4 ± 6.6%, 72.9 ± 5.5% and 65.7 ± 5 . 1 %  o f  control, respectively. When
ranolazine was included in the consecutive wash periods, contractile force
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Figure 5.2 The comparative effects of ranolazine, 
nicardipine and nifedipine on contractile activity in the 
paced guinea-pig papillary muscle preparation
The effects o f 0.01, 1 and lOpM ranolazine (n=6, filled squares) on 
contractile force were compared with nicardipine (n=6, open squares) and 
nifedipine (n=6, open circles). Each increasing concentration was perfused for 30 
minutes and changes to contractile force at the end of this period were expressed as 
a % of the measurement made at the end o f the 60 minute equilibration period.
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decreased to 86.8 ± 7.5% (0. IpM ), 68.0 ± 5.2% (lpM ) and 46.9 ± 3.8% (lOpM), 
respectively. Compared to the corresponding control values, 10pM ranolazine had 
a small but significant negative inotropic effect (p< 0.05) on contractile force 
during the pre-treatment period. This was similar to the results described in section
5.3 .1 .1 .
5.3.1.4. The effects of ranolazine on the positive inotropic response to 
orciprenaline
In the control experiments, the 4 consecutive responses to orciprenaline were 
406.5 ± 62.0%, 379.1 ± 67.2%, 322.1 ± 57.6% and 294.5 ± 55.1% of control 
(Figure 5.3a). This reduction of the orciprenaline responses would be expected on 
repeated exposure to a 13-adrenoceptor agonist due to desensitisation of the tissue.
Using the same protocol, the effects o f ranolazine on consecutive orciprenaline 
responses were studied in a separate series of experiments. In these experiments, 
the first response to orciprenaline was only 319.1 ± 44.2% of control (Figure 5.3a) 
but this was not significantly different from the first response to orciprenaline in the 
control experiments described in the previous paragraph. Ranolazine was included 
in the perfusate after this response had been obtained and the subsequent responses 
to orciprenaline in the presence of ranolazine were 239.2 ± 30.9% (0.1 JiM), 171.8 
± 23.8% (lp M ) and 92.3 ± 12.5% (10^M ).
The regression co-efficients of the responses to orciprenaline with and without 
ranolazine present were compared (Figure 5.3b) and statistical analysis showed that 
the regression slopes were significantly different (p< 0.01). The regression 
analysis showed that although the consecutive responses to orciprenaline decreased 
in the control experiments, this decrease was significantly greater when 
orciprenaline was used in the presence of ranolazine.
The effect of ranolazine on the response to orciprenaline suggested an
interaction with cardiac 13-adrenoceptors. The binding affinity (pK,) of ranolazine at
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Figure 5.3 The effect of  ranolazine on the positive
inotropic response to orciprenaline in the paced guinea-pig
papillary muscle preparation
The data shown are comparisons of repeated responses to orciprenaline (see 
section 5.2.3) with (n=16, dark hatch bars) and, in a separate group of tissues, 
without (n=8, light hatch bars) ranolazine (Figure a). The values are mean ± S.E. 
expressed as a % of the measurement made at the end of the 60 minute equilibration 
period. Figure b) shows a regression analysis of this data. The regression slope 
calculated for orciprenaline in the presence of ranolazine (closed circles) was 
significantly greater (p< 0.01) than the control group (open circles).
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rat cardiac 6i-adrenoceptors is 5.1 (unpublished data of C.M.Brown, Syntex 
Research Scotland), however, Ferrandon et al. (1992) showed that ranolazine 
inhibited isoprenaline-induced cAMP elevation in rat heart, in the nanomolar 
concentration range. Therefore, it was unclear whether the inhibitory effects of 
ranolazine observed in the guinea-pig papillary muscle preparation, were due to a 
direct effect on the 6-adrenoceptor or the result o f an indirect intracellular action 
involving cAMP. The latter possibility was investigated further using forskolin to 
elevate the cAMP concentration.
5.3.1.5. The effects of ranolazine on the positive inotropic response to forskolin
Compared to the time-matched control group, ranolazine had no significant 
inhibitory effects on contractile force during the 20 minute pre-treatment period. In 
the control group, contractile force decreased to 80.6 ± 4.5% of control during this 
period and the values for 0.01, 0.1, 1 and IOjiM ranolazine were 97.0 ± 5.4%,
97.9 ± 3.8%, 82.1 ± 1.9% and 74.9 ± 2.9% of control, respectively (Figure 5.4).
Superfusion with forskolin for 30 minutes increased contractile force to 361.8 ± 
72.5% of control. Ranolazine inhibited this response in a concentration-dependent 
manner and the respective values for 0.01, 0.1, 1 and 10p.M ranolazine after 30 
minutes were 265.4 ± 18.7%, 252.6 ± 36.7%, 142.1 ± 10.5% and 88.5 ± 5.0% of 
control (Figure 5.4). The time-course of the response to forskolin and the effects 
of ranolazine were statistically analysed by measuring the area under the curves and 
this showed that the inhibitory effects of 1 and IOjiM ranolazine were significant 
(p< 0.01).
Since these tissues were electrically-paced, one possible explanation for the 
positive inotropic response to forskolin in these experiments was that 6- 
adrenoceptor activation by release of endogenous catecholamines also contributed to 
cAMP elevation. Thus, ranolazine could, by affecting 6-adrenoceptor activation, 
reduce cAMP elevation in the presence of forskolin under these conditions.
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Figure 5.4 The effects of ranolazine on the positive
inotropic response to forskolin in the paced guinea-pig
papillary muscle preparation
0.3pM  forskolin was introduced after a 20 minute pre-treatment period with 
0.01 (n=12, open circles), 0.1 (n=13, open triangles), 1 (n=26, open squares) or 
lOpM (n=18, closed squares) ranolazine. Ranolazine was also included in the 
forskolin solutions. Control tissues (n=14, filled circles) were perfused with 
normal PSS during the pre-treatment period. The values shown are mean ± S.E. 
and are expressed as a % of the measurement made at the end of the 60 minute 
equilibration period. The area under the curve for each treatment group was 
calculated and was compared to the control group by analysis of variance and 
application o f Dunnett's t-test.
162
50
0n
t 1--------1--------1--------r
o o o o oto o m o lo
00  CO C\J C\J •»—
( I 0 J 1 U 0 0  JO % )  
OOJOJ. 0 |! P B J J U O Q
163
Pe
rfu
sio
n 
tim
e 
(m
in
s)
Therefore, a second similar study was carried out in which the cAM P concentration 
in the tissues was measured at the end o f  the treatment periods.
5.3.1.6. The effects of ranolazine on cAMP and the positive inotropic response to 
forskolin
Two groups of tissues were used in this study and a control response to 
forskolin was obtained at the start of each experiment, forskolin increased 
contractile force to 317.9 ± 11.4% and 301.7 ± 24.0% of control in both groups, 
respectively. In the latter group, subsequent treatment with ranolazine decreased 
contractile force to 270.8 ± 18.3% (O.ljiM), 229.5 ± 18.5% (ljiM ) and 130.9 ± 
18.7% ( I O j i M )  of control. The corresponding values in the untreated forskolin 
control group were 281.0 ± 19.7%, 286.8 ± 23 .0%  and 245.3 ± 22.1% of control 
(Figure 5.5a).
Measurements of the tissue concentration of cAMP showed that basal levels in a 
group of tissues stimulated at 3.3V and superfused with normal PSS for the 
duration of these experiments were 4.8 ± 0.5pmol/mg protein (n=12). In the 
untreated forskolin control group (n=12), the cAMP concentration was 14.1 ± 
1.4pmols/mg protein compared to 16.1 ± 3.0pmol/mg protein in the ranolazine- 
treated forskolin group (n=8). Statistical analysis showed that compared to the 
basal concentration, cAMP was significantly higher in both the forskolin control 
and ranolazine-treated forskolin groups, however ranolazine did not reduce cAMP 
in the presence of forskolin (Figure 5.5b).
The levels of cAMP determined in this study indicated that the protocol used to 
increase contractile force in the presence of forskolin was associated with an 
increase in cAMP concentrations. However the decrease in contractile force 
observed in the presence of ranolazine was not associated with a decrease in cAMP.
The 6-adrenoceptor binding affinity of ranolazine is low in comparison to 
known 6-adrenoceptor blockers (e.g. propanolol p K j  7.9 ) and one possible
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Figure 5.5 The effects of  ranolazine on cyclic AMP and
the positive inotropic response to forskolin in the paced
guinea-pig papillary muscle preparation
The effects of ranolazine (n=10, closed circles) on the contractile response 
to 0.3pM forskolin (Figure a) were compared with control tissues perfused with 
forskolin alone (n=12, open circles). The values shown in Figure a) are mean ± 
S.E. expressed as a % of the measurement made at the end of the 60 minutes 
equilibration period prior to the addition of forskolin. Each concentration of 
ranolazine was perfused for 20 minutes and changes to contractile force were 
measured at the end of this period. Forskolin was present throughout the 
ranolazine treatment period. Statistical analysis comparing the inotropic effects of 
forskolin with and without ranolazine treatment was by analysis of variance and 
application of a 2-sided t-test (*p< 0.05; ***p< 0.001).
The concentration of cyclic AMP in tissues sampled at the end of these 
experiments after treatment with forskolin alone (light hatch bars) or forskolin + 
ranolazine (dark hatch bars) was compared to that o f control tissues (shaded bars) 
perfused with normal PSS over the same experimental duration. Statistical 
comparison between the control group and the treated groups was by analysis of 
variance and application of Dunnett's t-test (**p< 0.01).
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interpretation of these results is that ranolazine interacts with a post-cAMP 
phosphorylation site (e.g. cAM P-dependent protein kinase). However, the 
observed effects of ranolazine may be the result of a more complex interaction. 
Recent evidence has suggested that the elevation of cAMP by forskolin and B- 
adrenoceptor stimulation may involve separate intracellular compartments 
(Worthington and Opie, 1992).
5.3.2 The effects of ranolazine in the paced Iow-flow ischaemic  
perfused heart
Ranolazine exerted pronounced effects on contractile force when cAMP was 
elevated under normoxic conditions. Hoever, since no evidence for increased 
cAMP had been found in the guinea-pig low-flow ischaemic heart, it was of interest 
to study the anti-ischaemic effects of ranolazine in this model. The effects o f a 
concentration (IOjiM) which had been shown to give maximal protection against 
several indices of ischaemic damage in in vitro rat heart preparations (Ferrandon et 
al., 1988; 1990) were investigated.
5.3.2.1 The effects of ranolazine on contractile activity during pre-treatment and 
low-flow ischaemia
The effects of ranolazine during the 20 minute pre-treatment period and during 
ischaemia were compared to control measurements from ischaemic hearts perfused 
in the absence of ranolazine (Figures 5.6a and 5.6b). At the end of the pre­
treatment period, contractile force in the control group was 79.1 ± 13.4% of control 
compared to 93.5 ± 4.3% after ranolazine treatment. Diastolic tension in the two 
groups was 96.1 ± 4.6% and 99.2 ± 2.5% of control, respectively. Therefore 
lOpM ranolazine did not affect contractile function prior to ischaemia.
In the First 5 minutes of ischaemia, contractile force decreased rapidly to 12.9 ±
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Figure 5.6 The effects of ranolazine on contractile
function during pre-treatment and low-flow ischaemia in
the paced perfused guinea-pig heart
After 20 minutes pre-treatment with lOpM ranolazine, each heart was 
perfused under low-flow ischaemic conditions for 30 minutes (n=6, closed circles). 
Ranolazine was also present during the ischaemic period. Control hearts (n=5, 
open circles) were perfused with normal PSS during the pre-treatment period. 
Changes to contractile force (Figure a) and diastolic tension (Figure b) were 
expressed as a % of the measurement made at the end of the equilibration period 
prior to the addition of ranolazine and the values shown are mean ± S.E.
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Table 5.1 The effects of ranolazine on the metabolic
characterist ics of paced low-flow ischaemic perfused
guinea-p ig  hearts
Experimental conditions and treatments were as described in the legend for 
Figure 5.6. A group of time-matched normoxic hearts was included for 
comparison with the ischaemic hearts. The values shown are mean ± S.E. Cyclic 
AMP values are expressed as nmol/gm dry wt and all other values are |imol/gm dry 
wt. Statistical comparison to the corresponding normoxic values was by analysis 
o f variance and application of Dunnett's t-test (**p< 0.01). An additional 
comparison between the ranolazine-treated group and ischaemia alone was by 
unpaired t-test (#p< 0.05).
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4.0% in the control group and 10.8 ± 0.6% of control in the ranolazine treated 
group. After this time, contractile force remained similar in both groups and was 
8.8 ± 2.4% and 6.7 ± 0.5% of control, respectively, at the end of the ischaemic 
period. Diastolic tension in the two groups was reduced to 52.6 ± 3.6% and 50.9 
± 2.4% of control, respectively, after 30 minutes of ischaemia and these values 
were not significantly different.
5.3.2.2 The effect of ranolazine on the metabolic characteristics of the low-flow 
ischaemic heart
The effects of ischaemia with and without IOjiM  ranolazine on ATP, creatine 
phosphate, glycogen and cAMP contents were compared to values obtained from 
normoxic hearts perfused over the same time-period (Table 5.1.)
During low-flow ischaemia there was a reduction of ATP and creatine 
phosphate to approximately 50% and 18% of the normoxic values, respectively. 
Similarly, glycogen was reduced to approximately 40%. However, at the end of 
the ischaemic period in the ranolazine-treated group, ATP was approximately 75% 
of the normoxic value which was significantly higher than after ischaemia alone. 
Ranolazine did not affect the amount of creatine phosphate and glycogen present at 
the end of the ischaemic period. As in previous low-flow ischaemic experiments, 
no changes to cAMP concentrations were found in the ischaemic hearts.
Although tissue lactate concentrations in both ischaemic groups were not 
significantly different (Table 5.1), the concentration of lactate in the perfusate 
sampled from the ranolazine group was significantly lower than that of ischaemia 
alone (Figure 5.7a). A similar reduction of creatine kinase release was also found 
in the ranolazine group (Figure 5.7b).
The preservation of ATP and the reduction of lactate and creatine kinase release
was not associated with changes in cAMP concentrations in the ischaemic hearts.
This suggested that, in this model, the anti-ischaemic effects of ranolazine were
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Figure 5.7 The effects of ranolazine on lactate and
creatine kinase release during low-flow ischaemia in the
paced perfused guinea-pig heart
Experimental conditions and treatments were as described for Figure 5.6. 
Lactate release into the perfusate with (n=6, closed circles) and without ranolazine 
(n=5, open circles) is shown in Figure a) and creatine kinase release with (n=4, 
closed circles) and without ranolazine (n=6, open circles) are shown in Figure b). 
The values shown are mean ± S.E. and statistical analysis comparing the control 
and treated groups was by analysis of variance and application of a 2-sided t-test. 
Statistical significance (p< 0.05) was found at all points except where indicated.
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Figure 5.8 The comparative effects o f  ranolazine on ATP
and PDHa following low-flow ischaemia in the paced
perfused guinea-pig  heart
The tissue content of ATP (Figure a) and PDHa (Figure b) were measured 
in time-matched normoxic (n=5, shaded bars), low-flow ischaemic (n=5, light 
hatch bars) and low-flow ischaemic + IOjiM  ranolazine treated hearts (n=6, dark 
hatch bars). Ranolazine was perfused for 20 minutes prior to the 30 minute 
ischaemic period. The values shown are mean ±  S.E. and statistical comparison of 
the ischaemic groups and normoxia was by analysis o f variance and application of 
Dunnett's t-test (**p< 0.01). An additional comparison between the ranolazine- 
treated group and ischaemia alone was by unpaired t-test (#p< 0.05).
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independent of cAMP-mediated events. At this stage, changes to the activity of 
pyruvate dehydrogenase in the ischaemic tissues were considered as a possible 
explanation for the effects of ranolazine in these experiments.
The level of activated pyruvate dehydrogenase (PDHa) measured in normoxic 
perfused control hearts was 84.2 ± 5.5% o f the total PDH content of the tissues 
(Figure 5.8). At the end of the low-flow ischaemic period, PDHa was significantly 
reduced to 44.2 ± 3.2% of the total PDH content. The amount of PDHa measured 
at the end of ischaemia in the ranolazine treated group was 67.2 ± 6.8% of the total 
PDH content and was not significantly different from the normoxic value.
5.4 DISCUSSION
This study has shown that ranolazine can prevent some of the deleterious 
consequences of ischaemia in this in vitro model and is supportive of the reports of 
the cardioprotective effects seen in vivo and in vitro. The preservation of ATP may 
contribute to the improvement of functional parameters on reperfusion following 
ischaemia observed in some earlier studies.
PDH occupies a key site in metabolic substrate selection and is subject to 
complex regulation (Randle, 1986). The values obtained for total PDH activity in 
this study are similar to those found previously (Bunger et al., 1983) but the control 
values for PDHa are high as a % of total activity (McCormack and Denton, 1989). 
However, they are similar to those previously found in glucose-perfused guinea-pig 
hearts (Hansford et al., 1990). In rat heart, ischaemia has been shown to lead to 
inactivation of PDH (Kobayashi and Neely, 1983; Patel and Olson, 1984) and the 
present study shows that a similar situation may occur in the guinea-pig.
The anti-ischaemic effects of ranolazine appear to differ from that of many 
commonly prescribed anti-anginal agents (e.g. 6-adrenoceptor and calcium channel 
blocking agents) since general haemodynamics are unaffected (Allely and Alps,
1988; 1989). Although it is not clear whether activation o f PDH or prevention of
177
the ischaemic inhibition of this enzyme is involved in the cardioprotective action of 
ranolazine, such a mechanism could account for the reduction of lactate release and 
preservation of the ATP concentration by allowing more lactate to be used as a 
substrate. Since carbohydrate metabolism utilises less oxygen, this effect would be 
most beneficial under conditions of limited oxygen supply such as reduced 
coronary flow. Tissue ATP preservation and perhaps reduced lactic acidosis may 
thus allow increased preservation of cellular viability and hence account for the 
observed effects on CK release as an indicator of ischaemic cell damage.
The present observations offer some insights into the potential mechanisms for 
the cardio-protective and anti-anginal effects of ranolazine but it will be important to 
determine whether these effects are due to a direct action on PDH or are the 
consequence of an indirect metabolic action elsewhere.
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CHAPTER SIX
THE INVOLVEMENT OF KAtp-DEPENDENT CHANNEL 
ACTIVATION IN EARLY CONTRACTILE FAILURE 
DURING CARDIAC ISCHAEMIA AND HYPOXIA
I N  V I T R O
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6.1 INTRODUCTION
Early contractile failure (ECF) is a well recognised phenomenon in oxygen- 
deprived tissue under both ischaemic and hypoxic conditions, however, the specific 
mechanism underlying this effect has not been identified (Allen and Orchard, 1983, 
1987). Although several mechanisms have been considered including acidosis and 
effects on the contractile process, depletion o f ATP and the subsequent opening of 
ATP - dependent K+ channels (KatpX identified by Noma, (1983), may be of
importance in this rapid loss of contractile activity in ischaemic and hypoxic 
myocardium. During ischaemia and hypoxia, the activation of KATP-channels has 
been associated with shortening o f the action potential duration (Nichols etal.,
1991) and loss of intracellular K> (Vleugels et al., 1980) but whether these events 
are linked remains unclear (Askenes, 1992).
This chapter investigates the ECF reponse to ischaemia and hypoxia in the 
guinea-pig perfused heart model developed in this thesis and examines the effects of 
KATp-channel activation using cromakalim (Escande et a l., 1988) and KATP-channel 
blockade using glibenclamide (Kantor et al., 1990) under normoxic and hypoxic 
conditions in the guinea-pig papillary muscle preparation.
180
Figure 6.1 The cardiac action potential and related 
transmembranal ionic changes
Figure a) shows the stages of depolarisation and repolarisation of the action 
potential during normal pacemaker activity. Depolarisation (0) is associated with a 
rapid influx of Na+ and a resultant change in membrane potential from around 
-90mV to +30mV (1). This is followed by the influx of Ca++ (2) and the efflux of 
K+ (3) which contribute to the repolarisation phase. When complete, the next 
depolarisation phase commences (4). The duration of the absolute or effective 
refractory period (ERP, for definition see text) is shown in Figure b).
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Figure 6.2 Effective refractory period (ERP) 
measurements in the paced guinea-pig papillary muscle 
preparation
This representative trace shows the stable contractile response of this 
preparation during continuous stimulation at a frequency of 1Hz. The duration of 
the ERP was determined by introducing a second additional electrical impulse at 
increasing intervals (220, 230, 240msec) following the preceding impulse. The 
initiation of an additional twitch response by this second stimulus indicated that the 
action potential had repolarised beyond the ERP (see Figure 6.1). In the example 
shown, no additional response was observed at 220msec but the ERP response did 
occur at 230msec. Note that when the additional twitch response occurred it was 
followed by a potentiated response.
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6.2 METHODS
6.2.1 The guinea-pig perfused heart preparation
The paced perfused hearts were prepared as described in Section 2.3.1.
6.2.2 The guinea-pig papillary muscle preparation
The papillary muscles were prepared as described in Section 2.3.2. In addition 
to changes in contractile force, the effects on action potential duration were 
determined indirectly by measuring changes in the effective refractory period (ERP) 
in this preparation. All contractile force and effective refractory period 
measurements were expressed as a % of the measurement made at the end of the 60 
minutes equilibration period unless stated otherwise.
The ERP (Figure 6.1) has been defined as the period between action potentials
at the end of which a second stimulus can induce a propagated mechanical response 
The ERP was measured using the following procedure.
6.2.2.1 Measurement of the effective refractory period
ERP measurements were made by applying a second additional electrical
impulse of identical strength to that applied during the normal 1Hz stimulation
cycle. The timing of this extra impulse could be varied in 1msec steps and was
electronically triggered by the preceding impulse. In this way, the time period
between the normal 1Hz impulse and the exna stimulus could be increased until a
second additional contraction was induced. This time period represented the ERP
as previously defined and was usually between 170 and 250msec duration. A
representative trace is shown in Figure 6.2.
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Figure 6.3 The comparative effects of repeated hypoxia in 
the paced guinea-pig papillary muscle preparation
The effects of a single hypoxic insult (30 mins, open circles/bars n=5) 
followed by a second hypoxic insult (30 mins, closed circles/bars n=5) after a 60 
minute oxygenated recovery period are shown. Changes to contractile force and 
ERP are presented in Figure a) and Figure b), respectively. The values shown are 
mean ± S.E. and are expressed as % of the measurements made immediately before 
each hypoxic insult.
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6.2.2.2 Experimental conditions in hypoxic studies using the paced guinea-pig 
papillary muscle preparation
Hypoxia was induced by superfusion of the papillary muscles with PSS in 
which equimolar mannitol was substituted for glucose and the oxygen tension was 
reduced by gassing with 95%N2i5%C0 2 - Initial experiments showed that the 
response to a single 30mins hypoxic period was not marked and may have been 
insufficient to demonstrate any protective effects of drug intervention. However, if 
the tissues were allowed a 60 minutes recovery period o f oxygenated glucose 
perfusion, the effects of a second hypoxic insult were more pronounced (Figure 
6.3).
At the end of the 60 mins equilibration period, the ERP was measured.
Hypoxia was introduced and the ERP was measured at 10 mins intervals for 30 
mins. The tissues were re-oxygenated and allowed to recover for 60 mins. The 
ERP was measured at 40 and 60 mins during this recovery period at the end of 
which a second 30 mins hypoxic period was started. As before, the ERP was 
measured at 10 mins intervals throughout the hypoxic period. The contractile 
measurements were made prior to each ERP determination. When appropriate, the 
tissues were pre-treated with glibenclamide (20 mins) during the recovery period, 
as shown below. The drug was present throughout the second hypoxic period. In 
the absence of drug, normal perfusion was continued during these periods.
Equilibration Hypoxia 1 Recovery Drug________Hypoxia 2
60 mins 30 mins 40 mins 20 mins 30 mins
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Figure 6.4 Early contractile failure (ECF) in response to 
ischaemia and hypoxia in the paced perfused guinea-pig 
heart
Measurements of the decrease in contractile force during 5 minutes of no­
flow ischaemia (open triangles, n=7), low-flow ischaemia (open circles, n=6) and 
glucose-free low-flow ischaemia (open squares, n=6) are shown in a). The 
corresponding measurements during hypoxia (filled circles, n=4) and glucose-free 
hypoxia (filled squares, n=5) are shown in b). Values are mean ± S.E. and are 
expressed as % of the measurements made prior to the introduction of ischaemia or 
hypoxia.
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6.3 R E S U L T S  A N D  D IS C U S S IO N
6.3.1 The ECF response during ischaemia and hypoxia in the paced perfused 
guinea-pig heart
Previous experiments in the isolated perfused guinea-pig heart (Chapters 3 and 
4) have shown that the initial response to ischaemia was a rapid decline of 
contractile force within 5 minutes of either low-flow or no-flow ischaemia (Figure 
6.4a). Since one factor in ECF may be the rapid emptying of the ventricular cavity 
leading to a loss of contractile force through decreased intraventricular pressure, the 
effects of hypoxia on ECF were also examined. Under hypoxic conditions, ECF 
was not so pronounced and although still relatively rapid in onset, the degree and 
rate of decline clearly differed from that of ischaemia (Figure 6.4b).
Under low-flow ischaemic conditions, contractile force decreased to 35.9 ± 
2.5% of control within 60 seconds and to 13.4 ±  2.7% of control after 5 minutes. 
Under no-flow ischaemic conditions, contractile force decreased to 31.2 ± 1.8% 
and 1.7± 0.4% of control at these time-points, respectively (Figure 6.4a). 
Therefore, no-flow ischaemia was associated with a greater decrease of contractile 
force during the ECF period (0 - 5mins). During hypoxia (Figure 6.4b), contractile 
force was 80.0 ± 2.2% of control after 60 seconds and 49.6 ± 4.5% after 5 
minutes.
For comparison *50 ( time to 50% decrease of contractile force) values were 
calculated. The respective values for no-flow, low-flow and glucose-free low-flow 
ischaemia were 32.6 ± 3.4, 37.7 ± 2.7 and 22.8 ± 3.2 seconds and for hypoxia 
and glucose-free hypoxia were 156.0 ± 33.8 and 72.8 ± 4.9 seconds, respectively .
No significant differences were observed in the ECF responses during low-
flow ischaemia with and without glucose (Figure 6.4a). However, the response to
hypoxia was shifted towards that of low-flow ischaemia by the withdrawal of
glucose (Figure 6.4b). After 60 seconds of glucose-free hypoxia, contractile force
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Figure 6.5 The effect of gl ibenclamide on cardiac
function during normoxic perfusion in the paced perfused
guinea-pig  heart
This representative trace shows the effect of 3mcM glibenclamide on a) 
coronary perfusion pressure and b) contractile force in the normoxic perfused heart. 
The control perfusion pressure was 40mmHg and contractile force was 
approximately 0.7g prior to the addition of glibenclamide.
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Figure 6.6 Time-dependent changes of contractile force 
and ERP in the paced guinea-pig papillary muscle 
preparation superfused under normoxic conditions
The effects o f perfusion time on contractile force (n=5) and ERP (n=5) are 
shown in Figures a) and b), respectively. Contractile force and ERP were 
measured at the end of the 60 minute equilibration period (60 mins). All 
subsequent values are expressed as % of this measurement. All values shown are 
mean ± S.E.
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had decreased to 58.6 ± 3.5% of control and was 12.4 ± 2.7% of control after 5 
minutes. While it was not possible to eliminate the effects of loss of ventricular 
pressure as a contributing factor in the ischaemic experiments, glucose utilisation 
was clearly of major importance in the ECF response during hypoxia.
6.3.2 The effect of glibenclamide in the paced perfused guinea-pig heart
Perfusion with 10p.M glibenclamide, a concentration which has been shown to 
reduce K+ loss during ischaemia in the perfused rat heart (Kantor et al., 1990), 
caused a rise in perfusion pressure in the guinea-pig model. This was also the case 
for 3fiM glibenclamide (Figure 6.5a). Since this effect of glibenclamide was also 
associated-with impaired contractile function (Figure 6.5b), it was decided to do all 
further investigations on K a t p  activity and contractile force using isolated papillary 
muscles subjected to hypoxia.
6.3.3 The effects of cromakalim in the paced guinea-pig papillary muscle 
preparation
To demonstrate KATP~channel activation in this preparation, the effects of the 
KATP-channel opener, cromakalim, were examined. Time-matched control values 
obtained from tissues perfused over the same experimental duration in the absence 
of drug showed that this preparation exhibits a time-dependent "run-down" of 
contractile force during superfusion (Figure 6.6). The ERP, however, remained 
stable during the experiment and was 200 - 250msec which was within the normal 
range for cardiac muscle (Katz, 1992).
The effects of 0.1, 1 and IOj iM cromakalim on contractile force and the ERP 
are compared in Figure 6.7. Superfusion for 20 minutes with 0.1 and lmcM 
cromakalim had no significant effects on contractile force or the ERP. A higher 
concentration of cromakalim ( IOjllM) reduced contractile force to 37.1 ± 6.3% and
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Figure 6.7 The effects o f  cromakalim on contractile force
and ERP in the paced guinea-pig papillary muscle
preparation perfused under normoxic  conditions
The effects of 0.01, 1 and 10pM cromakalim (dark hatch bars), on 
contractile force (Figure a, n=5) and ERP (Figure b, n=5) were compared with time- 
matched responses obtained from normoxic-perfused papillary muscles (light hatch 
bars, n=5) in the absence of drug. Each concentration was perfused sequentially 
for 20 minutes. All measurements were made at the end of each 20 minute period 
and the values shown are mean ± S.E. expressed as % of the control measurement 
made at 60 minutes as described in the legend for Figure 6.6. Statistical analysis 
was by analysis of variance and application of a two-sided t-test ( *** p< 0.001)
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Figure 6.8 Time-dependent effects of cromakalim on 
contractile force and ERP in the paced guinea-pig 
papillary muscle preparation superfused under normoxic 
conditions
This figure shows the effects of prolonged superfusion with a single 
concentration of 10|iM cromakalim (closed circles/dark hatch bars, n=4) on a) 
contractile force and b) ERP. These measurements were compared with time- 
matched responses (open circles/light hatch bars, n=5) obtained from papillary 
muscles superfused under normoxic conditions in the absence of drug. All values 
are mean ± S.E. expressed as described in the legend for Figure 6.6.
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the ERP to 66.1 ± 5.4% of co n tro l. The corresponding time-matched values for 
contractile force and ERP at these time-points were 79.6 ± 3.0% and 105.5 ±
2.4%, respectively. The effects of cromakalim were not increased by prolonged 
superfusion (Figure 6.8). These results suggested that the shortening of the ERP 
was associated with a negative inotropic effect. If both events were the result of 
KATp-channel activation, then these effects should be reversed by glibenclamide.
6.3.4 Inhibition of the effects of cromakalim by glibenclamide in the paced guinea- 
pig papillary muscle preparation.
Superfusion for 30 minutes with a single concentration of IOjiM  cromakalim 
resulted in a decrease of contractile force to 34.1 ±  3.7% of control and the ERP 
was shortened to 51.3 ± 3.7% of control (Figure 6.9). Cromakalim was present 
throughout the remainder of the experiment and each glibenclamide concentration 
was superfused fro 20 minutes. While the effect on the ERP was partially reversed 
to 79.0 ± 2.9% of control by 0.1 p.M glibenclamide and almost completely reversed 
to 94.3 ± 1.9% and 97.7 ± 1.4% of control by 1 and IOjiM glibenclamide, 
respectively, the effects of cromakalim on contractile force were not fully reversed 
(Figure 6.9). This indicated that the effects on the ERP and contractile force could 
be dissociated.
The "run-down" effect already described (see section 6.3.3) may have 
contributed to the lack of reversabilty of contractile force since over the duration of 
this experiment a decrease to around 65% of control would be expected 
(extrapolated from the data shown in Figure 6.6).
A non-specific action of cromakalim and glibenclamide on contractile force was 
also considered. However, in a further set o f experiments, it was found that 
superfusion with l()p.M glibenclamide alone for 20 minutes did not effect contractile 
force or the ERP. Pre-treatment with glibenclamide was effective in preventing the 
subsequent effects of cromakalim (Figure 6.10). The decrease in contractile force
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Figure 6.9 The effect of g l ibenclamide on the response to
cromakalim in the paced guinea-pig papillary muscle
preparation superfused under normoxic conditions
This figure shows the effects of 0.01, 0.1, 1 and 10|iM glibenclamide (dark 
hatch bars, n=5), superfused sequentially for 20 minutes at each concentration, on 
changes to a) contractile force and b) ERP following 30 minutes perfusion with 
10pM cromakalim (light hatch bars, n=5). For reference, control levels are 
indicated by white bars. All values are mean ± S.E expressed as described in the 
legend for Figure 6.6. Statistical comparison of the control group and cromakalim 
(mm or msec values) was by unpaired t-test (# p< 0.01 compared to control value). 
The effects of glibenclamide on the response to cromakalim (% values) were 
compared using analysis of variance and application of Dunnett's t-test ( * p< 0.05 
compared to cromakalim, ** p< 0.01 compared to cromakalim).
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Figure 6.10 The effects of cromakalim on contractility and 
ERP following pre-treatment with glibenclamide in the 
paced guinea-pig papillary muscle preparation superfused 
under normoxic conditions
This figure shows the effects of 0.01, 0.1, 1 and IOjiM cromakalim (light 
hatch bars, n=5), perfused sequentially for 20 minutes at each concentration, on 
changes to a) contractile force and b) ERP following 20 minutes perfusion with 
10)iM glibenclamide (dark hatch bars, n=5). For reference, control levels are 
indicated by white bars. All values are mean ± S.E expressed as described in the 
legend for Figure 6.6. Statistical comparison between the control group and 
glibenclamide (mm or msec values) was by unpaired t-test. The effects of 
glibenclamide on the response to cromakalim were compared using analysis of 
variance and application of Dunnett's t-test. No significant differences were 
detected between the control and glibenclamide or between the glibenclamide and 
cromakalim groups.
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to 67.2 ± 3.3% of control during this experiment was similar to that expected of 
the "run-down" effect. The " run-down" of contractile force in this preparation 
does not appear to be associated with changes in ERP.
6.3.5 The effects of glibenclamide on the response to hypoxia in the paced guinea- 
pig papillary muscle preparation.
In the studies on the effects of hypoxia, all measurements were expressed as a 
% of the 40 mins recovery value (see section 6.2.2.2.)
In this series of experiments, hypoxia caused a time-dependent decrease in 
contractile force and shortened the ERP (Figure 6.11). These effects were most 
rapid in the initial 10 minutes of hypoxia during which contractile force decreased 
from 92.7 ± 2.9% to 33.9 ± 6.5% of control and ERP shortened from 100.6 ± 
0.6% to 57.0 ± 3.4% of control. At the end of 30 minutes hypoxia, contractile 
force was 4.5 ± 0.6% and the ERP was 34.6 ± 4.5% of control.
The effects of glibenclamide pre-treatment were compared to time-matched 
measurements obtained from tissues superfused with normal PSS. Pre-treatment 
(20 mins) with glibenclamide had no significant effect on contractile force or ERP 
(Figure 6.11 a and b). Glibenclamide attenuated the effect of hypoxia on the ERP 
which shortened from 102.8 ± 0.9% to 75.5 ± 2.9% of control over 30 minutes o f 
hypoxia. During the first 10 mins of hypoxia, contractile force decreased from
88.2 ± 3.4% to 45.3 ± 6.5% of control. This effect was not different from that of 
hypoxia alone. However, after this timepoint, contractile force began to increase 
and was 60.6 ± 7.3% of control at the end of the hypoxic period.
In order to determine whether this improvement in contractile activity was 
reflected in changes to ATP depletion, the ATP content of the tissues was 
measured. The papillary muscles were frozen in liquid nitrogen at the end of the 
hypoxic period and the ATP content was measured as described in Section 2.3.4. 
The normoxic ATP content was measured in papillary muscles perfused under 
oxygenated conditions over the same duration.
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Figure 6.11 The effects of  g l ibenclamide on the response
to hypoxia in the paced guinea-pig  papillary muscle
preparation
When used, glibenclamide (lOfiM) was superfused for 20 minutes over the 
period between 40 and 60 minutes of oxygenated recovery following the first 
hypoxic insult (see section 6.2.2.2) and also throughout the second hypoxic period. 
The effects of hypoxia (open circles/light hatch bars, n=7-21) and hypoxia + 
glibenclamide (closed circles/dark hatch bars n=20-22) on contractile force and ERP 
during the second hypoxic insult are shown in a) and b), respectively. All values 
are mean ±  S.E. expressed as % of the measurements made prior to the addition of 
glibenclamide. Statistical analysis of the effect o f hypoxia alone was by analysis of 
variance and application of Dunnett's t-test (# p< 0.01 compared to control value). 
The effect of glibenclamide on hypoxia was evaluated using a non-parametric Mann- 
Whitney test (*** p< 0.001 compared to the corresponding hypoxic value).
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Figure 6.12 The effects o f  g l ibenclamide on ATP
depletion during hypoxia in the paced guinea-pig papillary
muscle preparation
ATP levels were measured in papillary muscles subjected to 30 minutes of 
hypoxia with and without 10|iM glibenclamide treatment as shown in Figure 6.11. 
A group of time-matched tissues superfused under normoxic conditions in the 
absence of glibenclamide were included for comparison. The values shown are 
mean ± S.E. and represent the levels determined in pooled groups of 3-6 tissues. 
Statistical comparison between time-matched normoxia (open bar, n=4 groups; 5 
muscles/group), hypoxia (light hatch bar, n=5; 3-5 muscles/group) and hypoxia + 
glibenclamide (dark hatch bar, n=4; 5-6 muscles/group) was by analysis of variance 
and application of Dunnett's t-test. (** p< 0.01 compared to normoxia; # not 
significantly different from hypoxia).
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Normoxic ATP concentrations were 0.7 ± 0.04p.mol/gm wet wt. After 30 mins 
of hypoxia alone, ATP was significantly reduced to 0.2 ± 0.04j_imol/gm wet wt. In 
the presence of glibenclamide, the reduction of ATP to 0.3 ± 0.06p.mol/gm wet wt 
was not significantly different to that o f hypoxia alone (Figure 6.12).
Glibenclamide did not affect the ECF response to hypoxia but was associated 
with an improved contractile response later in the hypoxic period. ATP depletion 
was similar in both hypoxic groups.
6.3.6 The effect o f glibenclamide on the response to prolonged hypoxia in the 
paced guinea-pig papillary muscle preparation
The effects of glibenclamide on contractile force and ERP shortening were 
investigated over a longer duration o f hypoxia (90 mins). These results are shown 
in Figure 6.13.
As observed in the previous experiment, 20 mins pre-treatment with 10}iM 
glibenclamide had no significant effects on contractile force or the ERP. At the end 
of the pre-treatment period, contractile force and the ERP were 83.8 ± 9.0% and 
105.8 ± 3.3% of control, respectively, compared to 100.5 ± 12.1% and 103.3 ± 
2.1% of control in the absence of drug.
In the presence of glibenclamide, the ERP shortened from 105.8 ± 3.3% to
74.2 ± 5.6% of control during the initial 10 mins of hypoxia. This was not 
significantly different from the response to hypoxia alone. After this time, as in the 
previous experiment, the rate and degree of ERP shortening in the presence of 
glibenclamide was less than that in hypoxia alone. After 20 mins of hypoxia, the 
ERP had decreased to 75.0 ± 2.9% in the glibenclamide-treated group compared to
43.3 ± 7.8% of control in the absence of drug. At the end of the hypoxic period, 
the respective values for the ERP in each group were 63.8 ± 8.3% and 35.9 ±
9.2% of control.
The decrease in contractile force during the initial 10 mins of hypoxia was
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Figure 6.13 The effects o f  g l ibenclamide on the response
to prolonged hypoxia in the paced guinea-pig papillary
muscle preparation
This experiment was as described in the legend for Figure 6.11 except that 
the hypoxic period was extended to 90 minutes. Hypoxia (open circles/light hatch 
bars, n=2-5); hypoxia + glibenclamide (closed circles/dark hatch bars, n=5). 
Hypoxia significantly reduced contractile force and shortened ERP as in the 
previous experiments shown in Figure 6.11. The effect o f glibenclamide on 
hypoxia was evaluated using a non-parametric Mann-Whitney test (*p< 0.05, 
**p<0.01) compared to the corresponding hypoxic value). For clarity, only the 
statistical comparison between hypoxia and hypoxia + glibenclamide has been 
shown.
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similar in both groups. Hypoxia in the absence of drug caused a decrease in 
contractile force from 100.5 ± 12.1 to 31.9 ± 3.7% of control, while in the 
presence of glibenclamide contractile force decreased from 83.8 ± 8.9 to 25.7 ± 
3.0% of control during this period. In the absence of glibenclamide, contractile 
force continued to decrease and was 8.7 ±  5.3% of control at the end of the hypoxic 
period. As in the previous experiment, glibenclamide prevented the progressive 
loss of contractile force and contractile force recovered to 71.2 ± 17.4% of control 
after 30 mins of hypoxia compared to 12.1 ± 2.2% of control during hypoxia 
alone. This protective effect o f glibenclamide was transient and contractile force 
decreased again after 40 mins o f hypoxia. Nevetherless, at the end of the hypoxic 
period, contractile force was 29.9 ± 11.0% of control in the presence of 
glibenclamide compared to 8.7 ± 5.3% of control after hypoxia alone.
6.4 DISCUSSION
Early contractile failure occurred in both low-flow and no-flow ischaemia and 
also in hypoxia in glucose-perfused hearts. The degree of ECF was greater during 
ischaemia than in hypoxia which probably reflects the potential of energy 
production from continued glycolysis in addition to the maintenance of 
intraventricular pressure during hypoxia. However, the loss of perfusion pressure 
can only partially account for ECF since these experiments have shown that 
removal of exogenous glucose during hypoxia resulted in a marked increase in the 
degree of ECF. This intervention was less effective in low-flow ischaemia where 
glycolytic flux is reduced.
Since H+ and lactate accumulation would be expected to be less under glucose- 
free hypoxic conditions, these results suggest a major component of the ECF 
response involves glucose metabolism rather than the loss of intraventricular 
pressure or acidosis. ECF was also observed in the superfused papillary muscle in
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which perfusion pressure is not involved in the contractile response.
Another factor which must be considered is the possibility that the removal of 
glucose could have a selective effect on membrane stability. This has been 
addressed previously in Chapter 4 but would be relevant here if this effect involved 
the early activation of KATP_channeIs. Both ischaemia and hypoxia have been 
associated with APD shortening (Vleugels e ta i ,  1980) although additional ionic 
currents may contribute to this effect. It was clear from the studies in the normoxic 
papillary muscles that the KATP-channel activator, cromakalim, shortened the ERP 
and this effect was sensitive to the KATP-channel inhibitor, glibenclamide. 
Although channel activation was not measured directly, this interaction supported 
the conclusion that the effects on ERP and contractile force induced by these 
compounds were the result o f changes to KATP-channel activity. This showed that 
activation of the KATP-channel alone has a marked effect in cardiac tissue. 
Cromakalim caused ERP shortening and reduced contractile force which would 
support a role for KATP-channels in ECF. The apparent failure of glibenclamide to 
reverse the effects of cromakalim on contractile force could be explained by "run­
down" during the duration of the experiments. The suggestion that the 
inneffectiveness of glibenclamide may be due to inhibition of calcium entry by 
glibenclamide (Bosmith et a l., 1989) is unlikely since glibenclamide had no effect 
on contractility either during pre-treatment or when superfused over longer 
durations in the present studies.
The effects of hypoxia in the papillary muscle preparation were similar to those 
of cromakalim in that ERP shortened and contractile force decreased. While 
glibenclamide reduced the effect o f hypoxia on ERP, this was not fully prevented 
indicating that factors other than KATP-dependent channel activation may be 
involved in this response. Nevertheless, the results showed that a major 
component of hypoxia-induced ERP shortening does involve activation of these 
channels.
215
The effects of glibenclamide on the contractile response to hypoxia were more 
complex. Glibenclamide did not prevent the initial rapid failure of contractile force 
caused by hypoxia but did have a significant protective effect at later stages of 
hypoxia. This did not appear to involve changes in ATP content. In the normoxic 
papillary muscle, pre-treatment with glibenclamide completely inhibited the effects 
of subsequent superfusion with cromakalim. Since glibenclamide was present 
before hypoxia was introduced, it could be assumed that any effect o f Katp-
dependent channel activation as a result o f hypoxia would also be completely 
inhibited. This was supported by the marked reduction of ERP shortening during 
hypoxia in the presence o f glibenclamide. However, no reduction o f the ECF 
response was observed. Despite the finding that glibenclamide improved contractile 
force later in the hypoxic period, the results suggested that ECF involves 
mechanisms other than KATP-dependent channel activation and cannot be directly 
linked to changes in action potential duration .
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CHAPTER SEVEN
EPILOGUE: THE POTENTIAL OF METABOLIC 
INTERVENTION FOR FUTURE DRUG DEVELOPMENT
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7.1 The role o f  metabol ic  substrates  in cardiac ischaemia
A first objective of this thesis has been the development of the guinea-pig 
perfused heart model for the investigation o f cardiac ischaemia. The guinea-pig 
was chosen because previous work had shown that the myocardium of this species 
compared more closely to human while rat heart exhibited noteable differences in 
calcium handling and action potential configuration (Clarke and Patmore, 1984) and 
in receptor profile (Flynn et al., 1978; Steinforth et al., 1992). In this thesis, the 
guinea-pig model has been shown to be responsive to both hypoxia and ischaemia 
and proved a suitable experimental system for investigations into the aspects of 
myocardial substrate utilisation.
The normoxic myocardium uses both glucose and fatty acids as the major 
substrates for ATP production and preferentially metabolises fatty acids when these 
are available. However, during ischaemia, impairment of the metabolism of either 
substrate has important implications for the subsequent recovery of the heart. In the 
studies presented in this thesis, the deleterious consequences of ischaemia (e.g.
ATP depletion, contracture development, enzyme release ) were increased when the 
heart was deprived of glucose or when fatty acid was present in addition to glucose. 
This showed directly that substrate availability could influence the consequences of 
ischaemia and indicated that promotion o f glucose utilisation in preference to fatty 
acids may be beneficial during ischaemia.
Contracture development appears to be characteristic of conditions in which 
glucose metabolism is limited. In the studies carried out, it was common to both 
glucose-free low-flow ischaemia and hypoxia and to no-flow ischaemia. 
Interventions which prevent the development o f contracture could offer advantages 
for reperfusion therapy because o f the increased resistance to coronary flow (the no­
reflow  phenomenon) associated with contracture (Eberli et a l., 1991). It has been 
shown both in this thesis and by Owen et a l., (1990), that glucose metabolism can 
prevent or at least delay the onset o f ischaemic contracture. Glucose-insulin therapy
also markedly increases reperfusion recovery ( Eberli et a l., 1991). The promotion
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of glucose metabolism may help prevent the development of contracture perhaps by 
increasing cytosolic ATP.
Potassium loss is also a common feature of ischaemia, but the mechanism of 
activation and closure of the KATP'dependent channel and the contribution of this 
channel to other ischaemic events (e.g. early contractile failure) have been less well 
characterised. The majority of research into the effects of KATP-channel modulation 
has been directed towards activation of the channel as a mechanism of reducing 
ischaemic injury (Escande and Cavero, 1992). Cromakalim has a selective action 
on smooth muscle in comparison to heart (Quast and Cook, 1989) and 
vasodilatation of coronary vessels is likely to be a major factor in the protective 
action of these compounds. However, Auchampach et al. (1991) have reported that 
cardioprotection occurs in the absence o f significant haemodynamic changes and 
have suggested that the protective effects o f KATP-channel activators may result 
from a direct effect on the myocytes. Cellular K+ loss and extracellular K+ 
accummulation have been closely linked to the generation of ventricular arrhythmias 
during myocardial ischaemia, therefore, increased KATP-channel activation could 
precipitate or lower the threshold for arrhythmias.
The association of these channels with cardiac arrhythmia has also encouraged 
investigations into the effects of blocking K^rp-channel activation during hypoxia
and ischaemia. Glibenclamide has been shown to reduce K+ loss and to have 
potential anti-arrhythmic effects in isolated rat hearts (Kantor et al., 1990), in dogs 
in vivo (Bekheit et al., 1990) and in rabbit papillary muscles (Hicks and Cobbe,
1991). While these effects of glibenclamide may be beneficial, the involvement of 
KATP-channel activation in hypoxic and ischaemic dilation of coronary arteries 
(Daut et al., 1990) may oppose the use of glibenclamide under these conditions.
As with contracture development, glucose metabolism has an important role in 
KATP_channel activity and it has been reported that glycolytic ATP preferentially 
inhibits KATP'c hannel activation in cardiac m yocytes (Weiss and Lamp, 1987).
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These findings again suggest that the key intervention during ischaemia could be 
increased glycolytic flux provided that sufficient stimulation of the pathway is 
possible.
7.2 Strategies to alter cardiac metabolism during ischaemia
Since the initial hypothesis of the glucose-fatty acid cycle, put forward by 
Randle in 1963, much has been learned about the regulation of glucose and fatty 
acid metabolism under normoxic and ischaemic conditions. Yet, clinical success in 
protecting the ischaemic heart by a selective action on substrate metabolism has 
been limited. With the exception o f directly increasing the concentration of 
exogenous glucose (and insulin), the mechanisms through which myocardial 
glucose utilisation can be increased are limited.
7.2.1 Targetting fatty acid metabolism
Glucose metabolism can be increased by reducing fatty acid oxidation. This 
approach has two important consequences for the ischaemic heart. Glucose 
oxidation is increased and the potential deleterious effects of impaired fatty acid 
metabolism are diminished. A selective action targetted at ischaemic cells would 
represent an extremely effective method of achieving ischaemic protection. The 
inhibition of fatty acid metabolism during ischaemia is known to result in the 
accummulation of both fatty acyl-CoA and long-chain acylcamitine (LCA) which 
may increase cell damage (Katz and Messineo, 1981; Corr et a l., 1981). In 
addition, the influence of fatty acids on glucose metabolism during ischaemia and 
reperfusion can profoundly affect the consequences of ischaemia in the heart 
(Lopashuk et al., 1990). It is a widely accepted concept that reduction of fatty acid 
metabolism would be beneficial during ischaemia, however success in 
demonstrating the clinical effectiveness of this intervention has been limited
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Initial studies were aimed at reducing lipolysis using nicotinic acid derivatives.
It may be more important to inhibit lipolysis rather than fatty acid uptake alone, 
because lipolysis of endogenous triglycerides within the myocardium can contribute 
significantly to fatty acid metabolism (Saddik and Lopaschuk, 1992). Nicotinic 
acid inhibits lipolysis of triglycerides in adipose tissue (Vik-Mo et al., 1986), but 
although analogues of nicotinic acid have been shown to be beneficial in 
experimental cardiac ischaemia (Vik-Mo e ta i ,  1986; van Bilsen et al., 1990), their 
clinical usefulness is restricted because of adverse side-effects such as nausea, 
gastric irritation and possible hypotension. In addition, withdrawal from this type 
o f drug results in rebound elevation o f arterial fatty acids to concentrations in excess 
of the pre-treatment level (Vik-Mo and Mjos, 1981).
Another approach has been inhibition of the CPT-1 enzyme and reduction of 
long-chain fatty acid oxidation. Methyl-2-tetraglycidic acid was shown to be 
effective in increasing carbohydrate utilisation in diabetic patients (Tutwiler et al., 
1978). Further development led to the discovery of etomoxir (W olf et al., 1981) 
and although the CPT-1 inhibitors were initially aimed at improving glucose 
homeostasis in diabetes, it was also realised that this mechanism may have a 
potential use in reducing fatty acid metabolism in the ischaemic heart. The 
beneficial effects of CPT-I inhibition during ischaemia (Lopashuk et al., 1990) 
may be related to the ability of these drugs to reduce both LCA accummulation 
(Paulson et al., 1986) and myocardial oxygen consumption which is increased in 
the presence of fatty acids (Mjos, 1971). While these effects would be of limited 
value under conditions of no-flow ischaemia, they may be of importance under low- 
flow conditions where residual substrate and oxygen supply remain.
However, at the present time, CPT-1 inhibition, although effective in reducing 
fatty acid metabolism, has also failed to produce a successful clinical application. 
One reason for this may be that irreversible inhibition of the CPT-I enzyme and 
long-term inhibition of fatty acid metabolism may be deleterious to the heart and 
other tissues (Selby and Sherratt, 1989). Such an effect has been described for
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oxfenicine which has CPT-1 inhibitory activity (Bielefeld et al., 1985) and has been 
shown to produce cardiac hypertrophy (Greaves et al., 1984). Although this may 
be an adaptive change in response to chronic inhibition of fatty acid metabolism, 
some other effect by oxfenicine itself cannot be excluded.
Secondary activation o f PDH with subsequent stimulation of carbohydrate 
utilisation has also been reported for oxfenicine. This was due to inhibition o f CPT- 
1 by 4-hydroxyphenyl-glyoxylate, a metabolite o f oxfenicine (Higgins et al.,
1981). Oxfenicine demonstrated a cardio-selective action which represented an 
important development in this area. This property was due to greater oxfenicine 
transaminase activity in the heart and a higher degree of sensitivity of heart CPT-1 
compared to liver (Stephens et al., 1985). Two important properties are therefore 
required in the further development o f this type of drug. Firstly, the CPT-1 
inhibitor should be cardio-selective and secondly the inhibition should be 
reversible. Recently, a series o f reversible CPT-1 inhibitors, indicated for use in 
cardiac ischaemia, have been patented by Hoffmann La Roche (European Patent 
Application EP 0 512 352 A2) and the clinical effectiveness of these compounds 
will be of great interest.
7.2.2 Targetting glucose metabolism
Another mechanism by which fatty acid metabolism could be reduced and 
glucose oxidation increased is through activation of pyruvate dehydrogenase (PDH, 
McAllister et al., 1973; W hitehouse and Randle, 1973). A number of studies have 
shown that dichloracetate (DCA), an activator o f PDH (Whitehouse and Randle, 
1973), is associated with reduced myocardial ischaemic damage (Mjos et al., 1976; 
Racey-Burns et al., 1989; Lopashuk and Saddik, 1992). Although DCA has been 
shown to enhance myocardial efficiency and stimulate myocardial lactate utilisation 
in patients with coronary artery disease (Wargovich e ta i ,  1988), it has also been 
associated with potential toxicity and therefore clinical investigations have been
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limited (Stacpoole, 1989).
Despite the overwhelming evidence that stimulation of glucose oxidation and 
inhibition of fatty acid oxidation are beneficial to the ischaemic myocardium (see 
summary table), at the present time no suitable drug has been identified which can 
successfully manipulate this "metabolic switch". The results described for 
ranolazine in this thesis, with regard to the protective effects associated with PDH 
activation, provide a possible mechanism by which this compound may reduce 
myocardial ischaemic damage. Clearly, however, further investigation is required 
to determine whether this is a direct effect on PDH or the consequence of some 
other interaction.
In conclusion, myocardial substrate regulation in the ischaemic myocardium is 
an area of research which offers much promise for future dmg development.
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